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Abstract 
 
Non-communicable diseases (NCD) such as cancer, heart disease and cerebrovascular 
injury are dependent on or aggravated by inflammation.  Their prevention and treatment is 
arguably one of the greatest challenges to medicine in the 21st century.  The pleiotropic, 
proinflammatory cytokine; interleukin-1 beta (IL-1β) is a primary, causative messenger of 
inflammation.  Lipopolysaccharide (LPS) induction of IL-1β expression via toll-like 
receptor 4 (TLR4) in myeloid cells is a robust experimental model of inflammation and is 
driven in large part via p38-MAPK and NF-κB signaling networks.  The control of 
signaling networks involved in IL-1β expression is distributed and highly complex, so to 
perturb intracellular networks effectively it is often necessary to modulate several steps 
simultaneously.  However, the number of possible permutations for intervention leads to a 
combinatorial explosion in the experiments that would have to be performed in a complete 
analysis. We used a multi-objective evolutionary algorithm (EA) to optimise reagent 
combinations from a dynamic chemical library of 33 compounds with established or 
predicted targets in the regulatory network controlling IL-1β expression. The EA 
converged on excellent solutions within 11 generations during which we studied just 550 
combinations out of the potential search space of ~ 9 billion. The top five reagents with the 
greatest contribution to combinatorial effects throughout the EA were then optimised pair-
wise with respect to their concentrations, using an adaptive, dose matrix search protocol.  
A p38α MAPK inhibitor (30 ± 10% inhibition alone) with either an inhibitor of IκB kinase 
(12 ± 9 % inhibition alone) or a chelator of poorly liganded iron (19 ± 8 % inhibition 
alone) yielded synergistic inhibition (59 ± 5 % and 59 ± 4 % respectively, n=7, p≤0.04 for 
both combinations, tested by one way ANOVA with Tukey’s multiple test correction) of 
macrophage IL-1β expression.   
Utilising the above data, in conjunction with the literature, an LPS-directed transcriptional 
map of IL-1β expression was constructed.  Transcription factors (TF) targeted by the 
signaling networks coalesce at precise nucleotide binding elements within the IL-1β 
regulatory DNA.  Constitutive binding of PU.1 and C/EBP-β TF’s are obligate for IL-1β 
expression.  The findings in this thesis suggest that PU.1 and C/EBP-β TF’s form scaffolds 
facilitating dynamic control exerted by other TF’s, as exemplified by c-Jun.  Similarly, 
evidence is emerging that epigenetic factors, such as the hetero-euchromatin balance, are 
also important in the relative transcriptional efficacy in different cell types.   
Evolutionary searches provide a powerful and general approach to the discovery of novel 
combinations of pharmacological agents with potentially greater therapeutic indices than 
those of single drugs.  Similarly, construction of signaling network maps aid the 
elucidation of pharmacological mechanism and are mandatory precursors to the 
development of dynamic models.  The symbiosis of both approaches has provided further 
insight into the mechanisms responsible for IL-1β expression, and reported here provide a 
platform for further developments in understanding NCD’s dependent on or aggravated by 
inflammation  
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Lay Abstract – ‘Sifting drug combinations to treat disease’ 
A computer program which can select effective drug combinations from a billion others is 
set to improve our understanding of cancer, heart disease, stroke and many other diseases.  
 
Inflammation-best known in arthritis, is common to many chronic diseases.  Inflammation 
causes the release of a whole array of molecules that help our bodies fight infection but can 
also be very damaging in long term diseases. A key molecule called IL-1 is produced by 
blood cells called macrophages and these cells can be studied in the laboratory.  Only 30 
drugs are required to generate over a billion possible combinations, so it would take over 
100 years to test all possible combinations even with the assistance of the lab robot!   
We bypassed this problem with a computer program: an evolutionary algorithm (EA) that 
compared the results of a few combinations that we tested in the lab, and selected those 
that were most effective in blocking IL-1 production.  We repeated this cycle until the best 
combination was found, but in 10 weeks rather than 100 years! (see Figure)  
Although the promise of future remedies is a distant one, using this approach, of computer 
program with experiments will vastly speed up the search for remedies and provide a better 
understanding of chronic diseases such as cancer, cerebrovascular injury and heart disease. 
 
Figure.  The search for new drug combinations inhibiting the production of an 
inflammatory protein.  In this graphic the sieve represents how the computer program 
chooses good (inhibitory) combinations through repeated rounds of combination testing 
and selection.   
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Preface and Quotes 
 
I was minded of the words of the famous pharmacologist Sir Jack Gaddum who in an 
article outlined the then achievements of pharmacology and its likely future directions. 
(Gaddum, 1954).  Within this forward looking précis he eludes to the interdisciplinarity 
required for advancement in the field of pharmacology.  I think this has particular 
resonance within systems biology (and has recently been echoed (Dollery et al., 2007); 
(Sharp et al., 2011)) which is undoubtedly the most recent effort to provide an integrated 
approach to a mechanistic biology. 
 
“Believe nothing, no matter where you read it, or who said it, no matter if I have said it, 
unless it agrees with your own reason and your own common sense.” 
 
Hindu Prince Gautama Siddharta, the founder of Buddhism, 563-483 B.C. 
The scientist has a lot of experience with ignorance and doubt and uncertainty, and this 
experience is of very great importance, I think. When a scientist doesn’t know the answer 
to a problem, he is ignorant. When he has a hunch as to what the result is, he is uncertain. 
And when he is pretty damn sure of what the result is going to be, he is still in some doubt. 
We have found it of paramount importance that in order to progress, we must recognize 
our ignorance and leave room for doubt. Scientific knowledge is a body of statements of 
varying degrees of certainty — some most unsure, some nearly sure, but none absolutely 
certain. Now, we scientists are used to this, and we take it for granted that it is perfectly 
consistent to be unsure, that it is possible to live and not know. But I don’t know whether 
everyone realizes this is true. Our freedom to doubt was born out of a struggle against 
authority in the early days of science. It was a very deep and strong struggle: permit us to 
question — to doubt — to not be sure. I think that it is important that we do not forget this 
struggle and thus perhaps lose what we have gained.  
Richard Feynman "The Value of Science," address to the National Academy of Sciences 
(Autumn 1955) 
“Three months in the lab, can save you a whole afternoon in front of the computer” 
 
Douglas B Kell (http://blogs.bbsrc.ac.uk/) 
 
And finally, I am an aspirant of the sentiment expounded in this verse.  
 
“…What in me is dark Illumin, what is low raise and support; That to the highth of this 
great Argument I may assert Eternal Providence, And justifie the wayes of God to men”. 
 
John Milton “Paradise Lost”, Book 1, 22 – 26 (1674). 
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Introduction 
1.1 Inflammation: a central problem for medicine 
 
Understanding the inflammatory process is perhaps, the critical challenge for medicine 
within the 21st century.  Inflammation is an adaptive, physiological and hence protective 
response of cells and tissues to noxious chemical or physical stimuli; danger or pathogen 
associated molecular patterns (DAMP's or PAMP's; e.g. viral particles, virulence factors, 
bacterial lipopolysaccharides or fungal membrane peptides or proteins) and tissue injury 
(Weiss, 2008, Medzhitov, 2008, Medzhitov, 2010).  Inflammation can often be described 
as deleterious when reflecting on the time taken for the condition to develop, where often 
identification of pathology precedes that of a corresponding physiological inflammatory 
episode that successfully resolves, if indeed these exist at all.  A notable exception to this 
includes the wound healing and repair response. 
 
Inflammatory responses occur over two ill-defined timescales; acute and chronic (Mosser 
and Edwards, 2008).  Acute inflammation resulting from an initial infection (e,g, PAMPs) 
or injury (e.g. release of sterile particulates and intracellular cytokines from necrotic cells) 
is characterised by the activation of tissue resident macrophages via pattern recognition 
receptors (PRR), specifically; toll-like receptors (TLR), nucleotide-binding oligomerisation 
domain (NOD)-like receptors, nucleic acid sensor or  RIG-1 (retinoic acid-inducible gene 
1)-like receptors (RLR), absence in melanoma receptors (AIM2) and C-type lectin 
receptors (CLR) (Barton, 2008, Chen and Nunez, 2010, Iwasaki and Medzhitov, 2010).  
This leads to the subsequent generation of a variety of signaling molecules (e.g. cytokines, 
pro-inflammatory mediators, chemokines and eicosanoids inter alia).  These mediators 
affect the integrity of post capillary venules also causing their vasoconstriction, whilst 
vasodilitatory effects are seen in pre capillary beds.  Additionally, these signaling 
molecules recruit leukocytes (e.g. neutrophils and monocytes) to the endothelial surface of 
the capillaries proximal to the site of injury or infection, allowing a 'staging post' for the 
migration of these cells to this site.  The combination of increased hydrostatic pressure 
within the capillary bed and its now porous nature causes an exudate of leukocytes and 
proteins of the complement system to the inflamed area resulting in redness and oedema of 
the tissue or organ.  Continued swelling owing to this leukocyte invasion of the tissue 
results in local increases in temperature, leading to pain and potential loss of function of 
the tissue or organ if left untreated.  However, in the majority of acute inflammatory 
conditions, resolution is realised via the recognition and phagocytosis of apoptotic 
neutrophils by monocytes and macrophages, with subsequent phagocyte mediated 
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secretion of anti-inflammatory mediators (i.e. interleukin-10 (IL-10). prostaglandin E2 
(PGE2)) that aid repair (Murphy, 2007, Soehnlein and Lindbom, 2010).  The activation of 
macrophages by versican (a proteoglycan found in the extracellular matrix and up-
regulated in tumours) via TLR2 receptors results in their expression of cytokines (e.g. 
interleukin-6 (IL-6) and tumour necrosis factor-alpha (TNF-α)) that contribute to tumour 
metastasis (Mantovani, 2009, Kim et al., 2009).  However, pro-inflammatory cytokines 
and particularly interleukin-1 (IL-1) (Dinarello, 2011) are implicated in a variety of 
chronic and therefore non-resolving inflammatory conditions such as atherosclerosis, 
obesity, chronic obstructive pulmonary disease, asthma, inflammatory bowel disease, 
neurodegeneration and rheumatoid arthritis (Nathan and Ding, 2010).  These non-resolving 
inflammatory conditions appear to be driven by an intersection between tissue injury and 
subsequent exposure to microbial signals (i.e. infection) or extensive tissue damage that the 
host interprets as being part microbial (i.e. sterile inflammation) (Nathan and Ding, 2010, 
Chen and Nunez, 2010).  Despite the maturity of a field whose recognition transcends and 
is blurring its boundaries, a summary of current thinking with respect to the genesis and 
pathophysiology of inflammation is in order. 
 
The maxim 'you are what you eat' although clichéd is no truer of macrophages whose 
phenotype changes in response to not only extracellular mediator signals but also the 
material they phagocytose.  Mosser and Edwards (Mosser and Edwards, 2008) suggest that 
the binary classification of macrophage populations as classically or alternatively activated 
is too simplistic (Gordon, 2003) and suggest viewing macrophage activation in terms of a 
functional spectrum encompassing wound healing, host-defence and immune response.  
The macrophages used in the studies presented herein are heterogenous populations, likely 
consisting of both classic and alternatively activated macrophages.  The ‘functional 
spectrum’ concept becomes evident when one considers the macrophage and dendritic cell 
precursor population (MDP) that developmentally transit via monocytes to form 
macrophages (Auffray et al., 2009).  The potential combinatorial complexity of 
differentially expressed markers used in the classification of human monocytes (e.g. 
(cluster of differentiation (CD)14, CD16, CD64 and CD32 positive cells are responsible 
for lipopolysaccharide (LPS)-dependent production of pro-inflammatory cytokines; 
(Auffray et al., 2009)) is large.  Similarly, the spectrum of functions that macrophages 
embrace (i.e. host defence, wound healing and immune regulation) can be superimposed 
onto a colour wheel, thus capturing the subtler aspects of macrophage activation and their 
unique physiologies.  Secreted mediators inform macrophage and target tissue 
physiological function, controlling the macrophage mediated repair of tissue damage.  
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Conversely, chronic inflammation is depicted by a prolonged, poorly regulated damage to 
tissue with periodic attempts at tissue repair.  Causative principles of chronic systemic 
inflammatory processes (or as Medzhitov labels this - 'para-inflammation') that switch 
tissue function from the physiological to pathological is the aberrant synchronisation and 
placement of mediator secretion leading to tissue injury.  The underlying development of 
chronic inflammation has recently been reviewed (Renz et al., 2011) and increasingly 
epigenetic factors (i.e. deoxyribonucleic acid (DNA) modifications, e.g. methylation inter 
alia) are thought to play a role in linking an individuals genetic susceptibility and their 
environment.  Thus understanding the biology of these inflammatory mediators and in 
particular the cytokines involved is a key focus for beginning a search for the elusive 
'smoking gun' of chronic systemic inflammation. 
 
1.2 Interleukin-1; a pro-inflammatory cytokine 
 
Cytokines are responsible for orchestrating host-defence responses to injury and infection 
with their expression up-regulated in disease (Dinarello, 1996, Steinman, 2008).  The 
interleukin-1 family is composed of 11 members (i.e. ILF1 – ILF11) (Dinarello, 2011) and 
interleukin-1 alpha (IL-1α) and interleukin-1 beta (IL-1β) are regarded as `proto-typical' 
pro-inflammatory cytokines.  The measurement and description of IL-1β undertaken in this 
thesis refers to both pro and mature forms unless explicitly stated otherwise.  IL-1β 
concentrations are elevated in human plasma (albeit to lower levels than IL-6 or TNF-α) in 
chronic systemic inflammatory states (Dinarello, 1996) (Rothwell and Luheshi, 2000).    
The discovery of IL-1 is the story of the hunt for the causative principle of endotoxin 
induced fever which was initially labeled ’endogenous pyrogen’ and discovered by Elisha 
Atkins in 1955 (Dinarello, 2010).  Bacterial endotoxin and particularly LPS derived from 
gram negative bacteria are potent inducers of IL-1 cytokines from the monocytes / 
macrophages which are primarily responsible for driving auto-inflammatory syndromes 
(Dinarello, 2011) such as Cyropyrin Associated Periodic Syndromes (CAPS) (McDermott 
and Tschopp, 2007).  The realisation that macrophages were primary cellular factories for 
IL-1β was first uncovered in 1972 by Gery and Waksman (Gery and Waksman, 1972).  
They demonstrated that splenically derived mouse cells (that consisted largely of 
macrophages) produced supernatants in response to LPS that stimulated the incorporation 
of [3H]-Thymidine (a surrogate measure of mitosis) into thymocytes.  Similarly, removal 
of macrophages from human leukocyte preparations destroyed their ability to produce 
these active supernatants (Gery and Waksman, 1972).  However, it was not until thirteen 
years later that that the complementary DNA (cDNA) for  human IL-1α and β isoforms 
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was cloned into Xenopus oocytes and the supernatants shown to stimulate IL-2 release 
from a murine lymphoma cell line stimulated with phytohaemagglutin, an assay reported to 
be 1,000 times more sensitive for IL-1 activity than the thymocyte mitogenesis assay used 
by Gery and Waksman (March et al., 1985).  
 
Physiological roles for IL-1 have been difficult to establish owing to its low expression, 
although in addition to its pyrogenic properties, neurologically it's thought to impair long-
term potentiation (a proposed cellular correlate of learning and memory) and influence 
sleep patterns (Steinman, 2008, Rothwell and Luheshi, 2000).  Both molecules are 
synthesised as precursor forms in the cytosol.  Pro-IL-1α remains intracellularly associated 
with microtubules and chromatin and is converted to its mature 17 KDa form by the 
calpain family of calcium-dependent proteases.  Often pro-IL-1β is released during 
necrotic cell death and converted into its mature form by extracellular proteases secreted 
from neutrophils (e.g. particularly proteinase 3, but also elastases and chymases) 
(Dinarello, 2011).  IL-1α has been postulated as an autocrine growth factor being involved 
in the differentiation of cells.  A number of lines of evidence point to this, its association 
with chromatin and the existence of a nuclear localisation sequence in its N-terminal 
domain that engages in transcription (Luheshi et al., 2009).   In contrast, IL-1β is as a 
paracrine signaling molecule which is released from macrophages and extensively 
negatively regulated via competitive interactions with Interleukin receptor antagonist (IL-
1RA) to its cognate receptor; interleukin receptor I (IL1-RI).   
 
Transduction of the IL-1β and IL-1α response via IL-1RI is mediated by co-association of 
the receptor with the interleukin-1receptor accessory protein (IL-1RAcP).  Similarly, decoy 
receptors termed IL-1RII and SIGIRR (single IgG IL-1 related receptor; which also acts on 
TLR4 dependent signals) (Dinarello, 2011) both sequester IL-1β from the circulation and 
in the former instance also IL-1RAcP from the membrane.  Differential expression of these 
receptors regulates the inflammatory response.   
 
1.2.1 The release of IL-1 
 
The intracellular cascade of events leading to release of IL-1β involves the assembly of a 
multiprotein complex: the inflammasome.  Signals that mediate the processing and release 
of IL-1β have been reviewed for bacterial infection (Mariathasan and Monack, 2007) and 
for certain inherited autoimmune disorders, such as the cryopyrin associated periodic 
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syndromes (CAPS) (Ogura et al., 2006).  These syndromes are of interest as they are 
distinct from other autoimmune disorders (e.g. rheumatoid arthritis) in that affected 
individuals don't display high titres of auto-antibodies or antigen specific T-cells 
(McDermott and Tschopp, 2007) and have been termed auto-inflammatory (Dinarello, 
2011).  These hereditary syndromes are associated with mutations in the cold induced 
autoinflammatory syndrome 1 (CIAS1) gene which encodes a NACHT-, LRR- and Pyrin-
domain-containing (NALP3) protein 3.  The NACHT (domain present in NAIP, CIITA, 
HETE and TP1 (see abbreviations) ) domains within NALP3 mediate NALP3 
oligomerization which exposes previously hidden pyrin domains (PYD) that in turn, via 
homotypic protein - protein interactions, complex with an adaptor molecule: apoptosis-
associated speck-like protein containing a CARD (ASC).  This is the final step in 
recruiting pro-caspase-1 via its caspase recruitment domain (CARD) prior to its cleavage 
and activation.   Structurally, this complex unit forms the 'inflammasome' and once 
activated, caspase 1 is capable of cleaving pro-IL-1β and pro-IL18 resulting in the release 
of mature IL-1.  Thus, mutations in CIAS1 result in the spontaneous oligomerisation of 
NALP3 and its constitutive activation of the chain of events that release IL-1β.   
 
Understanding events downstream of the inflammasome is aided by these CAPS which 
provide interesting parallels with sterile inflammation, albeit in the absence of an 
endogenous stimulus.  During sterile inflammation which can arise from tissue injury, 
trauma and ischaemia, necrotic cell death results in the release of DAMPs that include heat 
shock proteins, hyaluronan, adenine triphosphate (ATP), monosodium urate (MSU) and 
the high mobility group box 1 (HMGB1) ligand (McDermott and Tschopp, 2007), (Rock 
and Kono, 2008).  However, confirming a 'pure' sterile inflammatory episode is hard to 
achieve, because minor infections normally contaminate the inflammatory background.  
Interestingly, in a murine model of ischaemic stroke HMGB1 is thought to signal via a 
receptor for advanced glycation end products (RAGE) enhancing ischaemic brain damage 
via inflammation.  Addition of an anti-HMGB1 antibody or HMGB1 box A (an antagonist 
of RAGE) decreased ischaemic brain damage (Muhammad et al., 2008).  The complex 
assembly and activation of the inflammasome reveals a tight regulation of its function; that 
is the unit acts as a coincidence detector (i.e. two inputs or more are required in order to 
achieve an output).  The first signal is responsible for expression of the cytokine, detected 
via activation of the TLR / NLR network and the secondary signal which often involves a 
depolarising ion flux (e.g. K+ efflux via P2X7) necessary for release (Mariathasan and 
Monack, 2007).  However, stimuli that trigger the synthesis of IL-1 cytokines via their 
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interactions with toll-like receptors are of particular interest in understanding 
inflammation. 
1.3 Toll-like receptor 4 and the synthesis of IL-1β 
 
TLR’s akin to other PRR’s have evolved to recognise the penetrance of microbial 
pathogens (via PAMP’s) across host immune barriers (e.g. the skin and mucous 
membranes).  Classes of TLR respond to a variety of PAMP and DAMP signals.  TLR’s 1, 
2 , 4, 5, 6 and 11 detect lipids, proteins and lipoproteins of bacterial, fungal and viral origin 
and are localised at the plasma membrane in contrast to TLR3, 7, 8 and 9 that are nucleic 
acid sensing and are selectively distributed across intracellular compartments (e.g. 
endoplasmic reticulum, endosomes and lysosomes) to monitor non-self signals and prevent 
auto-inflammatory events from occurring (Kawai and Akira, 2010).  LPS-induced TLR4 
stimulation of macrophages is a widely used experimental model (Lu et al., 2008) that 
mimics key aspects of inflammation including IL-1β expression (Hsu and Wen, 2002, 
Matsuzawa et al., 2005).  Nevetheless, the expression of IL-1β mRNA has been 
demonstrated in primary murine (C3H/OuJ) macrophages using Pam3Cys, a TLR2 agonist.  
However, it appears that TLR4 agonism triggers a wider range of responses in C3H/OuJ 
macrophages via STAT1 phosphorylation and subsequent transcription of MCP-5, iNOS 
and IP-10 (Toshchakov et al., 2002).  The recognition of LPS by TLR4 was demonstrated 
by Poltorak (Poltorak et al., 1998) who showed that an LPS unresponsive strain of mouse; 
C3H/HeJ was homozygous for the co-dominant Lpsd allele (heterozygotes showing an 
impaired LPS response).  Additionally, the Lps allele mapped to the Tlr4 locus, strongly 
suggesting that the encoded proteins were one and the same (Poltorak et al., 1998).     
 
TLR4-dependent signaling is described by a convoluted and sequential assembly of 
proteins beginning with the titrating out of circulating LPS by the soluble protein; LPS-
binding protein (LBP).  This interaction facilitates the binding of the LPS-LBP complex to 
either the glycosylphosphatidylinositol-anchored protein CD14 or its soluble counterpart, 
which in turn facilitates recruitment of either lymphocyte antigen 96 (MD2) alone or a 
TLR4-MD2 dimer (Bryant et al., 2010).  The evolutionary maintenance of these proteins 
suggests that the LPS signal and unsurprisingly by proxy, that bacterial infection is 
sufficiently noxious to warrant their co-ordinated expression.  Dimerisation of TLR4 
facilitates the binding of adaptor proteins via the toll/interleukin-1 receptor (TIR) domain 
to the complex.  There are five TIR domain containing proteins or adaptors (highlighted in 
bold in the following text) that are relevant to TLR4 mediated signaling, these include: 
myeloid differentiation primary response gene 88 (MyD88); TIR domain containing 
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adaptor (TIRAP) also often called MyD88 adaptor like (MAL) which is essential for the 
MyD88 dependent production of pro-inflammatory cytokines (Yamamoto et al., 2002).  
IL-1 is capable of autocrine signaling, acting via this MyD88 dependent route providing 
positive feedback that probably enhances the inflammatory process.  TIR domain 
containing adaptor protein inducing interferon-β (TRIF) also called (TICAM -1) which 
couples TLR3 / TLR4 heterodimers to MyD88-independent signaling pathways mediating 
the inhibitory kappa kinase-epsilon (IKKε) and transforming growth factor (TGF) β-
activated kinase 1 (TBK1) activation of the interferon regulated factor 3 (IRF-3) 
transcription factor that leads to IFN-β induction (Yamamoto et al., 2003).  Similarly, this 
MyD88 independent pathway appears to be important for IL-1β signaling in neurones via 
the protein kinase; v-akt murine thymoma viral oncogene homolog (Akt) which has anti-
apoptotic effects (Kenny and O'Neill, 2008) (Davis et al., 2006).  Other adaptor proteins 
also play an important role in signaling; TRIF related adaptor molecule (TRAM) or TIRP 
(TIR domain containing adapter protein) when over-expressed activates the transcription 
factor; nuclear factor- kappa-light-chain-enhancer of activated B cells (NF-κB), but unlike 
TRIF, it does not produce interferon-β (IFN-β), TRAM is also critical to the TLR4 
mediated transduction of MyD88 independent signaling leading to IL-1RI activated kinase 
(IRAK1) (Kenny and O'Neill, 2008).   Finally, to date, the sterile - and armadillo-motif-
containing protein (SARM) has a contentious role in TLR signaling with some positing 
that SARM negatively regulates TRIF and others who contend that it plays no role in TLR 
signaling (Kenny and O'Neill, 2008). 
 
1.3.1 Consideration of the TLR4 signaling network  
 
Oda and Kitano (Oda and Kitano, 2006) have manually mapped the trans-cellular TLR 
network from 411 literature sources involved in innate and longer term adaptive immunity 
(Oda and Kitano, 2006).  They suggest that understanding the logic of TLR directed 
immune circuitry and its phenotypic consequences are arguably a crux issue for the 
comprehensive understanding of immunological regulation.  A prominent sub-system 
identified within the network is the MyD88-IRAK4-IRAK1-TRAF6 system that forms the 
'tie' of the 'bow tie' motif that in turn signals to nuclear-factor kappa-B (NF-κB) and 
mitogen activated protein kinase (MAPK) cascades activating transcription of cytokine 
targets such as IL-1.  Conversely, guanine nucleotide triphosphatase (GTPase) and 
phosphatidylinositol phosphate (PIP) signaling modules are considered separate from the 
MyD88 signaling protein core as they are capable of integrating inputs as described above 
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and sending signals to NF-κB and MAPK systems downstream of this protein.  This is an 
appropriate juncture to move away from the network level to examine the modular 
complexities of TLR mediated NF-κB and MAPK signaling cascades. 
 
Numerous studies point to the dependence of cytokine expression on NF-κB  and p38 
mitogen activated protein kinase (MAPK) cascades in a variety of tissues including BV2 
microglia (Jung et al., 2009), rat derived microglia (Xu et al., 2009), murine bone marrow 
derived neutrophils (Asehnoune et al., 2004), bovine articular chondrocytes (Mendes et al., 
2003), J774A.1 macrophages (Hsu and Wen, 2002), RAW264.7 macrophages, splenocytes 
and dendritic cells  (Matsuzawa et al., 2005).   
 
The NF-κB cascade shows well established oscillatory behaviour that in turn switches NF-
κB mediated gene transcription on and off with inhibitors of kappa B (IκB; isoforms α, β, 
and ε) tethering the common p50/p65 NF-κB heterodimer in the cytoplasm thus inhibiting 
its activity.  Stimulation of the NF-κB cascade occurs via receptor dependent (e.g. TLR4) 
phosphorylation of the IκB moiety by IκB kinases (IKK), which are associated with the 
scaffold protein; NF-κB essential modulator (NEMO) (O'Neill, 2006). After 
phosphorylation IκB is targeted for ubiquitination and degradation.  This allows the 
p50/p65 heterodimer to translocate to the nucleus and associate with the promoter regions 
of target genes such as IκB, which in turn promotes the dissociation of NF-κB from DNA 
binding elements and its relocation to the cytoplasm.  Hence, repeated oscillatory cycles 
can be established that in part are regulated via the differential assembly of structural 
components (e.g. NF-κB dimer composition, promoter sequences) and provide specific and 
selective spatio-temporal patterns of gene expression within the cell.  TRAM dominant 
negative mutants transfected into 293 cells and coupled to NF-κB luciferase reporter 
constructs whilst over-expressing either IL-1 receptors, TRAF6, IKKβ, TLR2 or TLR4 
showed significant inhibition of NF-κB activation by IL-1RI (and it's accessory protein) 
but only marginal inhibition was observed for TLR2 over-expressing cells (Bin et al., 
2003).  However, this experiment must be viewed with caution given that there was no 
comparison made with wild-type TIRP and 293 cells do not endogenously express this 
protein.  Bin et al, (Bin et al., 2003) measured luciferase catalysed chemiluminescence 16 h 
after mutant TRAM transfection of 293 cells and therefore TLR4 mediated MyD88 
dependent effects appear to be independent of TRAM at this time.  This result indicates 
that TLR4 can activate NF-κB in the absence of TRAM.  This maybe a compensatory 
effect of MyD88 as Kenny and O'Neil (Kenny and O'Neill, 2008) point out that TRIF / 
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TRAM and MyD88 / MAL are thought to be involved in late versus early TLR4 signaling 
respectively.  
 
The p38 MAPK's are serine / threonine kinases and at least in their interactions with 
apoptosis signal regulating kinase (ASK1) are considered evolutionarily older than the NF-
κB cascade (Matsuzawa et al., 2005).  The considered opinion on p38 MAPK's are that 
they are detectors of cellular stress (Raman et al., 2007). The p38 family consists of α, β, γ, 
and δ subtypes and are parts of a larger family of MAPKs including extracellular signal-
regulated kinases (ERKs) and c-Jun N-terminal Kinases (JNKs).  Gamma and delta p38 
isoforms catalyse an initial phosphorylation of protein kinase C epsilon (PKCε) resulting in 
this becoming a substrate for glycogen synthase kinase 3 (GSK3) after which further 
phosphorylation by GSK3 renders PKCε able to interact with 14-3-3 proteins for further 
downstream signaling events.  These are TLR4 and MyD88 dependent events as 
demonstrated by MyD88 gene knockouts where PKC and 14-3-3 phosphorylation were 
markedly reduced.   Also, PKC phosphorylation of TRAM is also required for TLR4 
transduction to the transcription factor; IRF3 via TRIF (Kenny and O'Neill, 2008).  
 
Returning to the network, Oda and Kitano mention that as MyD88 is the central element of 
the 'bow-tie' structure, diverse inputs that converge on this protein can only change its level 
of activation and in principle cannot produce differential responses (Oda and Kitano, 
2006).  However, this observation and the fact that the network furnishes varying outcomes 
dependent on its combinatorial input can be reconciled by their invocation of the non-
obvious notion of mathematical hyperspace.  This concept is most easily conceived in 
terms of Cartesian x, y and z co-ordinates, where, for example each axis corresponds to a 
signaling protein and the relative distance along these axes representing the level of 
activation / inhibition of the protein.  Discrete levels of network response can be mapped 
onto this three dimensional space and this idea can be extended to encompass N-
dimensional (i.e. many proteins or signaling modules) hyperspace, elegantly describing 
different response outcomes to diverse inputs.  In essence, signal transduction networks 
can be thought of classifiers (as Oda and Kitano describe) that integrate diverse inputs and 
categorise them in hyperspace which in turn produce a set of responses (Oda and Kitano, 
2006).  Clearly, the interactions between MyD88 dependent and collateral and MyD88 
independent pathways remains to be defined, but provides an interesting focus for the 
study of biological network behaviour.  
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Therefore the selective spatio-temporal activation or silencing of network components may 
result in aspects of tissue stress with consequent disruptions in homeostasis that result in a 
bifurcation in tissue behaviour.  That is the inflamed tissue either restores its previous 
homeostatic 'set' points or shifts these variables to a new steady-state.  To effectively 
understand these disease state(s) within a complex biological network -we need to 
understand the key concept of robustness (Aderem, 2005). 
 
 
1.5 Inflammatory transformation of tissues: an issue of robustness 
 
Wells et al (Wells et al., 2005) describe inflammation as failure of resolution rather than an 
induction of the inflammatory process and point to the  
`inappropriately prolonged life of macrophages' to sites where they have been actively 
recruited as likely to lead to para-inflammation.  They point out that sets of genes that 
negatively regulate macrophage activation maybe considered 'inflammation suppressor 
genes' and that at many steps within the pathway of macrophage activation are subject to 
negative feedback regulation.  The majority of genes encoding these negative regulators 
are produced late on in the transcriptional response of macrophages to LPS and include 
regulators of receptor complexes, signaling and transcription.  One such candidate is a 
gene encoding the p47phox subunit of the NADP(H) oxidase.  Mice homozygous 
p47phox(-/-) for its absence displayed exacerbated lesions and slowed recovery to  
experimental arthritis.  Conversely, this gene maybe regarded as pro-inflammatory as it is a 
prima facie candidate for the oxidative damage caused by the production of reactive 
oxygen species (ROS) in macrophages during chronic inflammation (Halliwell, 1999).  
These seemingly contradictory observations between in vivo and in vitro models 
corroborate the chasm that exists between our reductionist understanding and that of the 
holism reflected in the study of a network or complete system. 
 
In the above example we can see that despite a plethora of genes that encode negative 
regulators of the LPS-TLR4 pathway in macrophages, seemingly mutation of any of these 
candidates directs the macrophage towards a para-inflammatory phenotype.  The reason for 
this probably lies in the polymorphic nature of these genes and conference of a 
evolutionary advantage to individuals that are maximally heterozygous at these 
`inflammatory suppressor' loci (Wells et al., 2005).   This ensures that a host response to a 
wide variety of different pathogens or chemical insults are robust.  Nevertheless, it's likely 
that only a subset of these inflammation suppressor genes are invoked within a particular 
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macrophage, selectively switching off a particular pathway within the network.  Hence, 
homozygous mutations at particular loci within alleles may result in the adoption of a para-
inflammatory phenotype (Wells et al., 2005).  This is a good example of a trade off 
between being robust to an enormous number of potential insults but extremely fragile to 
mutations in those genes mediating the response.  The themes of phenotypic stability and 
maintenance of states versus functions are defining characteristics of robust networks as 
espoused by Kitano (Kitano, 2007) which he defines thus: 
 
`Robustness is a property that allows a system to maintain its functions against internal and 
external perturbations.' After (Kitano, 2004). 
 
Kitano makes the distinction between homeostasis and robustness (i.e. maintaining states 
vs. functions).  However, this distinction is somewhat laboured as states ultimately form a 
continuum that defines and describes function.  However, Kitano eludes to the fact that 
robustness is a more general concept insofar that a system is 'robust' provided it maintains 
functionality even if it transitions through a new steady state or instability.  Robustness can 
be thought of as a general concept and stability and homeostasis as specific instances of 
this.  However, robustness although important, is only one such concern of systems 
biology and it is worth digressing to review the field, its decade long existence and how it 
can impact our understanding of the innate immune system.  
 
1.6 Systems biology a definition and its impact in innate immunity 
 
Much has been said of systems biology, but arriving at a definition of this science is still 
proving problematic some 43 years since this term was first coined by Mesarovic 
(Mesarovic et al., 2004).  Mesarovic’s intent in 1968 was to explain biological phenomena 
using decision making / control concepts from mathematical general systems theory.  
Likely, through the inability to make high-throughput parallel measurements at this time, 
this effort appears to have stalled.  Mesarovic also acknowledges the parallels of the 
systems biology challenge and complexity science (Kauffman, 2008, Kauffman, 1995), 
whereas other system biologists have emphasized evolution of the ‘two roots’ of traditional 
molecular biology and non-equilibrium thermodynamics that have led to systems 
approaches in biology (Westerhoff and Palsson, 2004).  In an attempt to arrive at a 
definition, a limited and far from exhaustive survey of reviews that discuss systems 
biology was performed.  Excerpts from these reviews are provided below and then 
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compiled for the respective frequency of words that occur in the text using wordle (Figure 
1.1): 
 
‘Systems biology is a comprehensive quantitative analysis of the manner in which all the 
components of a biological system interact functionally over time.’ (Aderem, 2005) 
 
‘…systems biology involves an iterative interplay between more or less high-throughput 
and high-content ‘wet’ experiments, technology development, theory and computational 
modelling, and that it is the involvement of computational modelling, in particular, in the 
process that sets systems biology apart from the more traditional and more reductionist 
molecular biology.’ (Kell, 2006a) 
 
‘Systems Biology is the science that aims to understand how biological function that is  
absent from macromolecules in isolation, arises when they are components in the system.’ 
(Westerhoff et al., 2008) 
 
‘The central task of systems biology is (a) to comprehensively gather information from  
each of these distinct levels [(i.e. molecules, cells, tissues, organs, organisms)]  for  
individual biological systems and (b) to integrate these data to generate predictive  
mathematical models of the system.’ (Ideker et al., 2001) 
 
‘[Systems Biology]…is an emerging field of biological research that aims at a system  
level understanding of genetic or metabolic pathways by investigating  
interrelationships (organisation or structure) and interactions (dynamics or behaviour)  
of genes, proteins and metabolites.’ (Wolkenhauer, 2001) 
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Figure 1.1.  A wordle generated from the extracted text of reviews on the science of 
systems biology presented above.  Although a trivial analysis it provides recurrent themes 
in definitions of systems biology. 
 
In conclusion the definition used in this thesis is ‘Systems biology is the spatio-temporal 
analysis of networks of biological components to elucidate their emergent function’   
 
The innate immune system is particularly suited to a systems biology analysis.  One does 
not have to disrupt physical syncytial connections at least at certain stages of development 
of the macrophage – aiding cellular isolation.  Aderem and Zak have reviewed the systems 
biology of innate immunity (Zak and Aderem, 2009) emphasizing three founding 
principles of systems biology: emergence; the likely recognition of multiple PRR’s by a 
pathogen,  robustness; the redundancy of PRR’s in detecting PAMP’s and modularity; 
activation of specific PRR networks that themselves have specific feedback architectures.  
1.7 The Problem 
 
Clearly, the transformation of the systems phenotype to an inflammatory condition, or 
moreover a para-inflammatory state, is a problem of unraveling an extremely complex and 
dynamic network of primarily proteins and nucleic acids that drive IL-1β expression and 
cannot necessarily be rectified by time alone.  This presents an inverse problem (Tarantola, 
2006); where one uses observations (e.g. expression of a protein) to infer parameters of the 
system (e.g. identities and concentrations of signaling molecules).  Given the degeneracy 
of the situation (i.e. a specific level of protein expression may correspond to many different 
sets of parameters) some posit that these problems cannot be solved (Brenner, 2010).  
However, this assertion is itself flawed; the outcome of testing any hypothesis does not 
‘solve’ the problem.  It is possible only to disprove a falsifiable, null hypothesis with a 
specified statistical confidence (α), at least according to the prevailing scientific worldview 
espoused by Popper (Popper, 2002).  Indeed, other systems biologists have remarked on 
the relevance of data-driven approaches as being complementary to hypothesis driven 
research and these are allied arguments for pursuing inverse problems (Kell and Oliver, 
2004).   
 
Other means need to be sought to readdress the balance and one such way is via the use of 
chemical genetics: ‘[which is] the application of small molecule probes as tools for 
understanding and manipulating biological pathways’ (Bucci et al., 2010).  Using 
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combinations of ligands or reagents that are selective for different signaling proteins in 
order to modulate their activities and the outcome of the measured variable is a primary 
concern of pharmacology.   A review on the field of combination chemical genetics (Lehar 
et al., 2008) outlines the advantages this approach as follows: 
 
1. The targeting of a single domain of a multi-domain protein 
2. Allows timely control of biological processes  
3. Targets orthologous and paralogous proteins  
4. Does not directly alter the concentrations of targeted species obviating indirect 
effects  
 
Pharmacology, although arguably a relatively modern science has a murky legacy in 
therapeutics and thankfully so, as new paradigms for drug development (Fitzgerald et al., 
2006) are harking back to original preparations for the treatment of disease which were in 
many cases unwittingly combinatorial (Rang, 1995, Ruiz-Mesia L Fau - Ruiz-Mesia et al., 
2005).  
1.8 The Question  
 
Nevertheless, the inverse problem still remains: how do we combine reagents in a coherent 
manner to target combinations of unknown signaling protein nodes that drive IL-1β 
expression?  Given the phenomena of combinatorial explosion that describes functions that 
grow rapidly in combination it is worth reviewing the science of combinatorics.   Consider 
the following formula that states a k combination of a set S is a subset of k distinct 
elements of S.  If the set has n elements then the number of combinations is equal to the 
binomial coefficient. 
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This enumeration holds true whenever k ≤ n.  For instance from a set (S) of thirty three 
elements (n), the subset (k) of all five membered combinations from this group number 
237,336.  However, this formula reduces to the following if considering all possible k. 
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Therefore, for S = n = 33 (i.e. evaluating the entire set) the calculation simply becomes 233 
= 8.59 x 109 where a reagent can either be present or absent resulting in some 8.5 billion 
possible combinations.  Despite the progress made in high-throughput screening 
technologies (Bajorath, 2002, Feng et al., 2009), the complete analysis of even modestly 
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sized chemical libraries is prohibitive due to this combinatorial explosion that occurs in 
pharmacological space (Paolini et al., 2006).  However, a solution for reducing this space 
and consequently the size of the inverse problem is at hand in the form of a widely used 
optimization technique in computer science – genetic or evolutionary algorithms (Mendes 
and Kell, 1998, Kell, 2006b).    
 
1.9 An Introduction to evolutionary computation 
 
The field of evolutionary computation studies and attempts to replicate and exploit 
biologically inspired methods (e.g. growth and development) of evolution in silico, one 
method encompassed within this broad church of techniques is that of the genetic 
algorithm (GA).  The original development of the GA by John Holland in the 1960's has 
been reviewed by Melanie Mitchell (Mitchell, 1996);  
 
 [The purpose of the GA is to]`...formally study the phenomenon of adaptation as it occurs 
in nature and develop ways in which the mechanisms of natural adaptation might be 
imported into computer systems.'  
  
The development of evolutionary computation and it's sub-fields (e.g. genetic algorithms, 
evolutionary programming and strategies) has blurred Holland's initial definition of what a 
GA was, with researchers often citing use of a GA which is less recognizable from 
Holland's original idea.  To this end I will refer to the methods outlined in this dissertation 
as evolutionary algorithms (EA), with our main aim being to use these methods as an 
optimization strategy in the search for a unique and efficacious set of reagent combinations 
that inhibit IL-1β expression.  The essence of the EA is a computational distillation of the 
process of natural selection; whereby heritable traits that positively influence the survival 
and fecundity of an organism are preferentially selected in that population.  Whitley 
(Whitley, 1994) summarizes the EA by stating that: 
 
 `These algorithms encode a potential solution to a specific problem on a simple 
chromosome-like data structure, and apply recombination operators to these structures in 
such a way to preserve critical information'  
 
The `chromosomes' mentioned in Whitley's quote refer to in silico lines or `strings' of one's 
and zero's, which are individually referred to as `bits'. Alone or in combination (depending 
on the problem one is trying to encode) these bits represent `genes' and the binary variation 
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of each bit (1 or 0) within a gene an `allele'.  A basic overview of the methods used by the 
EA for the generation of new solutions (i.e. combinations) is given in figure 1.2 and the 
relative balance between the contributing experimental and computational components 
given.  EA methods assume that high quality (i.e. high fitness) parent candidate solutions 
are available to undergo recombination and generate new offspring (Mitchell, 1996).  
 
 
 
Figure 1.2.  The basic principles behind the workings of evolutionary algorithms.   
 
A tick against a bit string (e.g. combination) represents its comparative fitness to other 
chromosomes in the population and subsequent selection for reproduction.  The string 
amongst others is then subjected to recombination (cross over) with other strings and 
mutation that determine the new generation. This new generation of strings is then 
evaluated experimentally and the cycle repeated iteratively until a suitable solution is 
located.  
 
Other important concepts in the use of EA's are those of `search space' and `fitness 
landscapes' (Mitchell, 1996). Simply put the `search space' is a set of different candidate 
solutions or chromosomes. It may at first appear strange to those unfamiliar with EA's, 
why if one is encoding a solution then why go and look for it?  The underlying issue is 
now familiar to the reader: that there are many numerous solutions to the potential problem 
(i.e. combinatorial explosion), more than it is often possible to evaluate sequentially.  
Conversely, the `fitness landscape' is a representation of all possible chromosomes and 
their fitnesses (Mitchell, 1996) and can be thought of as a l+1-dimensional plot where l  is 
the length of the bit string encoded and the fitness is plotted on the l+1st axis. So, for a 30 
reagent combination we have a 31-dimensional problem!  This `landscape' can be thought 
to have peaks (corresponding to local maxima) and troughs (minima), with changes made 
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in the bit strings via the action of recombination and mutation operators that allow 
exploration of new areas of this landscape.     
 
Although the discussion thus far has focused on the search for a unique and efficacious 
reagent combination, within this searches biological context it's also critically important we 
do not obviate the cells viability and to this end we are actually presented with conflicting 
objectives. This is a problem that can be solved via evolutionary multi-objective 
optimization (EMO) (Knowles, 2009, Knowles et al., 2008, Handl et al., 2007), any 
optimization is concerned with finding optimal values within functions and more often 
than not owing to the symmetrical nature of maximizing or minimizing a function; 
minimization is chosen (Mendes and Kell, 1998). Given that it's necessary to minimize the 
values of both objectives without a worsening in either the set of optimal solutions lie on 
what is termed the Pareto front. Solutions within the search space that are non-dominated 
are so called because they have a minimal value compared to any other solution in at least 
one objective.   
 
Knowles et al (Knowles et al., 2008) emphasize the applications of EMO which are 
perfectly suited to what in essence is a drug discovery initiative such as this. Mendes and 
Kell (Mendes and Kell, 1998) have compared and applied a variety of numerical 
optimization methods to a hypothetical metabolic network. In their comparison they 
optimized the network to maximize a flux parameter (J5) whilst either constraining or 
varying another specified flux parameter (J8). Without constraining J8 the GA and 
evolutionary programming methods were found to locate a value for J5, 30-fold higher 
than the wild-type flux, this was the maximal value attained by any method of 
optimization. Similarly, whilst constraining J8 within ~ 8 % of its wild-type value revealed 
the same result with evolutionary programming slightly superior to the optimal solution 
located by the GA (Mendes and Kell, 1998). 
 
A review covering the application of search algorithms to the discovery of novel drug 
combinations (Feala et al., 2010) classifies approaches to the search into six categories.  
These are; non-systematic, exhaustive enumeration, statistical association, explicit model 
based methods, model-free biological search algorithm (the approach adopted here) and 
model plus biological search algorithm (which is a combination of the 3rd, 5th and  6th 
approaches respectively).  This latter method provides the strengths of both in silico 
modeling and experimental analysis providing a dual assessment of prediction and 
confirmation respectively that can be coupled in iterative cycles to successively focus on 
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unique, selective and potent combinations.  Prediction using in silico models has been a 
neglected component in this discussion and warrants further scrutiny. 
1.10 A biochemists guide to In silico modeling of biochemical 
systems 
 
The preceding discussions of the TLR4 signaling network have focused on the protein 
players or nodes, their activation / deactivation and consequent effects on signaling.  These 
transformations are conducted via reactions or edges within these networks (Barabasi and 
Oltvai, 2004).  For the biochemist it is critical to consider the physical basis of these 
changes which are often abstracted and expressed in in silico representations as rates of 
change using ordinary differential equations (ODEs) (Mendes et al., 2009, Aldridge et al., 
2006, Sreenath et al., 2008, Pahle, 2009).  The modeling of dynamical systems using ODEs 
in biology and especially physiology (Hodgkin and Huxley, 1952) and ecology (Haefner, 
2005b) has a long and distinguished history.  An ODE describes the change (formally the 
derivative of a function and this is often concentration of a protein) with respect to an 
independent variable (nearly always time for the purposes of these discussions).  However, 
these abstractions naturally arise from a consideration of the law of mass conservation, put 
simply for any reactant: 
 
Rate of change = rate of appearance – rate of disappearence  
 
 
Figure 1.3.  An idealized uni-molecular reaction detailing the conversion of species A into 
B with corresponding mass fluxes (Γ).  (Beard and Qian, 2008). 
 
A B 
ΓAin ΓBin Γr
+
 
Γr- 
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For the example above (Figure 1.3) where we assume constant volume and that spatial 
gradients of species are negligible, with concentrations of species being continuous it 
becomes easy to derive ODE’s describing the system (Beard and Qian, 2008). 
We know that mass (n) is calculated from the volume (V) multiplied by concentration ([X]; 
where X is any species), thus:  
 
 
Rate of change = V.d[A] / dt        (3) 
 
Rates of appearance and disappearance are calculated from mass fluxes (Γ; in units mass / 
unit time), therefore, the concentrations of species A ([A]) and B ([B]) can be described by 
the following ODEs 
 
+− Γ−Γ+Γ= rr
in
Adt
AdV )(][         (4) 
−+ Γ−Γ+Γ= rr
in
Bdt
BdV )(][         (5) 
 
Summing both (4) and (5) leads to: 
 
in
B
in
Adt
Bd
dt
AdV Γ+Γ=





+
][][
        (6) 
 
A closed system (one where matter is not transferred) do not have transport fluxes and 
therefore (6) is rendered equal to zero (the masses of both reactants remain constant).  This 
is an important result as we shall see later.  In biological and thermodynamic senses this 
can be interpreted as the system being dead or at equilibrium respectively.  It is often more 
convenient to express fluxes in terms of concentration (J) and this is simply established via 
the following relation (J = Γ / V) .   
 
Thermodynamically (and independently of the kinetics of the reaction scheme), it can be 
shown that the change in Gibbs free energy (∆G – a measure of the chemical work done on 
a system in this context) is proportional to the ratio of forward and reverse concentration 
fluxes. 
 
( )−+−=∆ JJRTG /ln          (7) 
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Often, simulations of biochemical systems are built on the simplistic kinetic scheme of 
mass action kinetics which assumes that molecules of the same species do not affect their 
ability to react.  For our simple reaction (Figure 1.3), the law of mass action implies: 
 
J+ = k+[A]          (8) 
J-  = k
- 
[B]          (9) 
 
Where k+ and k- are forward and reverse rate constants of the reaction.   Using equations (8) 
and (9) it is possible to re-write equations (4) and (5) in terms their concentration fluxes. 
 
])[][(][ AkBkJ
dt
Ad in
A +− −+=         (10) 
])[][(][ BkAkJ
dt
Bd in
B −+ −+=         (11) 
 
Open systems with constant transport fluxes may approach stable steady states that are not 
equilibrium states (e.g. (10) and (11)), when ==−= JJJ inBinA constant, then: 
 
0])[(
][ XkJAkk
dt
Ad
−+− +++−=        (12) 
 
Where X0 is a constant ([A] + [B] = X0).  Previously, as we had done for (6), constraining 
(12) to zero yields the steady state concentrations of the reactants. 
 
( )+−
−
+
+
=∞→=
kk
XkJ
tAA ss
)()(][ 0          (13) 
 
Numerical integration of systems of ODEs (see Figure 1.4 for this example) allows us to 
arrive at approximate solutions as their solution analytically (in contrast to the example 
above) is often not an option.  In the instance of this uni-molecular reaction, it’s possible to 
intuitively arrive at the solution, but in systems that have increased dimensionality with 
respect to the number of ODE’s they have it most often is not.  Integration is usually 
carried out using specialised software for biochemical modeling and simulation (i.e. the 
computational implementation of a formal model) such as COPASI (Hoops et al., 2006). 
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Figure 1.4.  Simulation of the uni-molecular reaction A = B (outlined in Figure 1.3) 
performed in COPASI.  Parameters were set as follows: k+ = 1 s-1 and k- = 1 s-1, V = 1 mL, J 
= 0.2 mM s-1.  Initial conditions were [A]0 = [B]0 = 0.5 mM (After (Beard and Qian, 
2008)).  
  
ODE modeling in the context of biochemical systems has to span large changes in space 
and time and hence this provokes problems if there are reactions present within the sets of 
ODE’s that occur on markedly different time scales (e.g. hours vs. seconds) or in different 
cellular compartments.  Problems of this nature are termed 'stiff', fortunately, complex 
pathway simulation COPASI solves the temporal problem by using LSDODA (Mendes et 
al., 2009).  Methods and solutions for obviating these issues have been reviewed (Dada and 
Mendes, 2011, Martin et al., 2009).    
 
The purpose or objectives of modeling per se as summarised by Mendes (Mendes et al., 
2009) could be to challenge assumptions, think about a problem in depth, aid experimental 
design and to identify unknown parameters that are important in determining the system.  
Haefner (Haefner, 2005a) similarly makes the point that models have one of three purposes 
either to understand, predict or control a system.  Similarly, questions asking what is the 
model to be compared to and how will the model output be used? are also pertinent to this 
project. 
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1.11 Combinatorial solutions to complex problems?  
 
Given the complexity biological signaling during inflammatory episodes and divergent 
signals generated, studying the downstream signaling events of activating just a single 
receptor subtype (i.e. TLR4), highlights the need for a systems approach to address how 
the network responds to inputs and modulates outputs.   
Using a ‘reverse’ combination chemical genetic approach (Lehar et al., 2008) our aim was 
to optimize combinations of reagents that minimize LPS-induced macrophage IL-1β 
expression, and simultaneously minimize the number of component reagents in the 
combination and their propensity to induce macrophage cell death.   Subsequently we 
sought to optimise reagents to inhibit IL-1β expression at concentrations lower than the 
component reagents used in isolation.  This was achieved by application of an EA-directed, 
semi-automated robotic assay of IL-1β expression to a dynamic chemical library of a total 
of 33 reagents (see Methods, and also (Knight et al., 2008, O'Hagan et al., 2005, Knowles, 
2009)).  The specific algorithm used here was the indicator based evolutionary algorithm 
(IBEA) (Zitzler and Künzli, 2004), as in preliminary simulations (Allmendinger and 
Knowles, 2009) this proved superior to a variety of other multi-objective optimization 
algorithms. This was followed by a dose matrix search of resultant top ranked reagents 
from the EA-directed search.  We demonstrate that the EA converges efficiently on good 
solutions, and that dual p38 MAPK inhibition and either IκB kinase inhibition or iron 
chelation yields synergistic and biologically-relevant inhibition of macrophage IL-1β 
expression.  
Similarly, the construction of an IL-1β transcriptional map from the primary literature in 
human and murine monocytes and macrophages, specifically focused on proteins and 
regulatory DNA elements where evidence existed for their dynamic transcriptional effects 
provided insights into the modulation of the experimentally observed inhibition of IL-1β 
expression. 
 
1.12 Aims and objectives 
 
1. To locate combinations of signaling protein inhibitors, pro / anti-oxidants and / or 
iron chelators that inhibit IL-1β expression using an EA directed search coupled to 
a semi-automated robotic assay of IL-1β expression in J774.A1 macrophages. 
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2. To optimise pairs of five top-ranked reagents (from the post-hoc analysis of the 
EA-directed search) in combination with respect to their concentration using an 
adaptive dose-matrix search protocol in J774.A1 macrophages. 
 
3. To construct a human / mouse TLR4 - IL-1β signaling map from the primary 
literature.    
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Abstract 
The control of biochemical fluxes is distributed and to perturb complex intracellular 
networks effectively it is often necessary to modulate several steps simultaneously. 
However, the number of possible permutations leads to a combinatorial explosion in the 
number of experiments that would have to be performed in a complete analysis. We used a 
multi-objective evolutionary algorithm (EA) to optimize reagent combinations from a 
dynamic chemical library of 33 compounds with established or predicted targets in the 
regulatory network controlling IL-1β expression. The EA converged on excellent solutions 
within 11 generations during which we studied just 550 combinations out of the potential 
search space of ~ 9 billion. The top five reagents with the greatest contribution to 
combinatorial effects throughout the EA were then optimized pairwise.  A p38 MAPK 
inhibitor with either an inhibitor of IκB kinase or a chelator of poorly liganded iron yielded 
synergistic inhibition of macrophage IL-1β expression.  Evolutionary searches provide a 
powerful and general approach to the discovery of novel combinations of pharmacological 
agents with potentially greater therapeutic indices than those of single drugs.   
   
 iii 
Acute or chronic (non-resolving) inflammation is a well established mediator of major 
diseases including vascular disease (e.g. atherosclerosis, stroke), chronic obstructive 
pulmonary disease (COPD), cancer, diabetes, obesity, rheumatoid arthritis, psoriasis and 
inflammatory bowel disease 1,2 . Each of these conditions exhibits an elevated expression 
of the potent and pleiotropic, pro-inflammatory cytokine interleukin-1β (IL-1β) 2,3. 
Pharmacological therapies targeted against IL-1β are largely focused on biologics that are 
only likely to act extracellularly 4 (e.g. Anakinra; an IL-1 receptor antagonist), which have 
shortcomings such as poor CNS penetration.  Small molecule modulation of IL-1β may 
offer benefits in certain conditions such as in cerebrovascular injury where IL-1β mediates 
significant cerebral damage during acute ischaemia and excitotoxic insult 5.   
The lipopolysaccharide- (LPS-) induced Toll-like receptor 4 (TLR4) stimulation of 
macrophages is a widely used experimental model that mimics key aspects of  
inflammation including IL-1β expression 6.  Signal transduction induced by TLR4 
stimulation proceeds through the activation of a complex array of multi-protein signalling 
networks (e.g. MyD88, TRAF6, p38 MAPK, NF-κB), ultimately resulting in the 
expression of the IL-1B gene.  Possibly based on the ‘one gene, one drug, one disease 
paradigm’ 7 a plethora of reagents has been developed to modulate individual proteins 
within these signalling networks.  However, it is well known that multiple steps must be 
modulated simultaneously to have significant effects on biochemical fluxes 8. Thus, a 
single-target approach is unlikely to be optimal in inhibiting the expression of a pro-
inflammatory cytokine such as IL-1β, where there is both inherent degeneracy and 
considerable complexity within the signal transduction network 9.  More generally, there is 
an increasing recognition of the need to target multiple steps within signalling networks for 
their effective pharmacological modulation 7.   
Combinatorial chemical genetics 10 uses combinations of small molecules that allow 
dissection of cellular phenomena via their selective modulation of individual biological 
targets.  Despite progress made in high-throughput screening technologies 11, the analysis 
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of even modestly sized chemical libraries is prohibitive due to the combinatorial explosion 
that occurs in pharmacological space 12 (233  or ~ 9 billion combinations for all possible 
combinations of the chemical library explored here).  Thus we sought heuristic solutions 
(i.e. reagent combinations) that are good but not provably globally optimal.  
 
The terms ‘evolutionary computing’ and ‘evolutionary algorithms’ describe a set of 
approaches based loosely on Darwinian evolution by the natural selection of individuals 
and populations.  In this case the population consists of individuals that each encode a 
candidate solution to the problem at hand. The ‘fitness’ of each solution is reflected in the 
objective function(s) designed by the experimenter, but normally includes the concept that 
fitter individuals provide more accurate solutions.  There may be multiple fitness functions.  
For instance a simpler solution may be deemed to be a fitter solution, and algorithms with 
multiple objectives (multiple fitnesses), as in this work, are known as multi-objective 
evolutionary algorithms.  Multi-objective evolutionary algorithms (EA) allow for the 
specification of multiple and distinct optimization objectives and their simultaneous 
handling 13-15.  Based on the fitness(es), a selection step determines which individuals will 
be allowed to remain under consideration for the next generation.  Some of these 
individuals are retained by simply being copied unchanged into the subsequent 
generation(s), but new diversity, based on the parents selected, is then produced from them 
by processes analogous to mutation and recombination.  The fitnesses of these new 
individuals are then evaluated as above, and the algorithm continues cycling through the 
steps of selection, breeding and fitness evaluation until an acceptable solution is found.  
Decades of research within the field of evolutionary computing (e.g. 16,17) have revealed 
that optimization of multivariate problems can be highly effective using small numbers of 
experimental tests.  Although the present study used an EA and an adaptive dose matrix 
search strategy, we recognize that other kinds of combinatorial optimization approaches 
might also prove effective.  
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Using a ‘reverse’ combination chemical genetic approach 10 our aim was to optimize 
combinations of reagents that minimize LPS-induced macrophage IL-1β expression, and 
simultaneously minimize the number of component reagents in the combination and their 
propensity to induce macrophage cell death.   Subsequently we sought to optimize reagents 
to inhibit IL-1β expression at concentrations lower than the component reagents used in 
isolation.  This was achieved by application of an EA-directed, semi-automated robotic 
assay of IL-1β expression to a dynamic chemical library of a total of 33 reagents (see 
Methods, and also 18-20).  The specific algorithm used here was the Indicator Based 
Evolutionary Algorithm (IBEA) 21, as in preliminary simulations 22 this proved superior to 
a variety of other multi-objective optimization algorithms. This was followed by a dose 
matrix search of top-ranked reagents resulting from the EA-directed search.  We 
demonstrate that the EA converges efficiently on good solutions, and that dual p38 MAPK 
inhibition and either IκB kinase inhibition or iron chelation yields synergistic and 
biologically-relevant inhibition of macrophage IL-1β expression.  
 
 
Results 
 
Rapid convergence of Multi-objective IBEA to near-optimal solutions  
 
Concentration-effect curves for a selection of reagents with known or predicted targets in 
the IL-1β expression network were determined in order to identify the most appropriate 
concentration for use in the EA (Supplementary Fig. 2). On the basis of these data we 
selected a sub-optimal dose (3µM) which would provide scope for observing combinatorial 
synergy. 
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The Indicator Based Evolutionary Algorithm (IBEA) 21 directed a semi-automated robotic 
assay utilizing chemical combinations to inhibit IL-1β expression was initialized (Fig. 1, 
Loop 1).  As described in Methods (Implementation of the Indicator Based Evolutionary 
Algorithm (IBEA)), the IBEA generates subsets of combinations from the library and then 
assesses the performance of these subsets with respect to inhibition of IL-1β expression, 
decreases in LDH release (a marker for cell death) and the number of member reagents 
within the combination.  In the present case, we confined the number of experiments in 
each of the first and subsequent generations to 50 and those for generation 1 were selected 
randomly by the EA from the first-generation library of chemicals.  Superior combinations 
are retained and recombined with other library components in successive subsets and 
assessed iteratively until satisfactory combinations are found.  Assay of successive 
generations of chemical combinations from a dynamic chemical library (a total of 33 
reagents, each at a concentration of 3 µM, see supplementary methods) revealed their 
convergence towards a set of highly effective cocktails (Fig 2; see also Supplementary Fig. 
3 and Supplementary Table 3 and 4 (top) for data on the individual generations).  In 
addition, Supplementary Spreadsheet 1 gives all of the data on both reagent combinations 
and experimental measurements in tabular form. 
 
Convergence of solutions derived from the IBEA’s search of the chemical library was 
assessed by measuring the population average rank of the IBEA hypervolume (see 
supplementary methods) and the three objective functions (IL-1β expression, number of 
component reagents within combinations and LDH release (Fig. 3).  The observed plateau 
in IL-1β expression between generations 9 and 10 and very marginal decreases in LDH 
decrease (Fig 3 top and bottom left respectively) were triggers to halt the IBEA-directed 
search. By this stage, although not provably globally optimal, almost all IL-1β expression 
had been ablated by some combinations, with negligible toxicity. 
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A particular strength of this algorithm is the ability to add and remove reagents to/from the 
library during the evolution of the combinations 23 (see supplementary methods – reagent 
removal / addition and data analysis), and generations 10 and 11 explored these a little 
further.  We also noted that many of the more successful reagent combinations contained 
the p38 MAPK inhibitor SB203580.   
 
Post-hoc analysis of the IBEA search of combinatorial chemical space  
The search of combinatorial chemical space yielded 51 and 188 reagent combinations that 
exhibited an inhibition of IL-1β expression that was greater than or equal to either 95 % or 
70 % of the control response, respectively (Supplementary Table 3 and 4, (Top)) across all 
generations.  We chose to explore the inhibitory activities of other reagents independently 
of SB203580 because these effects might have been ‘masked’ in the EA by the dominance 
of SB203580 (70% (35/50)) of sampled combinations at generation 10 contained 
SB203580).  Thus, a ‘post hoc’ analysis was conducted of all data to assess the fitness 
contributions of single reagents (their overall score against our defined objectives) alone 
and in two- and three- component combinations (in the presence and absence of 
SB203580) for all reagents (Fig. 4 and see Methods).  These component reagents included 
the p38 MAPK inhibitor (SB203580), a sphingosine kinase inhibitor, (SKI-II), a statin 
(simvastatin), an iron chelator (SIH) and an inhibitor (BMS-345541) of the inhibitory κB 
kinase (IKKi).  Inhibitors of p38 MAPK and IKK are well established as inhibitors of IL-
1β expression, and (as well as its effects on HMG-CoA reductase) simvastatin is a known 
anti-inflammatory and an abundance of evidence implicates poorly liganded iron in 
inflammatory processes 24,25. However, the appearance of SKI-II may have been 
unexpected, albeit that there is evidence for the involvement of at least one sphingosine 
kinase in inflammation 26.  Despite the appearance of both wortmannin and the 
mitochondrial uncouplers in the post-hoc analysis, these compounds were not pursued 
further owing to their lack of specificity and potential toxicity, respectively.  The ability to 
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observe substantial inhibition of IL-1β expression with just pairs of inhibitors 
(Supplementary Table 3 and 4 (bottom)) led us to study the concentration-dependent pair-
wise optimization of the top-ranked reagents. 
 
Concentration-dependent search reveals combinatorial synergism 
The search over defined concentration ranges of all pairs of five top-ranked reagents was 
assessed using an adaptive dose matrix search protocol (Figure 1, Loop 2 and 
Supplementary Fig. 4).  Briefly, this protocol adaptively changes the concentrations of 
chosen reagents (See methods and compare SB203580 and SIH (Supplementary Fig. 4) 
versus the same combination presented here (Fig. 5)).  Reagents were assessed alone and in 
pairs (Fig 5).  Modes of pharmacological effect driven by reagent combinations have their 
own nomenclature 27-29.  Hence, additivity is the linear superposition of two different 
reagent effects and synergy a non-linear (excess) inhibition from a reagent combination 
beyond that expected for simple additivity 27.  Evidence of synergy (Fig 5(IKKi; c) or 
5(SIH; f)) was determined by subtraction of predicted additive effects (Fig 5(IKKi; b) or 
5(SIH; e)) of each combination (based on single reagent efficacy) from the actual 
experimental data (Fig 5(IKKi; a) or 5(SIH; d)).  Synergy was observed for most 
combinations; however, we noted in some instances that this was in fact attributable to a 
loss of a potentiating effect on IL-1β expression that occurred with either of the reagents 
when used alone. In these cases, the net (i.e. resulting) magnitude of IL-1β inhibition was 
minimal and therefore we focus here on examples of combinatorial synergy generating 
biologically-relevant levels of IL-1β inhibition.  SB203580 (0.1 µM) and IKKi (1 µM) 
alone inhibited IL-1β expression by 28 ± 7 % and 12 ± 9 % respectively (mean ± SEM, 
n=7) and SB203580 (0.1 µM) and IKKi (1 µM) in combination achieved significantly 
greater inhibition than did either drug alone (59 ± 5 %, n=7, p< 0.02 and p< 0.0005, one 
way ANOVA with Tukey’s multiple test correction versus SB203580 or IKKi alone 
respectively). The inhibitory effect of SB203580 (0.1 µM) and IKKi (1 µM) in 
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combination was 19% greater than that predicted for a purely additive effect thus 
demonstrating a marked synergistic interaction at these concentrations (Fig. 5(c)). 
Similarly, SB203580 (0.1 µM) and SIH (3 µM) alone inhibited IL-1β expression by 31 ± 
10 % and 19 ± 8 % respectively (n=7 plates) and combinatorially inhibited IL-1β 
expression by a significantly greater magnitude (59 ± 4 %, n=7 plates, p<0.04 and p< 
0.004, one way ANOVA with Tukey’s multiple test correction versus SB203580 and SIH 
alone, respectively).  This combinatorial inhibitory effect was 9% greater than that 
predicted for pure additivity therefore indicating a synergistic interaction (Fig. 5(f)).  We 
also observed marked synergistic effects for combinations of IKKi and SKI-II, IKKi and 
SIH and SB203580 and SIH (Supplementary Fig. 4), To assess whether a triple 
combination of SB203580, IKKi and SIH could provide an inhibition of IL-1β expression 
beyond the synergy already observed for both paired combinations (i.e SB203580 with 
either IKKi or SIH) we superimposed increasing concentrations of SIH (0, 0.1, 0.3, 1 and 3 
µM) onto SB203580 and IKKi dose matrices (Supplementary Fig. 5).  We did not observe 
any further synergy with the triple-combination. 
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Discussion 
There is a growing recognition that drugs, to be effective whether singly or in combination, 
must affect multiple steps simultaneously 7,10,30,31. This, however, leads immediately to a 
combinatorial explosion of experimental possibilities that limits the number of drugs that 
can reasonably be tested exhaustively. We have applied a multi-objective evolutionary 
algorithm (EA) to the optimization of reagent combinations, using a panel of candidate 
reagents selected from our own studies and the literature 32 as targeting the pro-
inflammatory IL-1β expression network.  The objective assessment of reagent 
combinations arising from the IBEA-directed search utilizing the ‘post hoc’ analysis of 
reagent fitness contributions is useful as it removes a layer of decision making 20, reducing 
bias and potentially enhancing ‘hidden’ phenomena (e.g. off target effects of reagents) that 
may have beneficial effects on the system output (i.e. IL-1β expression). In this regard, it is 
worth mentioning the increasingly effective use of adaptive dosing regimes in clinical trials 
of pharmaceutical drugs both singly and in combinations 33. 
 
Combination therapy is now returning to the fore with a greater understanding of 
pharmacological mechanism being uncovered by advances in parallel measurements of 
biological endpoints 11,34,35   The use of the Gur-game stochastic search algorithm has been 
reported 36,37 in elucidating the anti-viral and NF-κB-activating efficacy of drug and 
cytokine combinations, respectively.  Briefly, this algorithm functions by generating a 
random number (e.g. one representing a specified anti-viral activity) and switching the 
concentration of component drugs if their efficacy is below this value.  In contrast, 
stochastic and deterministic elements of our search were based on experimental data output 
and recombination of reagents in new cocktails that had not yet been evaluated.  In 
addition, the multi-objective nature of the EA-driven search presented here allows 
assessment of a number of biological endpoints. Following this approach with an adaptive 
dose-matrix driven search enabled a search of pharmacological space using just top-ranked 
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‘hits’. Applications of search algorithms and the use of machine learning in the 
optimization of combinatorial therapies have recently been reviewed 38, and within their 
categorization our method would fall into “E – Model-free Biological Search”. 
 
Recently, two papers have cited the pairing of reagent combinations as indicative / 
predictive of higher order effects 39,40.  The latter 40 used a series of chemotherapeutic 
reagents to monitor for additivity, antagonism or synergy of combinations on YFP-tagged 
protein dynamics in the H1299 cell line.  The authors propose that a linear superposition of 
weighted sums from the effect single drugs have on protein dynamics can predict higher 
order (i.e. combinatorial) effects for these reagents, although they were unable to 
demonstrate this for Wortmannin (a PI3K inhibitor).   
The former 39 looked for an enhancement in the [Ca2+]i signal of platelets using a pairwise 
agonist scanning approach of six reagents at three different concentrations.  Using these 
data the authors trained a neural network model to predict higher order effects and were 
successful in doing so.  However, the rapid and non-transcriptional signal transduction 
required for Ca2+ mobilization may not be entirely reflective of multi-protein signalling 
networks, where there is extensive cross-talk and feedback loops that modulate responses 
on timescales ranging in minutes to hours and beyond.    
In the present case, we found a substantial inhibition of IL-1β production by the p38 
MAPK inhibitor SB203580, that was enhanced synergistically by either the IKK  inhibitor 
BMS 345541 or the iron chelator SIH 41.  Perhaps surprisingly, the triple combination of 
SB203580, IKKi and SIH did not reveal additional effects beyond those observed for 
pairwise combinations of SB203580 and either of the other two reagents.  The effects of 
iron chelation are of especial interest here, as there is abundant but widespread evidence 
for the role of unliganded iron in a variety of inflammatory disorders 24,25,42.   
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p38 inhibitors have proved disappointing in clinical trials, but this is not so much because 
they are not active in vivo but because (at the doses used) they lose specificity for the α 
isoform of p38 and are toxic 43. The particular benefit of the synergy when combining a 
p38 inhibitor such as SB203580 with BMS345541 or SIH observed here is that we can use 
them at lower concentrations in combinations than those at which they would be used 
alone (Fig 5). We note too that such inhibitors seem not to have been designed to exploit 
the specificity of pharmaceutical drug transporters 44. Finally, it was noted too the efficacy 
of some combinations that did not involve the p38 inhibitor. 
 
In conclusion, the application of an EA in conjunction with semi-automated assay of a 
dynamic chemical library enables a rapid scanning of reagent combinations without the 
need of initial hypotheses 45 about likely higher-order effects.  Our results show that 
synergistic combinations can be revealed quickly, and that these combinations survived 
further experimental scrutiny, leading to pairwise combinations that seem promising to use 
in practice.  Synergism of the SB203580 and either IKKi or SIH combination presented 
here, in contrast to the comparatively marginal effect of the individual reagents at the same 
concentrations, shows that pharmacological modification of biological targets and 
processes may be effected at concentrations that are more likely to avoid toxicities.  This 
has particular relevance to the treatment of chronic inflammatory conditions such as 
irritable bowel syndrome46 and chronic obstructive pulmonary disease 47 where treatment 
may be maintained for extensive periods.  Our approach is essentially generic, and the time 
required per generation is determined by the time needed for setting up and running the 
assays (typically 3 days, one each for cell preparation, combination preparation and ELISA 
analyses), since the time needed for the algorithm to analyse the results and then to choose 
the cocktails for the next generation was negligible in comparison.  Overall, our new 
method substantially decreases the time taken for the triage of pharmacologically useful 
chemical diversity within chemical libraries 48.  Additionally, we demonstrate how 
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combinations of known drugs or reagents could allow them to be repurposed 49 and could 
provide an elegant adjunct to existing therapeutic strategies in chronic inflammatory 
conditions.  
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Methods 
All procedures, protocols and methods were carried out under aseptic conditions where 
deemed necessary. 
 
Construction and composition of the chemical library  
 
The choice of reagents with which to populate the chemical library searched here was 
guided in part by Oda and Kitano’s TLR signalling network 32 and via identification of 
suitable ligands from single reagent studies in peritoneal macrophages.  The following 
pharmacological classes of reagents were used:  Iron chelators, TPEN; a zinc chelator,   
anti / pro-oxidants, NADPH oxidase inhibitors, PI3Kinase inhibitors, MAPK pathway 
inhibitors, NF-κB pathway inhibitors, Genistein; a tyrosine kinase inhibitor, mitochondrial 
uncouplers (removed after generation 3), statins and small-GTPase inhibitors.  In the 
evolutionary optimization process each of these reagents corresponds to a single binary 
variable indicating whether the reagent is included in a combination or not; the 
combination itself represents a candidate solution to the problem.  Detailed information 
regarding the construction, storage, maintenance and removal and replacement of reagents 
within the chemical library can be found in the supplementary methods (Reagent removal / 
addition and data analysis). 
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Implementation of the Indicator Based Evolutionary Algorithm (IBEA) 
 
In order to select a suitable multi-objective evolutionary algorithm (EA) for addressing the 
search of the fitness landscape of the chemical library, a comparison of four EAs; IBEA, 
SPEA2 and NSGA2 with binary tournament and NSGA2 with probabilistic selection 50 
was undertaken 23.  All EAs were assessed on a family of test problems used to simulate 
the reagent combination problem.  The test problems model a scenario where 
pharmacological interactions among reagents can be described by single, binary, and 
ternary effects only.  A reagent combination can effect minimal IL-1β expression by 
killing cells; measured as a large release of LDH.  To de-risk the detection of lethal versus 
effective and benign combinations respectively, positive, negative, and no correlations 
were considered between these two objectives.  The different levels of correlation were 
realized by assigning certain probabilities to effect values; first for IL-1β expression and 
dependent on this value a subsequent probability determining an effect value for the LDH 
release.  Depending on the correlation level, the effect values were drawn uniformly from 
the interval [-1,0) and/or (0,1]. 
 
All EAs tested were capable of locating combinations of compounds of similar quality in 
the presence of 80 % and 10 % variability in IL-1β expression and LDH release 
measurements respectively.  However, IBEA had the best performance at finding effective 
compound combinations that contained only a few compounds (although its search was 
unrestricted and could have used any number of compounds).  This was the only EA tested 
that was not based on Pareto ranking; rather IBEA searches for those solutions that 
maximize their hypervolume within objective space.  Initialization of the 1st generation of 
reagent compounds in IBEA was conducted by fixing the probability of compound 
selection to 3 / 33 to ensure a random selection of compounds from across the library, with 
on average three compounds in a cocktail.  See the Supplementary methods (IBEA directed 
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evolutionary search of combinations inhibiting IL-1β expression) and results 
(Supplementary table 2) for other details of the algorithm and its parameters. 
 
Production and assay of reagent combinations 
 
A Sciclone ALH3000 laboratory robot (Caliper Life Sciences) under the indirect control of 
an Indicator Based Evolutionary Algorithm (IBEA) enabled the semi-automated assay of 
chemical combinations (Supplementary methods – Production of combinatorial chemical 
cocktails) in LPS stimulated J774.A1 macrophages.  The iterative searching and analysis of 
incremented generations of combinations was conducted via measurements of an IL-1β 
expression ELISA (R&D Systems; DY401) and LDH release (Promega) (see 
Supplementary methods – Measurement of LDH and IL-1β expression). 
 
Treatment of Peritoneal and J774.A1 macrophages with single reagents and 
combinations 
 
Peritoneal and J774.A1 macrophages were prepared and cultured (see supplementary 
methods) for either single reagent or combinatorial and dose matrix studies respectively.  
Peritoneal macrophages were exposed to either single reagents (0.01 µM - 100 µM) or 
DMSO (0.5 % v/v) for 0.5 h prior to stimulation with LPS (1 µg / mL).  Similarly, J774.A1 
macrophages were treated with chemical combinations (3 µM or varying concentration) or 
DMSO (0.5 % v/v or 0.1% v/v) during the EA-directed and adaptive dose-matrix search 
respectively for 10 min prior to stimulation with LPS (1 µg / mL).  After 4 h (Peritoneal) or 
2 h (J774.A1) aliquots of well supernatants were taken for the measurement of LDH during 
single-reagent and EA driven combinatorial assessment respectively (see supplementary 
methods) prior to disposal of remaining supernatant, lysis of cells and freezing before 
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measurement of IL-1β expression (see Supplementary methods – Measurement of LDH 
and IL-1β expression). 
 
Post-hoc analysis of IBEA search and calculation of reagent fitness  
 
Calculation of the fitness contribution of a single reagent within a combination was 
assigned as follows (1):   
 
−−
−= ni XXF 1           (1) 
 
Where; Fi is the fitness contribution of any given single reagent (i), and where 1
−
X  and 
−
nX are the mean IL-1β expression values of all combinations where this single reagent (i) 
was present or absent respectively.  Thus, a larger fitness contribution Fi indicates that a 
reagent is more efficient in decreasing IL-1β expression., 
 
 
 
Concentration-dependent optimization of paired reagent combinations using an 
adaptive dose matrix search protocol 
 
Upon completion and post-hoc prioritization of reagent combinations from the IBEA 
search a concentration-dependent optimization step was implemented.  Briefly, to assess 
the potentially synergistic effects of paired combinations on IL-1β expression we serially 
and logarithmically decreased the test concentrations of reagents from those used during 
the EA-directed search.  Similarly, after this initial optimization step, we extended the 
scanned concentration ranges of promising combinations by adding in test concentrations 
of reagents at approximate 0.5 log10 spacings within the dose-matrix.  This allowed effect 
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(i.e. IL-1β expression) comparisons at multiple doses of paired reagents.  Pseudocolor 
mappings were performed by linear interpolation between samples; those mappings that 
move away from the blue end of the spectrum within combination response shape plots are 
indicative of synergistic inhibition of IL-1β expression between two reagents. (Figure 5, 
Supplementary Fig 4).  
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Figure legends 
 
Figure 1.  Combinatorial evolutionary inhibition of IL-1β expression (Loop 1, clockwise, 
black arrows).  Known drugs were tested alone before being used at a single concentration 
(3µM) in a chemical library.  Initialization of the Indicator Based Evolutionary Algorithm 
(IBEA) creates a random selection of combinations that are incubated with stimulated cells 
before measurement of cell death (LDH release) and IL-1β expression.  Evaluation of these 
data against the number of compounds in the combination (All data n = 3) is performed by 
IBEA prior to a new generation of combinations being computed and tested.  After 11 
generations, concentration-dependent optimization (Loop 2) of five top-ranked reagents 
was undertaken.  Synergy was detected in novel dual-combinations. 
 
Figure 2.  Analysis of successive generations (Generations 1; initialization, 5 and 10) of 
reagent combinations reveals their convergence to a subset of highly effective 
combinations reflecting the inhibition of IL-1β expression with concomitant decreases in 
LDH release and the number of member reagents.  All data presented are the means of 3 
determinations.  Data points appearing as zero on the number of (#) reagents axis were 
reflective of positive control responses (LPS (1 µg / mL) and DMSO (0.5 % v/v). 
 
Figure 3.  Population average rank for inhibition of IL-1β expression (top left), number of 
component reagents in combinations (top right), LDH release (bottom left) and overall 
IBEA hypervolume (bottom right) respectively.  Error bars are the standard errors.  The 
IBEA hypervolume is a composite (see Methods; Implementation of the Indicator Based 
Evolutionary Algorithm (IBEA)) of the performance of the different generations with 
regard to the three objectives, a smaller number being better. 
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Figure 4.  Analysis of all EA generations (1 – 11) in the presence (top) and absence 
(bottom) of SB203580 yielded a rank order for the fitness contribution (see Methods; Post-
hoc analysis of IBEA search and calculation of reagent fitness) of each reagent within the 
library.  Only five top ranked reagents are displayed here either alone (i.e. single) or in 
double or triple combinations in the presence and absence of SB203580.   
 
Figure 5.  Concentration-dependent adaptive dose matrix optimization of paired reagent 
combinations was achieved by adaptively changing the concentrations of reagents after 
assessing the inhibition of IL-1β expression.  A p38 MAPK inhibitor (SB203580) and an 
Iκ Kinase inhibitor (IKKi) (a) or an iron chelator (SIH) (d) were assessed alone and as 
paired combinations.  Potential synergy of the SB203580 & IKKi (c) and SB203580 & 
SIH (f) combinations were revealed by subtraction of simple additive effects ((b) and (e); 
calculated from single reagent data in the absence of the other reagent respectively) of the 
respective combinations from the experimental data (a) & (d).  Synergistic inhibition of IL-
1β expression was revealed with the combinations of SB203580 & IKKi (c) and SB203580 
& SIH (f) as an ‘extra’ inhibition additional to the additive inhibitions of the individual 
reagents taken together.   
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SUPPLEMENTARY METHODS 
All procedures, protocols and methods were carried out under aseptic conditions where 
deemed necessary. 
 
SINGLE REAGENT STUDIES 
Preparation of primary peritoneal macrophages 
 
Batches (4 per batch) of C57BL/6J male mice (6 - 8 weeks old) were sacrificed by rising 
carbon dioxide asphyxiation in accordance with schedule 1 of the Animals (Scientific 
Procedures) Act 1986 as issued by the Home Office, U.K.  Slow intra-peritoneal (i.p) 
injection of pre-warmed (37°C, 8 mL) supplemented Dulbeccos Modified Eagles Medium 
(DMEM: penicillin and streptomycin (5 µg / mL); and foetal calf serum; 2.5%) was 
performed into the abdominal area of cadavers.  Peritoneal lavage was carried out and an 
incision made into the abdominal surface to create a pocket to drain the lavage fluid.  
Lavage fluid was aspirated using a hypodermic syringe and titrated into a conical tube (15 
mL).   
 
A cell count of peritoneal macrophages was conducted using an Improved Neubauer 
haemocytometer.  Macrophages were discriminated (large, circular, phase bright) from 
other cell types by their morphology.  Lavage fluid was centrifuged (250g, 5 min) and the 
resultant pellet re-suspended in fresh, pre-warmed (37°C) DMEM to a cell concentration of 
5.0 X 105 cells / mL.  Aliquots (200 µL) of cell suspension were subsequently pipetted into 
96-well plates (Costar, Corning; 3596) to ensure 100,000 cells / well.  Plates of cells were 
maintained at 37°C in a humidified 95 % O2 / 5 % CO2 atmosphere for up to 96 h prior to 
use.   
   
5 
Preparation of single reagents and lipopolysaccharide (LPS) stimulation of 
macrophages for assessment of inhibiton of IL-1β expression 
 
Stock reagents (Supplementary table 1) were prepared gravimetrically wherever possible, 
reconstituted to 20 mM in dimethylsulphoxide (DMSO) and serially diluted in log10 
spacings in DMSO down to concentrations of 2 µM.  The five stock concentrations of 
reagent were further diluted (1 : 20) into DMEM at 10 X their final concentration (0.1 µM 
- 1 mM).  Peritoneal macrophages were exposed to reagents for 30 min prior to LPS 
stimulation.  LPS (Sigma, serotype O26: B6) was diluted from a 1 mg / mL stock (in 
Phosphate Buffered Saline; PBS). LPS stimulated reactions were terminated after 4 h by 
addition of homogenising buffer (pH 7.6, 0.02 % NaN) supplemented with Triton X-100 (1 
% v/v) and protease inhibitor cocktail (1 % v/v; Calbiochem).  Plates were left on ice with 
regular agitation (to ensure maximal lysis of cells) for 20 min prior to freezing.  
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IBEA DIRECTED EVOLUTIONARY SEARCH OF COMBNATIONS INHIBITING IL-
1β EXPRESSION 
Multi-objective optimization of a chemical library and the implementation of an 
evolutionary algorithm: IBEA. 
 
A multi-objective optimization problem (MOOP) of generic form can be defined as1:   
 
Minimize 
 
)).(,),(),(()( 21 xfxfxfxf m
ρΚρρρ =    subject to xρ in X  (1) 
 
where xρ= (x1,...,xn) is a solution vector (here representing a particular combination of 
reagents) consisting of n decision variables (i.e. different reagents) for which values must 
be found and X the feasible search space.  The function f:X → Y represents a mapping from 
X into the objective space Y in Rm.  In general, a MOOP admits no single optimal solution, 
but rather a set of optimal trade-off solutions exist (also called Pareto-optimal solutions), 
none of which can be improved in all objectives simultaneously. The aim is to find this 
solution set, or an approximation of it, called the approximation set.  
 
Our solution vectors represent whether or not to include a particular reagent in a 
combination or not (the concentration of reagents is fixed), and there are no constraints 
restricting the search space, hence the space X is binary or nx }1,0{∈ρ where n is the number 
of reagents.  A 1 in the vector at position j means that the jth reagent is included in the 
cocktail, a 0 means do not include it.  There are three objectives fi, i =1, 2, 3, to be 
minimized: IL-1β expression, LDH release and the number of component reagents in a 
given combination.  The aim of the search process is to find reagent combinations that 
display the best trade-off between these objectives.   
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The field of evolutionary computation has proposed several techniques to solve MOOPs 
efficiently: after preliminary experimentation, we settled on using the indicator-based EA 
(IBEA) 2. The aim of IBEA is find a set of Pareto-optimal solutions that that maximizes 
some unary performance measure (indicator), which here is the hypervolume of the 
objective space dominated by the approximation set. 
Our experimental run of IBEA used the parameters given in Supplementary Table 2 
To monitor the progress of the evolutionary search, we use a population average rank 
measure (Figure 1(C)).  This is a nonparametric statistic related to the familiar rank sum 
tests, Mann-Whitney U and Kruskal-Wallis. All reagent combinations evaluated up to the 
current generation G are labeled by the generation in which they were tested. These 
samples are then ranked by fitness, and, for each generation g=1 to G, the average of the 
ranks associated with generation g is computed. The standard error of these ranks is also 
shown in the plots. This ranking statistic is computed separately for each of the three 
objectives, and also for the IBEA indicator (i.e. the three objectives combined). 
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Construction, storage and maintenance of the chemical library 
 
Reagents were purchased from either Sigma-Aldrich, Tocris, Chembridge Cheng-Du 
Biopurify Phytochemicals or Merck Chemicals and displayed purities ≥ 95 % as assessed 
by HPLC or TLC (except SIH; ≥ 90 % assessed by NMR).  All compounds were prepared 
wherever possible gravimetrically and dissoluted into DMSO (Supplementary table 1) to a 
stock concentration of 15 mM.  Subsequently, reagents were pipetted into a DMSO 
resistant, 2.0 mL, 96 deepwell plate (Starlab, E2896-0200) and sealed with a chemically 
resistant silicone mat (Starlab, E2896 3200) before being stored in an airtight plastic box 
partially filled with silica gel (Fisher Scientfic, S/0761/53) and kept in the dark at room 
temperature.  Stock reagents were transferred periodically to new deep well plates to 
ensure their pharmacological integrity.  A list of reagents and associated information (i.e. 
physicochemical properties) is given in Supplementary table 1. 
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Production of combinatorial chemical cocktails 
 
The generation of poly-combinatorial mixtures of compounds was conducted using a 
Sciclone ALH 3000 Liquid Handling Workstation under the control of Maestro and 
HitPicking (v9.0) software (Both Caliper Life Sciences) running on a Windows XP 
platform on a personal computer.  Compound combinations were specified in a 'Hitlist.csv' 
file; each line specifying the source and destination plate locations on the ALH3000 deck, 
source and destination well identities (e.g. D1, H12) and the volume (in µL) of compound 
required for transfer from the source to the destination plate.  Populations of combinations 
and vehicle wells were constrained to 50 and 5 wells per plate respectively (with an 
additional 5 empty wells per plate) and randomly assigned to positions D1 – H12 across 
the plate to control for position-dependent plate effects (Supplementary figure 7) in 
accordance with the following equation (2). 
 
1)( −−= nkPi           (2) 
 
Where Pi is the probability of the ith well position being assigned to one of the following 
treatments: a combination well, vehicle well or empty well.  The total number of k wells 
available (i.e. in this instance; 60) and n the number of wells currently assigned to any 
treatment.  Low volume (≥ 5 µL) dispense operations were executed after higher volumes 
of solvent (≥ 90 µL) had already been pipetted to ensure complete dispensing of these low 
volumes.  Combinations were tested at a final concentration of 3 µM (The detail behind the 
serial dilutions of combinations and the % solvent at each step of the transfer are detailed 
in Supplementary figure 1).   
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Preparation of J774.A1 macrophages  
 
J774.A1 macrophages were a kind gift from Prof. Anne-Marie Suprenant to DB’s lab, used 
between passages 12 – 19 and maintained in Dulbeccos modified eagles medium (DMEM) 
supplemented with high serum (10%, FBS) and penicillin / streptomycin (5 µg / mL).  
Cells were split once 80 % confluency had been attained.  Briefly, cells were removed 
from the base of a T75 flask (Costar) by aspirating existing media and replacing with a pre-
warmed (37°C) aliquot (5 mL) of supplemented DMEM prior to using a cell scraper to 
remove the cell monolayer.  After counting the resulting cell suspension was centrifuged 
(250 g, 5 min), the supernatant discarded and the resultant pellet re-suspended in fresh, 
pre-warmed (37°C) high serum DMEM to a cell concentration of 6.5 X 105 cells / mL.  
Aliquots (200 µL) of cell suspension were subsequently pipetted into 96-well plates 
(Costar, Corning; 3596) and were maintained at 37°C in a humidified 95 % O2 / 5 % CO2 
atmosphere 24 h prior to use.  
 
Treatment of J774.A1 macrophages with chemical combinations 
 
Previously prepared J774.A1 macrophages were treated with either chemical combinations 
(all component compounds at 3 µM) or IKK inhibitor (100 µM) or DMSO (0.5 % v/v) 
alone for 10 minutes prior to stimulation with LPS (1 µg / mL) or PBS (0.1% v/v).   
Subsequently, cells were maintained at 37°C in a humidified 95 % O2 / 5 % CO2 
atmosphere for 2h.  After this time, triplicate wells on each plate were exposed to lysis 
buffer (20 µL, 1X final concentration, Promega) prior to being returned to the incubator for 
a remaining ten minutes.  Immediately after this time, aliquots (50 µL) of well supernatants 
were taken and pipetted into a new 96-well plate for the measurement of LDH release (see 
below).  Termination of IL-1β expression and lysis of cells was conducted identically to 
that during the single reagent studies.
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MEASUREMENT OF LDH & IL-1β EXPRESSION 
Lactate dehydrogenase (LDH) cell viability measurements 
 
This protocol is adapted from the recommended procedure provided with the CytoTox™ 
96 Non-Radioactive Cytotoxicity Assay kit (Promega ; G1780).  Well supernatants (50 µL 
aliquots) were pipetted into a fresh 96-well plate prior to the addition of aliquots (50 µL) of 
substrate mix and covering and wrapping of the plate with laboratory film (Parafilm) and 
foil respectively.  The plate was placed on a mini-orbital shaker (50 rpm) for 30 minutes 
and subsequent addition of stop solution (acetic acid; 50 µL) added to each well prior to 
reading on a plate reader (Biotek Synergy HT; single reagent studies or FLUOstar Omega 
for combinatorial studies respectively) at an absorbance of 490 nm (A490nm).  During single 
reagent studies, treated wells (LPS and compounds) were compared to control wells 
(DMSO alone) to assess if there had been a reduction in cell viability.  Assessment of 
treated wells during the combinatorial study was conducted by expressing the A490nm of 
each well to that observed from the mean A490nm (of triplicate wells) that had been exposed 
to lysis buffer and then normalising this value relative to that seen for positive control 
(quintuplicate) wells. 
 
IL-1β ELISA 
 
This protocol is adapted from the recommended procedure provided with the mouse IL-
1β/IL-1F2 DuoSet ELISA development kit (R&D Systems; DY401). Coating of 96-well 
plates (Maxisorp) with aliquots (50 µL) of rat anti-mouse IL-1β capture antibody (cAb; 4.0 
µg / mL) was conducted and the plates left on a mini orbital shaker (50 rpm) overnight to 
ensure an even coating of cAb on all wells prior to the analysis of macrophage lysates. 
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Plates coated with cAb were aspirated of their cAb solution, washed three times with wash 
buffer (PBS with 0.05 % v/v Tween 20) after which any remaining well contents were 
blotted onto an absorbent paper towel until dry.  This procedure was followed for all wash 
steps forthwith.  Following this, blocking buffer (PBS and 1 % w/v BSA, Sigma) was 
aliquoted (50 µL) onto all wells, after which plates were covered with laboratory film and 
placed on a mini orbital shaker (50 rpm) until dilutions for the IL-1β standard curve had 
been made. 
 
All IL-1β standards were made by reconstitution into lysis buffer (homogenising buffer 
supplemented with TX-100; 1% v/v).  A recombinant mouse IL-1β standard (360 ng / mL, 
3 µL) was diluted (537 µL) to produce a final concentration of 2 ng / mL of a top standard 
(S1), this was further serially diluted by halving its concentration, this procedure was 
repeated to produce 9 standards in total, descending to a concentration of 7.8 pg / mL (S9).  
The blocked plate was subsequently aspirated of the blocking buffer prior to the aliquoting 
(50 µL) of samples and standards onto the plate   Plates were covered with laboratory film 
and placed on a mini orbital shaker (50 rpm) for 2 hours at room temperature (RT) prior to 
detection. 
 
Detection of bound IL-1β was carried out by aspirating plate wells of their samples and 
standards.  A biotinylated goat anti-mouse IL-1β detection antibody (dAb; 108 µg / mL) 
was diluted (10 µL) in blocking buffer (7.5 mL) to furnish a final concentration of (144 pg 
/ mL) and aliquoted (50 µL) onto all wells prior to covering with laboratory film and 
placing this plate on a mini orbital shaker (50 rpm) for 1 h.  Subsequently, plates were 
aspirated of their dAb solution, Streptavidin-Horse Radish Peroxidase (Strep-HRP) 
solution (50 µL) was diluted into blocking buffer (10 mL) and aliquoted (50 µL) onto 
wells before the plate was covered with laboratory film and foil and placing on a mini-
orbital shaker (50 rpm) for 20 mins.  3, 3', 5, 5' tetramethyl benzidine (TMB) substrate 
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reagents A and B were mixed in equal volumes (2.5 mL : 2.5 mL) in a foil covered tube 
(15 mL), plates were aspirated of their Strep-HRP solution and aliquots (50 µL) of the 
mixed TMB substrate reagents added to all wells of the plate, covered with laboratory film 
and foil and left on a mini-orbital shaker for 20 min.  Finally, plates were incubated with 
aliquots (50 µL) of dilute sulphuric acid (1M) and the resultant chromophore measured at 
an absorbance of 450 nm (A450nm) and background subtracted for non-specific fluorescence 
by measuring at 570 nm (A570nm) on a plate reader (Biotek Synergy HT).   
 
Data analysis was conducted by normalizing absorbance readings to LPS (1 µg / mL) and 
DMSO (0.5 % v/v) positive controls in order to ascertain % inhibitions / potentiations of 
combinations.  In instances where the majority of wells had not exceeded the IL-1β 
concentration of the top standard (2 ng / mL) measured, a standard curve was constructed 
and IL-1β concentrations interpolated for sample wells.  However, in all cases % changes 
versus positive control responses are quoted.        
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REAGENT REMOVAL / ADDITION AND DATA ANALYSIS 
Removal and replacement of reagents within the chemical library during the IBEA 
search 
 
During the course of the evolutionary search it was necessary to remove and introduce 
reagents respectively into the chemical library.  A simulation study revealed that it is 
possible to substitute small numbers of reagents (< 5) without undue effects on the course 
of the evolutionary search3.  To this end, solutions where these single reagents were 
present after generation 3 were discarded from the retained elite solutions and a new 
generation (4) built.  Similarly, Epigallocatechin gallate (ECGC) and Simvastatin were 
added to the chemical library from generation 4.  Melatonin, was not introduced until 
generation 10, in order to compensate for this reagents late arrival into the library it was 
assigned a higher probability of selection (1 / 5) across all bits present. 
 
Data analysis 
 
Quantile-Quantile plots of the positive control (LPS & DMSO) responses plotted against 
theoretical quantiles drawn from a normal distribution confirmed the data were normally 
distributed (Supplementary Figure 8)4.   
Means and standard errors of the mean (SEM) of data are given as a function of the 
number of preparations of cells (where primary cells were used).  That is 2 - 4 animals 
were used per preparation or plate of cells (n=1). Measurements were averaged across a 
minimum of triplicate wells per batch.  Significance was assessed using a one-way 
ANOVA and appropriate post-hoc multiple comparison tests reporting significance at the 
P<0.05(*), P<0.01 (**) and P<0.0001 (***) levels.  
Means and standard error of the mean of data are given as a function of the number of 
plates of cells per generation tested and were used for making inferences about the relative 
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efficacy of combinations during the evolution directed and dose-matrix adaptive search 
strategies.  A statistical measure of assay quality; Z’-factor 5 was calculated retrospectively 
for each generation of combinations tested in accordance with the following equation (3). 
 
np
npZ
µµ
σσ
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−
+
−=
)(31'          (3) 
 
Where Z’ is an estimate of the size of the statistical effect, pσ) and nσ)  are the sample 
standard deviations of the positive and negative controls respectively and pµ
)
and nµ
)
.the 
sample means for positive and negative controls. 
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SUPPLEMENTARY RESULTS 
THE EFFECT OF SINGLE REAGENTS ON IL-1β EXPRESSION IN PERITONEAL 
MACROPHAGES 
 
We characterized the potency and efficacy of single reagents selected to affect nodes (i.e. 
signalling proteins and processes respectively in this context)within the TLR4 signalling 
network and thought important for the expression of IL-1β6 in LPS-stimulated murine 
peritoneal macrophages.  In total, 24 different reagents were assessed over a 0.01 – 100 
µM concentration range from the following pharmacological classes: NF-κB, MAPK and 
PI3kinase inhibitors, pro / anti-oxidants and iron chelators (which indirectly effect 
antioxidant activity7,8).  In summary, VK-28, α-tocopherol succinate, PDTC, SB203580, 
LY294002, U0126 and IKK inhibitor III were effective inhibitors of IL-1β expression at 
concentrations between 1 and 100 µM (statistically significant at P<0.05 (*) and P<0.01 
(**) levels by one-way ANOVA and Dunnett’s test; see supplementary methods and 
Supplementary Fig. 2).  Our subsequent experiments were designed to discover 
combinations of these reagents that have inhibitory effects at lower concentrations than 
when used in isolation.  A fixed concentration of 3 µM was adopted, that was broadly sub-
optimal in inhibiting IL-1β expression by any of these reagents used alone. 
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REAGENT & ASSAY QC / VALIDATION 
Reagent physicochemical properties 
 
In order to check whether there were common physicochemical parameters that may have 
influenced the biological activity of combinations within the search we attempted to mine 
these parameters for all reagents within the chemical library (Supplementary table 1).  This 
was made possible by the recent provision of the publically accessible ChEMBL database 
of bioactive drug like small molecules (https://www.ebi.ac.uk/chembl/) AlogP is a 
calculated measure of the partition coefficient or lipophillic character of a drug molecule 
and is a ratio of a molecule’s dispersion between organic solvent and aqueous phases.  
There was no obvious trend in AlogP for the prioritized reagents (i.e. SB203580; 3.88, 
SIH; 1.29 and Simvastatin; 4.63.) we derived from the IBEA search.  However, all shared 
similar polar surface area (PSA) estimates, higher numbers of hydrogen bond accepting 
(HBA) moieties versus their hydrogen bond donating (HBD) counterparts and no rule of 5 
(RO5) violations.  Unfortunately, owing to SKI-II’s absence from the ChEMBL database 
we were unable to derive parameters for this molecule.  Clearly, assessment of 
physicochemical parameters can form another criterion for proposing reagents to populate 
chemical libraries. 
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Assessment of assay discrimination 
 
The ability of the IBEA2 directed semi-automated robotic assay of chemical combinations 
generated to inhibit IL-1β expression was scrutinized retrospectively via calculation of the 
Z’-factor (see data analysis) statistic (Supplementary table 2 and Supplementary figure 6) 
to determine its ability to locate ‘true’ efficacious combinations and discriminate against 
trivial solutions.  Although in two instances (at generations 2 and 5) this statistic fell 
beneath the acceptable range 9 across all other generations the assay was judged to have 
been of an acceptable or excellent standard and further to this the mean and median values 
for this statistic were 0.33 and 0.35 respectively, indicating overall that the assay was of an 
acceptable quality.  In summary, this statistic in tandem with the canonical abilities of the 
IBEA to locate combinations in the presence of 80 % noise in IL-1β expression (see main 
paper; methods) point to a robust assay for determining novel combinatorial solutions 
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TABLES 
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Name  Supplier Cat# Purity 
(≥ %) 
Lot# Mwt Pharmacological 
Class* 
chEBI 
ID 
Parent 
Mwt 
AlogP PSA HBA HBD RO5 
alpha-tocopherol Sigma T3251 96.0 078K1882 430.7 Antioxidant 103345 430.7 10.44 29.46 2 1 1 
EGCG ChengDu Biopurify 
Phytochemicals 
E07018 99.3 E090715 458.4 Antioxidant 167987 458.4 3.10 197.36 11 8 2 
alpha-tocopherol 
succinate 
Sigma T3126 98.0 14H0063 530.8 Prooxidant 229103 530.8 10.30 72.83 5 1 2 
NAC Sigma A9165 99.0 80K13495 163.2 Antioxidant 120881 163.2 -0.58 105.20 4 3 0 
Rotenone Calbiochem 557368 98.0 D00055180 394.4 Antioxidant 102812 394.4 3.93 63.22 6 0 0 
TEMPOL Tocris 3082 NA 1A/85506 172.2 Antioxidant 292703 173.3 0.32 43.70 3 2 0 
Calpain III Calbiochem 208722 95.0 B29649 382.5 Enzyme inhibitor 131775 382.5 3.53 84.50 4 2 0 
CA-074 Sigma C5732 99.0 NA 383.4 Enzyme inhibitor 560554 383.4 0.26 128.34 6 3 0 
NS-398 Calbiochem 349254 98.1 D00017723 314.4 Enzyme inhibitor 439249 328.4 2.68 100.81 5 0 0 
GM-6001 Calbiochem 364205 98.0 B69073 388.5 Enzyme inhibitor 123466 388.5 1.62 123.32 4 5 0 
Melatonin Sigma M5250 99.0 098K1117 232.3 Hormone 103012 232.3 1.56 54.12 2 2 0 
Desferrioxamine 
mesylate 
Sigma D9533 100.0 128K1205 656.8 Iron chelator 330444 560.7 -0.89 205.83 9 6 2 
SIH Chembridge 5109995 90.0 610065 225.3 Iron chelator 434094 241.3 1.29 74.58 4 2 0 
VK-28 Sigma V4264 97.0 034K46251 287.4 Iron chelator NA       
SR11302  Tocris 2476 99.3 1A/89800 376.5 MAPK pathway 
inhibitor 
NA       
PD98059 Calbiochem 513000 98.0 D00048465 267.3 MAPK pathway 
inhibitor 
150222 267.3 2.37 61.55 4 1 0 
U0126 
monoethanolate 
Calbiochem 662005 98.0 D00058335 403.5 MAPK pathway 
inhibitor 
257660 380.5 2.18 202.26 8 4 0 
U0126 
monoethanolate 
Tocris 1144 99.4 4A/93229 426.5 MAPK pathway 
inhibitor 
257660       
U0126 
monoethanolate 
Tocris 1144 99.4 4A/97041 426.5 MAPK pathway 
inhibitor 
257660       
IRAK 1/4 inhibitor Calbiochem 407601 99.9 D00050155 395.4 MAPK pathway 
inhibitor 
449907 395.4 2.60 105.21 6 1 0 
IRAK 1/4 inhibitor Calbiochem 407601 99.9 D00057214 395.4 MAPK pathway 
inhibitor 
449907       
SP600125 Calbiochem 420119 98.0 D00002116 220.2 MAPK pathway 
inhibitor 
431500 220.2 2.99 45.75 2 1 0 
SB203580 Sigma S8307 98.0 029K4619 377.4 MAPK pathway 
inhibitor 
100250 377.4 3.88 77.84 3 1 0 
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Name  Supplier Cat# Purity 
(≥ %) 
Lot# Mwt Pharmacological 
Class* 
chEBI 
ID 
Parent 
Mwt 
AlogP PSA HBA HBD RO5 
SB203580 Tocris 1202 98.7 4A/93107 377.4 MAPK pathway 
inhibitor 
100250       
2,4-dinitrophenol Sigma D19,850-
1 
97.0 554589-308 184.1 mitochondrial 
uncoupler 
110392 184.1 1.38 111.87 5 1 0 
CCCP Sigma C2759 97.0 088K1511 204.6 mitochondrial 
uncoupler 
474035 204.6 2.47 71.97 4 1 0 
FCCP Tocirs 0453 99.0 2A/93205 254.2 mitochondrial 
uncoupler 
615435 254.2 3.92 81.20 5 1 0 
Apocynin Calbiochem 178385 99.9 D00055492 166.2 NADPH oxidase 
inhibitor 
364242 166.2 1.31 46.53 3 1 0 
diphenylene 
iodonium (DPI) 
Calbiochem 300260 100.0 D00057661 314.6 NADPH oxidase 
inhibitor 
491098 279.1      
IKK inhibitor III 
(BMS-345541) 
Calbiochem 401480 96.0 D00034862 255.3 NF-kB pathway 
inhibitor 
513905 255.3 1.00 68.23 4 2 0 
IKK inhibitor III 
(BMS-345541) 
Sigma B9935 98.0 077K462Z2 291.8 NF-kB pathway 
inhibitor 
513905       
PDTC Sigma P8765 99.0 1299391 / 
106K1856 
164.3 NF-kB pathway 
inhibitor 
521017 147.3 2.48 74.13 2 1 0 
CAPE Calbiochem 211200 97 NA 284.3 tyrosine kinase 
inhibitor 
271563 284.3 3.57 66.80 4 2 0 
Wortmanin Sigma W1628 99.0 029K4036 428.4 PI3-Kinase inhibitor 111985 428.4 1.71 109.11 7 0 0 
LY294002.HCl Sigma L9908 98.0 017K4616 343.8 PI3-Kinase inhibitor 257152 307.3 3.34 38.76 4 0 0 
LY294002.HCl Tocris 1130 99.4 3*A/93270 343.8 PI3-Kinase inhibitor 257152       
NSC23766  Tocris 2161 99.0 2A/93470 558.0 Small GTPase 
inhibitor 
525412 421.6 3.22 91.99 7 3 0 
Y27632 
dihydrochloride  
Tocris 1254 98.0 12A/92215 329.3 Small GTPase 
inhibitor 
150239 247.3 1.11 68.01 3 2 0 
di-methyl 
sphingosine 
Calbiochem 310500 98.0 D00033039 327.6 sphingosine kinase 
inhibitor 
277963 327.6 5.79 43.70 3 2 1 
SKI-II Calbiochem 567731 98.0 Unknown 339.2 sphingosine kinase 
inhibitor 
NA 
      
SKI-II Sigma S5696 99.0 077K46181 302.8 sphingosine kinase 
inhibitor 
NA 
      
Mevastatin Sigma M2537 95.0 0001423869 390.5 Statin 184814 390.5 3.97 72.83 5 1 0 
Simvastatin Calbiochem 1965 98.2 2B/96951 418.6 Statin 238562 418.6 4.63 72.83 5 1 0 
Genistein Sigma G6649 98.0 018K1203 270.2 tyrosine kinase 
inhibitor 
102658 270.2 2.14 86.99 5 3 0 
DMSO Sigma D8418 100.0 108K01864 78.1 Vehicle 110009 78.1 -0.32 36.28 1 0 0 
TPEN Sigma P4413 99.0 078K1429 424.6 Zinc chelator NA       
 Supple
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Supplementary Table 1.  Identities and physicochemical properties of reagents populating the chemical libraries used in the assessment of the 
effects of single reagents and evolutionary (IBEA) directed combinations on LPS stimulated IL-1β expression in peritoneal macrophages and 
J774 macrophages respectively.  Reagents highlighted in bold were utilized in both single reagent and combination studies.  Those reagents 
highlighted in red and italicised (i.e. CA-074, NS-398, GM-6001, PD98059 and CAPE) were not pursued during the course of the evolution 
driven search for combinations inhibiting IL-1β expression.  Discrepancies between ‘Molecular Weight’ (supplied by the manufacturer) and 
‘Parent Molecular Weight’ (provided courtesy of the ChEMBL database) fields are attributable to the salt form of the compounds (i.e. NS-398, 
Desferrioxamine Mesylate, SIH, U0126, diphenylene iodonium, LY294002 hydrochloride, IKK inhibitor III, NSC23766, Y27632 
dihydrochloride).  * Pharmacological class is an arbitrary assignation defining biological targets / processes where we assume these molecules 
will exert their effects in the TLR4 stimulated macrophage IL-1β signalling network. Cat#; catalogue number, Mwt; Molecular weight, chEBI 
ID; Chemical Entity of Biological Interest  (database) Identity, AlogP; calculated partition coefficient, PSA; polar surface area, HBA; number of 
hydrogen bond accepting moieties, HBD; number of hydrogen bond donating moieties, RO5; number of rule of five violations, NA; Not 
Identified. 
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Category Parameter Description 
Assay Type of assay In vitro, evolution directed (IBEA) semi-automated 
robotic assay utilizing chemical combinations to 
inhibit LPS stimulated J774.A1 macrophage IL-1β 
expression. 
 
 Target IL-1β, UniProt (IL1B_MOUSE; P10749) 
 
 Primary measurement IL-1β expression measured  via ELISA 
 
 Key reagents  All antibodies and proteins were obtained from R&D 
systems. 
 
Capture Antibody (Part 840134, 1 vial) - 720 µg / 
mL of rat anti-mouse IL-1β when reconstituted 
with 1.0 mL of PBS. 
 
Detection Antibody (Part 840135, 1 vial) - 
108 µg / mL of biotinylated goat anti-mouse IL-
1β when reconstituted with 1.0 mL of blocking 
buffer (see supplementary methods for recipe). 
 
Standard (Part 840136, 1 vial) - 360 ng / mL of 
recombinant mouse IL-1β when reconstituted with 
0.5 mL of blocking buffer. 
 
Streptavidin-HRP (Part 890803, 1 vial) - 1.0 mL of 
streptavidin conjugated to horseradish 
peroxidase. 
 
 Assay protocol This protocol is adapted from the recommended 
procedure provided with the mouse IL-1β/IL-1F2 
DuoSet ELISA development kit (R&D Systems; 
DY401)  
 
 Additional comments see supplementary methods 
Library  Library size 33 reagents in total, never exceeding 30 reagents 
during the course of the iterative, IBEA directed 
search. 
 
 Library composition Small molecule reagents: drug like inhibitor 
molecules of biological targets (e.g. NF-κB and 
MAPK inhibitors) and processes (e.g. redox 
reactions – antioxidants and iron chelators). 
 
 Source Sigma-Aldrich, Tocris, Chembridge Cheng-Du 
Biopurify Phytochemicals or Merck Chemicals 
 
 Additional comments see supplementary table 1 
 
Screen Format 96-well plates (Nunc; Maxisorp) 
 
 Concentration(s) tested All reagents evaluated either alone or in 
combinations at 3µM. 
 
 Plate controls Randomized quintuplicate positive control wells 
(LPS, 1µg / mL & DMSO, 0.5 % v/v) and negative 
control (C11) well (IKK inhibitor III, 100 µM) 
 
 Reagent/ compound dispensing system Sciclone ALH3000 (Caliper Life Sciences) 
 
 Detection instrument and software BioTek Synergy HT plate reader used for the 
measurement of the IL-1β ELISA absorbance (A450nm 
– A570nm) readings under the control of Gen 5 
software. 
 
FLUOstar Omega (BMG LabTech) plate reader was 
used for the measurement of LDH reaction 
absorbance (A490nm). 
 
 Assay validation/QC The median Z’ factor for the assay was 0.35 
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indicating the assay was acceptable. 
 
Plate edge effects were assessed by the heat 
mapping of randomized positive control wells (n = 3 
minimum / data point) (see supplementary figure 7). 
 
 Correction factors NA 
 
 Normalization J774.A1 cell IL-1β expression data was expressed 
as a percentage of the measured IL-1β 
concentration (pg / mL) interpolated from the 
standard curve for a given well / plate to the mean 
IL-1β concentration (pg / mL) derived from five 
positive control wells for that plate.  Populations of 
generations were assayed in plates in triplicate. 
 
 Additional comments See supplementary information; supplementary 
figure 6. 
 
Post-HTS analysis Hit criteria Objective evaluation of all combinations across all 
generations (i.e. generation 1 – 11) was performed 
by measuring (post-hoc) the fitness contribution of 
reagents from combinations and deriving a ranked 
list. 
 
 Hit rate Reagents were selected from top five ranked 
reagents when assessed either singularly or as 
double or triple combinations in either the presence 
or absence of the dominant solution (i.e. SB203580). 
 
 Additional assay(s) Concentration-dependent adaptive dose matrix 
search of paired combinations from five selected 
reagents. 
  
 Confirmation of hit purity and structure Manufacturer specification and certificates of 
analysis were used as confirmatory evidence of hit 
purity and structure. 
 
 Additional comments See supplementary information, particularly 
supplementary table 1 (confirming reagent identities 
& physicochemical properties) and supplementary 
figure 7 detailing the variation in positive control 
responses across the plate. 
IBEA parameter 
settings 
Population size 50 reagent combinations were generated by IBEA at 
each generation.  
 
 Parental selection  Solutions (parents) for reproduction were selected 
using binary tournament selection with replacement. 
 
 Crossover probability  Offspring were generated by applying uniform 
crossover with a probability of 0.7 to the selected 
parents. In situations where crossover is not applied, 
offspring are simply copied versions of the parents. 
 
 Per-bit mutation probability Each decision variable (reagent) of an offspring 
(reagent combination) was mutated or flipped 
independently with a  probability of 1/33 (i.e. on 
average one solution variable was flipped). 
 
 Additional comments Recall that the initial population was generated at 
random such that each reagent combination 
contains on average 3 reagents; i.e. any reagent of 
the library was included with a probability of 1/33 into 
a reagent combination. A more detailed explanation 
of IBEA including a pseudocode of the algorithm can 
be found in Reference 8. We use the adaptive 
version of IBEA from that reference. The value of  
the scaling parameter, κ, was 0.05, and the 
hypervolume reference point used was (2,2,2), as in 
the original source reference. 
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Supplementary Table 2.  Summary of the screening and EA parameter settings 
for the assay of the evolution directed (IBEA) semi-automated robotic production 
of chemical combinations inhibiting LPS stimulated J774.A1 macrophage IL-1β 
expression.   
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Generation Number of 
combinations per 
generation showing 
≥ 95% inhibition of 
IL-1β expression 
Mean number of 
component 
reagents per 
generation 
(rounded to integer) 
Mean fractional 
LDH release of 
combinations per 
generation 
2 1 3 0.96 
4 4 5 1.01 
6 8 5 1.08 
7 3 4 0.99 
8 1 4 1.00 
9 27 3 1.05 
10 3 5 1.00 
11 4 4 0.97 
 
Number of reagents per 
combination 
Mean inhibition of IL-1β 
expression for 
combinations where 
inhibition was already ≥ 
95 % of the positive 
control response  
Number of combinations 
7 98.51 4 
6 99.10 2 
5 99.09 8 
4 99.20 16 
3 98.93 13 
2 100.00 5 
 
Supplementary Table 3.  Characteristics of reagent combinations found from 
the IBEA directed search that inhibited IL-1β expression in the LPS stimulated 
J774 macrophages by ≥ 95% of positive control responses.  Overall, successive 
generations of reagent combination yielded decreases in the number of 
component reagents and fractional LDH release (Top).  Despite decreases in 
component reagent number the search still located five very efficacious dual 
combinations (Bottom). 
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Generation Number of 
combinations per 
generation showing 
≥ 70% inhibition of 
IL-1β expression 
Mean number of 
component 
reagents per 
generation 
(rounded to integer) 
Mean fractional 
LDH release of 
combinations per 
generation 
1 8 4 1.06 
2 5 5 1.03 
3 32 4 1.02 
4 12 5 1.02 
5 18 4 1.01 
6 29 4 1.04 
7 27 4 1.06 
8 24 4 1.04 
9 28 4 1.05 
10 32 3 1.01 
11 18 3 0.98 
 
Number of reagents per 
combination 
Mean inhibition of IL-1β 
expression for 
combinations where 
inhibition was already ≥ 
70 % of the positive 
control response  
Number of combinations  
8 90.52 1 
7 91.51 10 
6 89.92 18 
5 91.93 35 
4 92.29 57 
3 90.20 58 
2 87.88 34 
 
Supplementary Table 4.  Characteristics of reagent combinations found from 
the IBEA directed search that inhibited IL-1β expression in the LPS stimulated 
J774 macrophages by ≥ 70% of positive control responses.  Overall, successive 
generations of reagent combination yielded decreases in the number of 
component reagents and fractional LDH release (Top).  Similarly, despite 
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decreases in component reagent number the search still located thirty four dual 
combinations (Bottom). 
   
29 
FIGURES 
FinalMix
Robot Manual
3 µM
0.5 %
30 µM
5 %
600 µM
100 %
15 mM
100 %
[Compound] 
DMSO  (v/v)
Stocks
@
15 mM
 
Supplementary Figure 1.  Reagent dilutions and the percentage of DMSO in the 
semi-automated production of chemical combinations 
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Supplementary Figure 2.  Pharmacological activities of selected reagents on LPS (1µg / mL) stimulated IL-1β expression in mouse primary 
peritoneal macrophages.  Comparison of different treatments to positive control (LPS and DMSO) was assessed by means of a one-way 
ANOVA and a post-hoc Dunnett's multiple comparison test reporting significance at the P<0.05 (*) and P<0.01 (**) levels.  Data are expressed 
as mean ± SEM (n=3 preparations). 
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Supplementary Figure 3.  Efficacy of chemical combinations with respect to 
LPS stimulated (1µg / mL) IL-1β expression (upper plot per generation) and 
LDH release (lower plot per generation) in J774.A1 macrophages for all tested 
generations (Gen 1 – Gen 11).  Vehicle (PBS; 0.1 % v/v) and positive control 
(LPS; 1µg / mL & DMSO; 0.5 % v/v) responses were tested in triplicate or 
quintuplicate per plate respectively.  Negative control (LPS; 1µg / mL & IKKi; 
100 µM, except Gen 11 where IKKi; 3 µM data was substituted) responses were 
tested in single wells per plate.  Fifty combinations were tested per plate and all 
data is expressed as n = 3 plates per generation ± SEM. 
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Supplementary Figure 4.  Adaptive dose-matrix search of paired reagent combinations for potential synergy in their inhibition of IL-1β 
expression.  Combination response shape plots shown are for a fully enumerated search of all possible pair wise combinations of the five 
   
42 
reagents prioritized from the post-hoc analysis of the IBEA search (i.e. SB203580 & SIH, SIH & SKI-II, SB203580 & SKI-II, SB203580 & 
Simvastatin, SIH & Simvastatin, Simvastatin & SKI-II, IKKi &. Simvastatin, IKKi &. SKI-II, IKKi &. SIH).  Three plots are shown (from left 
to right) representing: the experimental data; simple additive effects of the combination calculated from single reagent data in the absence of the 
other reagent; and detection of synergy in the paired combination by subtraction of additive effects from the experimental data.  Pseudocolor 
mappings were performed by linear interpolation between samples.  All data are expressed as n = 3 - 4 plates. 
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Supplementary Figure 5.  Dose-matrix search of the triple reagent combination (SB203580, IKKi and SIH) for potential synergy in its 
inhibition of IL-1β expression.  Combination response shape plots show the effect of increasing concentration (by row) of SIH (0, 0.1, 0.3, 1 and 
3 µM)  Three plots are shown (from left to right) representing: the experimental data; simple additive effects of the combination calculated from 
single reagent data in the absence of the other reagent; and detection of synergy in the paired combination by subtraction of additive effects from 
the experimental data.  Pseudocolor mappings were performed by linear interpolation between samples.  All data are expressed as n = 5 plates. 
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Supplementary Figure 6.  Calculation of the Z’-Factor statistic retrospectively for the 
IBEA directed search revealed mean and median values of 0.33 and 0.35 respectively 
indicating overall that the assay was of an acceptable quality.  The Z’-Factor was 
determined by four parameters (see data analysis); positive and negative control, mean and 
standard deviation respectively.  At each generation there were 15 positive control wells 
and 3 negative control wells. 
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Supplementary Figure 7.  Pseudocolor heat mapping of positive control (LPS (1µg / mL) 
& DMSO (0.5 % v/v)) responses (% IL-1β expression) to plates of J774.A1 macrophages 
during the assay of chemical combinations from all generations (Gen 1 – Gen 11). 
Quintuplicate positive control responses were randomly assigned across wells (D1 – H12) 
for each generation tested.  Data are expressed as a % of the mean positive control 
response of the plate they were assayed on (n=5 wells) with purple colors representing high 
positive control responses to mauve representing lower responses.  Orange space 
represented wells that were not sampled. 
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Supplementary Figure 8.  Quantile-Quantile plots of the positive control (LPS & DMSO) 
responses plotted against theoretical quantiles drawn from a normal distribution confirmed 
the data were normally distributed. 
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Generation # Combination # Objective 3_# component reagents
Reagent_1 Reagent_2 Reagent_3 Reagent_4 Reagent_5 Reagent_6 Reagent_7 Reagent_8 Reagent_9 P1 P2 P3 P1 P2 P3
1 1  Diphenylene iodonium (DPI)  FCCP  22.60 31.89 38.34 1.02 1.04 1.03 2
1 2 TPEN  N-acetyl cysteine  tempol  SR 11302  CCCP  39.13 57.11 61.97 1.02 0.96 0.99 5
1 3 N-acetyl cysteine  110.53 125.92 118.35 1.00 0.96 1.09 1
1 4 rotenone  SR 11302  PDTC 2-4-dinitrophenol  mevastatin  NSC23766 (Rac1 inhibitor)  43.64 59.31 58.66 1.00 1.00 1.02 6
1 5 alpha-tocopherol  U0126  PD98059  61.30 71.90 85.43 0.99 0.98 0.98 3
1 6 VK-28  NSC23766 (Rac1 inhibitor)  110.53 104.65 120.11 0.99 1.00 0.99 2
1 7 DMSO     116.89 101.55 115.70 0.97 0.97 0.98 2
1 8 alpha-tocopherol  N-acetyl cysteine  U0126  mevastatin  Y27632 dihydrochloride (ROCK inhibitor)  27.01 41.16 88.83 1.06 0.97 1.03 5
1 9 SIH  wortmannin IRAK 1  FCCP  NSC23766 (Rac1 inhibitor)  9.52 22.03 13.80 1.16 1.06 1.05 5
1 10 tempol  apocynin  LY294002 hydrochloride  193.03 224.10 227.19 1.00 1.10 0.99 3
1 11 SIH  tempol  SR 11302  NSC23766 (Rac1 inhibitor)  130.53 129.92 121.00 0.87 0.97 1.08 4
1 12 desferrioxamine  116.18 131.53 132.59 1.00 1.00 0.98 1
1 13 alpha-tocopherol  LY294002 hydrochloride  mevastatin  172.93 180.36 155.31 1.00 0.99 0.96 3
1 14 alpha-tocopherol succinate  wortman in  CCCP  13.23 22.73 19.27 1.06 1.03 1.06 3
1 15 di-methyl sphingosine  81.43 83.93 87.99 0.98 0.98 0.98 1
1 16 U0126  PDTC  NSC23766 (Rac1 inhibitor)  35.92 46.93 44.79 1.00 1.00 0.96 3
1 17 rotenone  58.00 61.52 86.28 0.97 0.99 1.01 1
1 18 tempol  PDTC  SKI-II  25.75 40.45 31.93 1.01 0.96 0.97 3
1 19 SKI-II  28.91 41.89 39.95 0.99 0.97 1.04 1
1 20 desferrioxamine  SB203580  30.18 29.77 27.95 1.02 1.04 0.99 2
1 21 desferrioxamine  wortmannin  28.91 32.60 27.95 1.07 1.05 1.09 2
1 22 TPEN  alpha-tocopherol succinate  SKI-II 50.78 45.48 45.59 1.03 0.97 0.98 3
1 23 wortmannin  23.23 29.77 27.16 1.06 1.09 1.04 1
1 24 LY294002 hydrochloride  PD98059  genistein  FCCP  20.72 33.31 29.54 1.02 1.02 1.02 4
1 25 SIH  apocynin  SB203580  15.72 25.54 22.42 0.99 1.00 1.00 3
1 26 N-acetyl cysteine  LY294002 hydrochloride IRAK 1  SKI-II  di-methyl sphingosine 2-4-dinitrophenol  11.99 21.33 21.63 1.10 0.96 1.05 6
1 27 alpha-tocopherol succinate  U0126 IRAK 1  CCCP  11.99 19.94 13.80 1.06 0.99 1.08 4
1 28 apocynin IRAK 1  Y27632 dihydrochloride (ROCK inhibitor)  32.09 42.60 43.97 1.05 0.98 1.03 3
1 29 LY294002 hydrochloride IRAK 1  di-methyl sphingosine  32.72 48.38 52.92 1.05 1.12 1.03 3
1 30 alpha-tocopherol succinate  tempol   Diphenylene iodonium (DPI) SR 11302  61.96 86.20 98.28 1.00 1.02 1.03 4
1 31 apocynin  SKI-II  32.09 35.44 35.12 1.00 1.04 1.14 2
1 32 DMSO     126.20 134.75 127.23 1.03 1.05 1.02 2
1 33 alpha-tocopherol  tempol  U0126  PD98059  82.79 68.18 61.14 1.04 1.02 0.99 4
1 34 DMSO     109.11 116.40 138.89 1.00 0.98 1.00 2
1 35 alpha-tocopherol  LY294002 hydrochloride IRAK 1  65.29 63.73 58.66 1.02 0.98 1.02 3
1 36 PD98059  di-methyl sphingosine  geni tein  76.02 83.17 82.04 1.01 1.01 1.01 3
1 37 U0126  SR 11302  CCCP  21.34 19.94 36.73 1.02 1.00 1.04 3
1 38  Diphenylene iodonium (DPI)  SP600125  SKI-II  genistein  43.64 63.00 40.75 1.09 1.05 1.06 4
1 39 IKK inhibitor (BMS-345541)  54.71 51.27 62.79 1.03 0.98 1.04 1
1 40 alpha-tocopherol succinate   Diphenylene iodonium (DPI) wortmannin  di-methyl sphingosine  16.96 24.84 28.75 1.18 1.20 1.21 4
1 41 PDTC  di-methyl sphingosine  geni tein  FCCP  18.21 35.44 28.75 1.03 1.03 1.09 4
1 42 TPEN  genistein  134.16 133.95 167.37 1.00 1.02 1.05 2
1 43 U0126  PDTC  SKI-II 2-4-dinitrophenol  18.21 22.03 24.00 1.04 1.04 1.01 4
1 44 SIH  alpha-tocopherol  rotenone   Diphenylene iodonium (DPI) IRAK 1  SR 11302  PDTC  27.01 32.60 25.58 1.10 1.06 1.07 7
1 45 desferrioxamine  78.03 132.34 156.24 1.09 1.00 1.00 1
1 46 U0126  di-methyl sphingosine  geni tein  52.09 53.46 66.11 1.08 1.00 1.00 3
1 47 VK-28  wortmannin  16.34 34.74 25.58 1.19 1.15 1.10 2
1 48 tempol  CCCP  27.01 44.76 43.17 1.00 0.98 1.02 2
1 49 LY294002 hydrochloride  NSC23766 (Rac1 inhibitor)  114.06 105.43 252.46 1.07 1.05 1.03 2
1 50 genistein  110.53 142.05 101.74 1.01 0.99 1.06 1
2 1 LY294002 hydrochloride  289.30 202.58 156.58 0.99 1.01 0.98 1
2 2 U0126  PDTC  NSC23766 (Rac1 inhibitor)  91.26 69.62 59.74 0.97 1.08 0.99 3
2 3 N-acetyl cysteine IRAK 1  SKI-II 2-4-dinitrophenol  35.74 35.50 22.13 0.98 1.04 0.97 4
2 4 desferrioxamine  142.39 82.81 92.67 1.00 1.00 0.98 1
2 5 alpha-tocopherol  alpha-tocopherol succinate  U0126 IRAK 1  CCCP  mevastatin  23.26 24.66 7.51 0.96 1.08 1.03 6
2 6 diphenylene iodonium (DPI)  w rtmannin  mevastatin  28.44 42.79 17.50 1.04 1.19 0.98 3
Combination reagent composition Objective 1_%IL-1b Objective 2_cell death
2 7 tempol  U0126  PDTC  SKI-II  20.15 37.32 8.28 1.03 0.99 0.98 4
2 8 wortmannin 2-4-dinitrophenol  23.26 41.87 22.90 1.00 1.01 1.00 2
2 9 alpha-tocopherol  U0126  SKI-II  di-methyl sphingosine  geni tein 2-4-dinitrophenol  65.35 25.56 0.00 1.02 1.01 0.98 6
2 10 diphenylene iodonium (DPI)  i-methyl sphingosine  69.62 78.08 31.44 1.03 1.01 1.05 2
2 11 alpha-tocopherol  tenone  apocynin  102.21 85.65 74.11 1.05 1.05 1.05 3
2 12 alpha-tocopherol succinate  wortman in  69.62 65.88 73.31 1.08 1.14 1.11 2
2 13 SIH  LY294002 hydrochloride  w rtmannin IRAK 1  di-methyl sphingosine  geni tein  FCCP  NSC23766 (Rac1 inhibitor) 36.78 25.56 0.00 1.14 1.14 1.06 8
2 14 apocynin IRAK 1  Y27632 dihydrochloride (ROCK inhibitor)  69.62 51.05 42.38 0.97 1.00 0.96 3
2 15 alpha-tocopherol  U0126  PD98059  SR 11302  85.81 71.50 65.32 0.99 1.02 0.98 4
2 16 wortmannin  genistein  NSC23766 (Rac1 inhibitor)  25.33 40.96 22.13 1.01 1.15 0.97 3
2 17 alpha-tocopherol succinate  SB203580  PDTC  SKI-II  13.97 18.38 12.11 1.02 1.00 0.95 4
2 18 di-methyl sphingosine  73.92 70.55 56.58 0.98 1.01 0.99 1
2 19 SR 11302  IKK inhibitor (BMS-345541)  di-methyl sphingosine  20.15 37.32 22.90 0.99 1.02 1.00 3
2 20 DMSO 121.02 117.45 83.76 0.98 0.99 0.99 0
2 21 desferrioxamine  125.49 184.83 117.24 1.03 1.03 1.04 1
2 22 tempol  LY294002 hydrochloride  PDTC  SKI-II  di-methyl sphingosine  FCCP  90.16 31.87 12.11 1.04 1.02 0.99 6
2 23 U0126  PDTC  FCCP  NSC23766 (Rac1 inhibitor)  55.75 28.26 12.88 1.01 1.04 1.02 4
2 24 desferrioxamine  rotenone  wortmannin  57.88 45.53 26.78 1.05 1.12 1.05 3
2 25 diphenylene iodonium (DPI)  U0126  genistein 2-4-dinitrophenol  92.34 60.29 32.22 1.00 1.04 1.28 4
2 26 di-methyl sphingosine  70.70 72.43 45.53 1.00 1.02 1.02 1
2 27 diphenylene iodonium (DPI) IRAK 1  SKI-II  0.00 24.66 0.00 1.06 1.08 1.01 3
2 28 tempol  U0126  CCCP  mevastatin  15.00 64.02 34.56 0.98 1.10 1.01 4
2 29 TPEN  rotenone  SR 11302  CCCP  115.46 109.65 95.93 1.15 1.14 1.06 4
2 30 alpha-tocopherol  U0126  PD98059  SP600125  di-methyl sphingosine  mevastatin  66.41 59.37 64.52 1.06 1.01 1.02 6
2 31 IRAK 1  91.26 69.62 60.54 1.03 1.01 1.07 1
2 32 tempol  wortmannin IRAK 1  CCCP  42.03 92.32 15.96 1.15 1.24 1.30 4
2 33 alpha-tocopherol succinate  N-acetyl cysteine  PDTC  genistein  FCCP  57.88 35.50 17.50 1.04 1.00 1.00 5
2 34 IRAK 1  SR 11302  NSC23766 (Rac1 inhibitor)  67.48 33.68 23.68 0.99 1.06 1.00 3
2 35 rotenone  PDTC 2-4-dinitrophenol  82.56 62.16 55.78 1.02 1.06 1.06 3
2 36 U0126  PD98059  63.20 80.92 62.93 0.98 1.10 0.95 2
2 37 desferrioxamine  alpha-tocopherol succinate  diphenylene iodonium (DPI) U0126  45.18 54.74 24.45 1.07 1.04 0.96 4
2 38 VK-28  U0126  NSC23766 (Rac1 inhibitor)  50.46 43.70 40.82 1.01 1.00 1.00 3
2 39 alpha-tocopherol succinate  tempol  apocynin  LY294002 hydrochloride  159.49 144.13 138.89 0.99 1.02 1.01 4
2 40 desferrioxamine  wortmannin  SB203580  genistein  FCCP  0.00 16.59 0.00 1.12 1.03 1.18 5
2 41 desferrioxamine  NSC23766 (Rac1 inhibitor)  Y27632 dihydrochloride (ROCK inhibitor) 166.38 94.23 75.71 1.02 1.01 0.97 3
2 42 N-acetyl cysteine  PDTC  142.39 88.50 91.87 1.01 1.10 1.03 2
2 43 SIH  tempol  137.86 100.00 77.32 0.99 1.04 0.93 2
2 44 alpha-tocopherol succinate  tempol  diphenylene iodonium (DPI)  SR 11302  genistein  107.70 90.42 58.16 1.04 1.04 1.02 5
2 45 VK-28  SIH  alpha-tocopherol  U0126  SR 11302  di-methyl sphingosine  mevastatin  NSC23766 (Rac1 inhibitor)  Y27632 dihydrochloride (ROCK inhibitor) 0.00 47.37 9.81 0.99 1.12 1.05 9
2 46 SB203580  PDTC  di-methyl sphingosine  FCCP  12.95 64.02 0.00 1.01 1.16 0.91 4
2 47 alpha-tocopherol  alpha-tocopherol succinate  U0126 PDTC  SKI-II  CCCP  21.19 28.26 6.74 1.07 0.98 0.92 6
2 48 N-acetyl cysteine  LY294002 hydrochloride  SR 11302  FCCP 2-4-dinitrophenol  30.52 40.96 55.78 1.00 0.93 1.07 5
2 49 SIH  desferrioxamine  tempol  SR 11302  NSC23766 (Rac1 inhibitor)  68.55 127.25 84.57 0.99 0.94 0.94 5
2 50 tempol  CCCP  51.51 63.08 43.17 0.97 1.02 1.00 2
3 1 TPEN  U0126  48.64 34.47 19.66 1.06 1.05 1.06 2
3 2 tempol  CCCP  27.13 13.59 19.10 1.00 1.05 1.02 2
3 3 apocynin  PDTC  SKI-II  13.90 8.61 11.92 1.11 1.03 1.03 3
3 4 DMSO 91.37 82.76 52.14 1.02 0.98 0.97 0
3 5 wortmannin 2-4-dinitrophenol 42.34 42.85 49.81 1.04 0.99 1.02 2
3 6 tempol  SP600125  SKI-II  CCCP  9.55 7.38 10.83 1.03 1.01 1.05 4
3 7 alpha-tocopherol U0126  PD98059  69.08 80.04 48.06 0.98 1.00 0.96 3
3 8 VK-28  PDTC  FCCP  7.93 7.38 6.46 0.98 1.01 0.98 3
3 9 VK-28  wortmannin  PDTC  IKK inhibitor (BMS-345541) SKI-II  5.77 0.00 19.66 1.10 1.08 1.28 5
3 10 tempol  apocynin  U0126  PDTC  FCCP  11.18 11.10 11.92 1.05 1.05 1.09 5
3 11 SIH  apocynin IRAK 1  31.60 35.12 41.70 1.02 1.00 1.03 3
3 12 SIH  tempol  apocynin  SB203580  PDTC  15.54 13.59 14.13 1.00 1.01 1.00 5
3 13 SB203580  PDTC  17.18 12.35 11.38 0.98 1.00 0.99 2
3 14 desferrioxamine N-acetyl cysteine SP600125  SR 11302  SKI-II  CCCP 2-4-dinitrophenol NSC23766 (Rac1 inhibitor)9.55 8.61 10.28 1.00 1.00 1.01 8
3 15 apocynin  U0126  PDTC 2-4-dinitrophenol Y27632 dihydrochloride (ROCK inhibitor) 70.26 78.67 50.97 0.99 0.99 0.97 5
3 16 desferrioxamine t mpol  SB203580  13.36 12.35 13.58 1.00 0.95 1.02 3
3 17 DMSO 76.23 78.67 108.86 0.97 1.00 1.01 0
3 18 rotenone  34.41 40.91 28.05 1.00 1.03 0.97 1
3 19 wortmannin 2-4-dinitrophenol 22.69 23.64 20.21 1.03 1.02 0.98 2
3 20 SIH  SB203580  SKI-II  0.00 0.00 0.00 0.97 0.98 0.93 3
3 21 SB203580  PDTC  di-methyl sphingosine geni tein  FCCP  0.00 0.00 6.46 0.98 1.00 1.04 5
3 22 2-4-dinitrophenol 121.42 185.91 191.90 0.99 1.01 1.06 1
3 23 VK-28  wortmannin  NSC23766 (Rac1 inhibitor) 33.29 38.98 41.70 1.02 1.00 1.06 3
3 24 tempol  U0126  PDTC  87.71 88.93 91.88 1.03 1.00 1.03 3
3 25 alpha-tocopherol succinate SB203580  U0126  PD98059  SKI-II  genistein  5.77 0.00 5.92 1.02 0.99 1.00 6
3 26 di-methyl sphingosine 79.23 65.22 86.95 1.00 0.98 1.02 1
3 27 tempol  wortmannin  SB203580  genistein  14.99 16.72 13.03 0.98 1.00 0.97 4
3 28 SIH  alpha-tocopherol succinate SB203580  SR 11302  PDTC  NSC23766 (Rac1 inhibitor) 11.72 9.86 11.38 0.97 0.95 0.99 6
3 29 SIH  SB203580  12.81 13.59 14.13 0.98 0.96 1.01 2
3 30 SIH  alpha-tocopherol succinate w rtman in  38.37 40.26 35.41 1.00 1.05 0.97 3
3 31 SIH  tempol  U0126  PDTC  SKI-II  di-methyl sphingosine 8.47 8.61 7.55 0.97 0.99 0.96 6
3 32 TPEN  alpha-tocopherol succinate w rtman in  SKI-II  9.01 6.76 8.09 1.39 1.56 1.40 4
3 33 alpha-tocopherol SB203580  PDTC 2-4-dinitrophenol 13.90 13.59 16.33 1.00 0.97 1.02 4
3 34 VK-28  desferrioxamine tempol  LY294002 hydrochloride SKI-II  Y27632 dihydrochloride (ROCK inhibitor) 18.28 16.09 17.99 1.02 1.02 1.02 6
3 35 SKI-II  12.27 11.10 13.58 1.00 0.98 1.01 1
3 36 alpha-tocopherol succinate apocynin  wortmannin  PD98059  CCCP  mevastatin  0.00 9.86 11.92 1.03 1.05 1.01 6
3 37 wortmannin  genistein  40.63 42.85 46.32 1.00 0.97 1.02 2
3 38 desferrioxamine N-acetyl cysteine tempol  NSC23766 (Rac1 inhibitor) 62.59 75.29 62.74 0.95 0.99 0.95 4
3 39 SIH  tempol  SR 11302  88.92 84.81 78.37 0.95 0.97 0.97 3
3 40 IRAK 1  SKI-II  NSC23766 (Rac1 inhibitor) 10.63 12.35 11.38 1.04 1.02 1.09 3
3 41 tempol  U0126  PDTC  SKI-II  NSC23766 (Rac1 inhibitor) 6.85 8.00 8.64 1.04 1.05 1.07 5
3 42 SKI-II  Y27632 dihydrochloride (ROCK inhibitor) 14.45 13.59 7.55 1.01 1.03 0.97 2
3 43 VK-28  SIH  alpha-tocopherol succinate SKI-II  13.36 14.22 15.78 0.97 1.00 1.05 4
3 44 CCCP  18.83 24.28 25.24 0.98 1.03 1.02 1
3 45 alpha-tocopherol PD98059  SKI-II  11.72 11.10 13.58 1.00 0.98 1.00 3
3 46 tempol  FCCP  9.55 10.48 11.92 1.00 0.99 1.00 2
3 47 SR 11302  CCCP  24.35 20.49 21.89 1.00 1.02 0.94 2
3 48 U0126  PDTC  82.85 91.68 59.78 0.99 1.01 0.98 2
3 49 U0126  SR 11302  CCCP  21.04 23.64 19.10 1.02 1.02 0.98 3
3 50 rotenone  SP600125  66.12 70.57 61.56 1.05 1.02 1.06 2
4 1 TPEN  alpha-tocopherol succinate  U0126 45.45 102.61 65.41 0.87 1.03 1.03 3
4 2 PD98059  107.75 148.58 83.08 0.97 1.02 1.01 1
4 3 apocynin  SKI-II  EGCG  44.99 50.34 42.37 1.01 1.12 0.98 3
4 4 tempol  SKI-II  18.64 35.98 45.59 0.92 1.02 1.00 2
4 5 SIH  desferrioxamine  diphenylene iodonium (DPI)  LY294002 hydrochloride  PD98059 IRAK 1  SKI-II  11.14 13.23 9.95 1.05 1.11 1.02 7
4 6 VK-28  TPEN  alpha-tocopherol succinate  EGCG 73.19 126.38 112.61 0.95 1.09 1.01 4
4 7 VK-28  desferrioxamine  SB203580  5.25 8.97 7.21 0.99 1.12 0.97 3
4 8 U0126  SKI-II  61.11 37.25 36.97 1.03 0.98 0.95 2
4 9 SIH  TPEN  apocynin IRAK 1  SKI-II  19.05 49.79 25.07 0.95 1.09 0.99 5
4 10 apocynin  PD98059  SR 11302  genistein  47.76 78.04 59.10 0.91 0.99 0.98 4
4 11 SIH  desferrioxamine  tempol  SR 11302  NSC23766 (Rac1 inhibitor)  Y27632 dihydrochloride (ROCK inhibitor) 56.18 107.14 57.38 1.04 1.01 0.92 6
4 12 diphenylene iodonium (DPI)  i-methyl sphingosine  22.13 55.74 37.29 0.91 1.10 1.09 2
4 13 tempol  rotenone  SR 11302  EGCG  50.13 42.78 36.89 1.04 1.05 1.06 4
4 14 SR 11302  IKK inhibitor (BMS-345541)  di-methyl sphingosine  71.03 65.83 40.93 1.02 1.08 0.96 3
4 15 DMSO 44.72 121.99 93.24 0.96 1.06 1.00 0
4 16 apocynin  PDTC  SKI-II  13.16 48.37 27.42 0.92 1.10 0.97 3
4 17 wortmannin  SB203580  SKI-II  genistein  3.32 4.32 3.66 1.04 0.99 1.01 4
4 18 PDTC  SKI-II  9.75 54.14 23.89 0.93 1.13 1.00 2
4 19 desferrioxamine  N-acetyl cysteine  tempol  di-methyl sphingosine  NSC23766 (Rac1 inhibitor)  simvastat n 35.18 67.47 50.42 0.92 1.00 0.97 6
4 20 SIH  desferrioxamine  PDTC  80.31 78.18 83.73 1.04 0.99 0.92 3
4 21 alpha-tocopherol succinate  apocynin  SKI-II  simvastatin  12.85 41.24 21.50 0.90 1.05 1.01 4
4 22 SIH  TPEN  N-acetyl cysteine  SB203580  PD98059  SR 11302  7.82 7.42 6.93 1.03 1.01 1.01 6
4 23 alpha-tocopherol  PD98059  70.33 108.51 73.77 0.99 1.04 0.95 2
4 24 SIH  alpha-tocopherol  SB203580  PDTC  SKI-II  2.02 3.97 3.93 0.88 0.99 0.99 5
4 25 SIH  tempol  SB203580  SR 11302  SKI-II  NSC23766 (Rac1 inhibitor)  4.47 5.46 3.45 1.00 1.04 0.95 6
4 26 apocynin  PDTC  SKI-II  10.83 40.94 25.01 0.91 1.04 0.97 3
4 27 desferrioxamine  rotenone  SKI-II  genistein  19.38 20.67 18.08 1.08 1.02 1.03 4
4 28 tempol  SB203580  PDTC  simvastatin  3.81 10.10 6.38 0.90 1.07 0.95 4
4 29 SIH  tempol  57.00 111.81 94.79 0.89 0.99 0.99 2
4 30 IRAK 1  NSC23766 (Rac1 inhibitor)  33.16 25.38 34.82 1.04 0.98 0.97 2
4 31 SIH  apocynin  SB203580  10.53 10.63 9.71 1.06 0.99 0.99 3
4 32 apocynin  SB203580  SP600125  PDTC  8.87 11.61 5.55 1.01 1.06 1.03 4
4 33 apocynin  PD98059  SKI-II  31.04 36.66 20.90 1.00 1.03 0.99 3
4 34 SIH  rotenone  21.57 38.34 43.40 0.92 1.04 1.06 2
4 35 SIH  SB203580  SKI-II  3.76 6.11 3.66 1.02 1.06 1.01 3
4 36 N-acetyl cysteine  apocynin  53.15 151.72 76.99 0.92 1.03 0.97 2
4 37 SIH  SB203580  SKI-II  2.56 5.11 3.45 0.93 1.05 1.01 3
4 38 SIH  113.26 109.03 82.95 1.01 0.97 0.99 1
4 39 TPEN  tempol  U0126  Y27632 dihydrochloride (ROCK inhibitor)  58.66 177.34 104.52 0.93 1.07 0.94 4
4 40 wortmannin  U0126 IRAK 1  45.45 36.66 42.28 1.03 0.96 0.98 3
4 41 SIH  SB203580  SKI-II  2.94 3.76 3.18 1.07 0.99 1.02 3
4 42 IKK inhibitor (BMS-345541)  49.75 97.44 47.65 1.00 1.13 1.05 1
4 43 VK-28  alpha-tocopherol succinate  SKI-II EGCG  38.58 19.17 31.19 1.00 0.97 1.03 4
4 44 SB203580  PD98059  SKI-II  di-methyl sphingosine  NSC23766 (Rac1 inhibitor)  simvastat n EGCG  2.51 3.62 2.81 1.03 1.09 1.07 7
4 45 diphenylene iodonium (DPI)  20.26 58.66 32.03 1.07 1.15 1.10 1
4 46 SKI-II  37.74 49.57 28.01 0.98 1.08 0.95 1
4 47 desferrioxamine  alpha-tocopherol  U0126  PD98059  IKK inhibitor (BMS-345541)  simvastatin  36.66 30.41 46.58 1.11 1.00 1.03 6
4 48 SIH  SB203580  SP600125 IRAK 1  3.98 6.11 4.52 1.08 1.13 0.94 4
4 49 tempol  wortmannin  SB203580  9.70 5.82 7.83 1.19 0.99 0.98 3
4 50 rotenone  30.34 32.36 28.30 1.10 1.04 1.07 1
5 1 apocynin  SB203580  SR 11302  16.47 15.44 13.58 1.01 1.05 1.01 3
5 2 SIH  SKI-II  di-methyl sphingosine  35.99 35.58 13.67 0.99 1.04 0.98 3
5 3 SIH  tempol  SKI-II  48.78 35.28 22.38 0.98 1.03 1.02 3
5 4 tempol  wortmannin  PDTC  simvastatin  111.97 28.97 19.28 0.99 1.06 1.01 4
5 5 tempol  SP600125  PDTC  SKI-II  di-methyl sphingosine  38.77 39.81 35.51 0.97 1.05 1.05 5
5 6 PDTC  IKK inhibitor (BMS-345541)  SKI-II  26.77 28.53 16.17 1.02 1.12 1.03 3
5 7 alpha-tocopherol succinate  diphenylene iodonium (DPI)  SB203580  PDTC  SKI-II  Y27632 dihydrochloride (ROCK inhibitor)  5.64 5.61 4.46 0.99 1.02 1.10 6
5 8 TPEN  tempol  apocynin  SB203580 IRAK 1  SR 11302  genistein  16.82 15.04 9.72 1.00 1.02 0.99 7
5 9 SB203580  SKI-II  7.08 6.51 4.63 1.03 1.00 0.98 2
5 10 alpha-tocopherol succinate  tempol  SB203580  PDTC  genistein  simvastatin  9.66 8.44 7.37 1.01 0.99 1.04 6
5 11 SKI-II  mevastatin  26.89 34.24 17.95 1.01 1.04 1.02 2
5 12 SIH  tempol  SR 11302  SKI-II  Y27632 dihydrochloride (ROCK inhibitor)  36.78 38.44 12.49 0.98 1.03 0.95 5
5 13 apocynin  PD98059  SR 11302  genistein  126.67 116.96 100.00 0.95 1.03 1.03 4
5 14 SIH  PD98059  SKI-II  genistein  30.81 35.58 26.78 1.00 1.04 1.04 4
5 15 VK-28  desferrioxamine  SB203580  SR 11302  Y27632 dihydrochloride (ROCK inhibitor)  12.39 12.24 9.11 0.99 1.05 1.01 5
5 16 SKI-II  29.41 33.35 15.89 1.00 1.03 0.98 1
5 17 SKI-II  di-methyl sphingosine  22.94 31.59 21.89 0.98 1.06 1.05 2
5 18 LY294002 hydrochloride  di-methyl sphingosine  149.98 122.44 74.77 1.00 1.02 0.97 2
5 19 TPEN  SKI-II  34.03 42.73 44.41 1.05 1.01 1.08 2
5 20 U0126  SR 11302  EGCG  151.80 129.18 139.91 1.00 1.03 1.01 3
5 21 SIH  apocynin  SB203580  11.59 14.37 10.70 0.99 1.02 1.00 3
5 22 tempol  105.71 139.67 103.44 0.98 1.03 0.96 1
5 23 tempol  SR 11302  SKI-II  di-methyl sphingosine  EGCG  23.67 27.96 25.87 1.02 1.04 1.07 5
5 24 wortmannin  PD98059  di-methyl sphingosine  87.12 90.33 69.38 0.99 1.06 1.00 3
5 25 DMSO 104.04 146.92 94.82 0.96 0.91 0.93 0
5 26 tempol  101.45 122.88 122.55 0.97 1.00 0.98 1
5 27 SKI-II  30.17 24.83 16.07 0.96 0.98 0.94 1
5 28 SB203580  SKI-II  6.41 6.12 4.63 1.00 0.99 0.96 2
5 29 alpha-tocopherol succinate  mevastatin  100.36 77.72 118.70 0.99 1.01 0.99 2
5 30 SIH  SB203580  PD98059  SKI-II  5.97 6.76 4.63 0.99 1.05 0.95 4
5 31 SIH  SB203580  SKI-II  Y27632 dihydrochloride (ROCK inhibitor)  6.30 6.76 5.31 0.97 0.99 1.01 4
5 32 DMSO 83.39 132.18 113.64 0.97 1.03 0.99 0
5 33 SIH  SKI-II  25.27 26.96 32.50 0.99 0.97 1.09 2
5 34 tempol  SB203580  PDTC  simvastatin  9.10 10.39 8.50 1.01 1.09 1.03 4
5 35 desferrioxamine  alpha-tocopherol  86.95 92.65 107.48 0.95 1.01 1.04 2
5 36 wortmannin  SB203580  simvastatin  10.22 12.50 8.93 0.98 0.98 0.96 3
5 37 tempol  SKI-II  22.57 34.24 26.68 0.92 1.00 1.02 2
5 38 SIH  SB203580  PDTC  9.43 8.70 7.89 0.94 1.01 0.98 3
5 39 SIH  SB203580  SP600125  SKI-II  9.66 8.57 6.93 1.00 0.98 1.01 4
5 40 rotenone  wortmannin  55.95 33.79 36.93 1.04 1.00 1.11 2
5 41 rotenone  PD98059  SKI-II  17.53 18.56 16.45 1.06 1.05 1.13 3
5 42 TPEN  wortmannin  SB203580  10.00 11.58 13.22 0.97 1.00 1.05 3
5 43 alpha-tocopherol succinate  tempol  U0126  PDTC  46.68 67.72 80.82 0.99 1.06 0.98 4
5 44 SB203580  SKI-II  5.53 5.99 5.31 1.02 1.09 1.00 2
5 45 apocynin  SR 11302  genistein  47.10 65.12 118.13 0.99 0.97 1.08 3
5 46 VK-28  55.08 75.72 96.63 0.98 1.02 1.01 1
5 47 SIH  SKI-II  19.67 33.06 21.99 0.94 1.02 1.02 2
5 48 PDTC  NSC23766 (Rac1 inhibitor)  46.40 44.44 76.52 0.96 0.97 0.99 2
5 49 SIH  SB203580  8.87 7.92 11.95 1.01 0.96 1.10 2
5 50 wortmannin  SKI-II  genistein  Y27632 dihydrochloride (ROCK inhibitor)  26.64 16.39 16.35 0.97 0.96 1.04 4
6 1 wortmannin  SB203580  SKI-II  0.00 4.87 2.66 1.06 1.04 1.03 3
6 2 N-acetyl cysteine  NSC23766 (Rac1 inhibitor)  119.95 133.27 112.91 1.02 1.06 0.96 2
6 3 IKK inhibitor (BMS-345541)  SKI-II 17.10 27.56 11.38 1.08 1.05 0.96 2
6 4 desferrioxamine  t mpol  wortmannin  SB203580  PD98059  Y27632 dihydrochloride (ROCK inhibitor)  simvastatin  0.00 2.97 2.66 1.27 1.23 1.18 7
6 5 SIH  alpha-tocopherol  SB203580  PDTC  SKI-II  3.10 4.39 0.00 0.98 1.07 0.89 5
6 6 SIH  SB203580  SP600125  SKI-II  6.78 6.46 5.02 0.93 1.00 0.86 4
6 7 desferrioxamine  t mpol  LY294002 hydrochloride  Y27632 ihydrochloride (ROCK inhibitor)  132.94 159.43 95.96 0.96 1.06 0.93 4
6 8 wortmannin  SB203580  PD98059  simvastatin  0.00 0.00 2.39 1.26 1.29 1.26 4
6 9 SB203580  simvastatin  5.30 8.06 6.56 1.00 1.04 0.93 2
6 10 N-acetyl cysteine  NSC23766 (Rac1 inhibitor)  74.83 97.98 55.48 1.04 1.02 0.93 2
6 11 SIH  alpha-tocopherol  SB203580  SP600125  simvastatin  7.52 14.39 7.82 1.04 1.05 0.99 5
6 12 VK-28  131.21 137.57 122.23 1.01 1.01 1.00 1
6 13 wortmannin  SKI-II  simvastatin  16.64 18.20 7.54 1.02 1.03 0.94 3
6 14 SB203580  7.52 7.89 8.81 0.99 1.00 0.98 1
6 15 desferrioxamine  SKI-II  25.01 27.21 14.26 1.03 1.08 0.92 2
6 16 SIH  desferrioxamine  tempol  SB203580  7.08 7.09 5.30 0.99 0.98 0.91 4
6 17 SB203580  di-methyl sphingosine  Y27632 dihydrochloride (ROCK inhibitor)  3.98 5.18 5.16 0.97 1.04 0.93 3
6 18 VK-28  tempol  103.08 83.38 95.16 0.93 0.97 1.04 2
6 19 SIH  alpha-tocopherol  SB203580  PDTC  SKI-II  2.96 3.60 2.25 0.99 1.04 1.00 5
6 20 SIH  LY294002 hydrochloride  SB203580  PDTC  9.62 9.83 7.12 1.03 1.03 0.96 4
6 21 tempol  wortmannin  98.69 95.31 118.73 1.01 0.98 1.06 2
6 22 alpha-tocopherol succinate  SB203580  genistein  10.22 19.54 10.23 1.01 1.02 0.96 3
6 23 SIH  tempol  SR 11302  SKI-II  24.37 32.63 12.82 1.00 1.01 0.91 4
6 24 VK-28  SP600125  96.31 102.71 95.76 1.00 0.98 0.98 2
6 25 SIH  SB203580  PDTC  7.97 8.22 4.88 1.05 1.02 0.93 3
6 26 rotenone IRAK 1  SKI-II  9.32 12.10 5.58 1.09 1.05 0.97 3
6 27 SIH  tempol  SR 11302  PDTC  SKI-II  23.56 29.99 12.67 0.99 1.04 0.92 5
6 28 SIH  SB203580  6.48 8.22 8.39 0.94 0.95 1.09 2
6 29 SB203580  SKI-II  simvastatin  0.00 4.55 0.00 1.01 1.03 1.03 3
6 30 SIH  tempol  wortmannin  SKI-II  7.23 9.83 7.12 1.52 1.52 1.26 4
6 31 SKI-II  di-methyl sphingosine  9.92 32.98 26.01 1.03 1.05 1.01 2
6 32 tempol  SKI-II  NSC23766 (Rac1 inhibitor)  15.09 17.04 17.33 1.04 1.03 0.96 3
6 33 apocynin  SKI-II  23.72 22.41 17.62 1.00 1.01 0.99 2
6 34 VK-28  SIH  tempol  diphenylene iodonium (DPI)  SB203580  SKI-II  0.00 3.13 2.25 1.07 1.11 0.97 6
6 35 SIH  alpha-tocopherol succinate  tempol 102.63 83.81 59.98 0.92 0.96 0.94 3
6 36 wortmannin  SKI-II  22.77 37.26 20.43 0.94 1.05 0.91 2
6 37 wortmannin  SB203580  mevastatin  simvastatin  0.00 2.97 4.60 1.18 1.15 1.20 4
6 38 desferrioxamine  t mpol  SB203580  6.93 9.50 5.44 1.00 0.99 0.94 3
6 39 SIH  SB203580  SR 11302  SKI-II  2.52 14.23 6.56 1.01 1.05 1.04 4
6 40 tempol  SP600125  SR 11302  PDTC  NSC23766 (Rac1 inhibitor)  83.29 75.22 43.72 1.01 1.02 0.99 5
6 41 rotenone  NSC23766 (Rac1 inhibitor)  29.40 37.80 36.77 1.07 1.05 1.14 2
6 42 SIH  desferrioxamine  tempol  SB203580  SR 11302  PDTC  7.23 6.77 8.39 0.96 0.99 0.99 6
6 43 SIH  tempol  SB203580  SR 11302  genistein  6.04 8.54 8.39 0.99 0.98 0.94 5
6 44 tempol  SB203580  PDTC  Y27632 dihydrochloride (ROCK inhibitor)  simvastatin  4.72 7.74 7.68 0.99 0.99 0.96 5
6 45 SIH  N-acetyl cysteine  SB203580  U0126  SKI-II  0.00 3.45 0.00 1.12 1.11 0.97 5
6 46 SKI-II  Y27632 dihydrochloride (ROCK inhibitor)  EGCG  14.17 26.00 15.42 0.99 0.97 0.93 3
6 47 SB203580  U0126  PDTC  simvastatin  2.38 0.00 0.00 1.02 0.96 1.05 4
6 48 LY294002 hydrochloride  wortmannin  SKI-II  35.21 33.69 18.51 1.03 1.01 0.98 3
6 49 IRAK 1  108.88 131.03 49.03 1.01 1.01 0.95 1
6 50 SKI-II  EGCG  33.87 34.93 40.63 1.03 1.02 1.09 2
7 1 tempol  SP600125  SKI-II  16.06 15.77 20.31 1.15 1.13 1.01 3
7 2 wortmannin  SB203580  simvastatin  4.04 0.00 9.03 1.32 1.41 1.69 3
7 3 SIH  SB203580  SP600125  SKI-II  NSC23766 (Rac1 inhibitor)  4.91 3.57 8.39 0.99 1.02 1.07 5
7 4 SKI-II  25.64 13.44 15.13 1.03 0.97 1.06 1
7 5 apocynin  SB203580  10.75 7.83 8.39 1.01 0.98 0.96 2
7 6 SB203580  SKI-II  simvastatin  4.91 3.57 4.58 1.05 1.02 0.94 3
7 7 alpha-tocopherol succinate  wortman in  SKI-II  di-methyl sphingosine  4.04 4.22 6.48 1.09 1.32 0.99 4
7 8 Y27632 dihydrochloride (ROCK inhibitor)  90.13 58.00 110.88 0.98 0.93 1.04 1
7 9 genistein  76.11 54.82 59.01 1.06 0.89 0.92 1
7 10 SB203580  SKI-II  0.00 0.00 5.21 1.05 1.06 1.00 2
7 11 SB203580  SKI-II  4.04 0.00 8.07 0.99 0.96 1.08 2
7 12 rotenone  SB203580  Y27632 dihydrochloride (ROCK inhibitor)  9.58 8.82 14.48 1.05 1.05 1.10 3
7 13 tempol  90.13 73.77 121.18 0.99 0.96 1.07 1
7 14 SIH  SB203580  SP600125  SKI-II  7.24 6.85 7.43 1.00 1.00 0.93 4
7 15 alpha-tocopherol  wortmannin  SB203580  simvastatin  5.49 4.22 4.89 1.59 1.29 0.97 4
7 16 SB203580  Y27632 dihydrochloride (ROCK inhibitor)  9.58 8.82 11.91 0.99 1.00 1.04 2
7 17 SIH  apocynin  SP600125  SKI-II  Y27632 dihydrochloride (ROCK inhibitor)  EGCG  82.07 94.74 72.37 0.96 1.00 0.93 6
7 18 SIH  SB203580  SP600125  SKI-II  NSC23766 (Rac1 inhibitor)  6.65 6.19 11.91 1.01 0.92 1.06 5
7 19 SKI-II  NSC23766 (Rac1 inhibitor)  89.79 52.00 49.35 1.00 0.93 0.92 2
7 20 diphenylene iodonium (DPI)  SB203580  IKK inhibitor (BMS-345541)  SKI-II  simvastatin  0.00 0.00 3.94 1.16 0.97 0.97 5
7 21 VK-28  SIH  desferrioxamine  alpha-tocopherol  diphenylene iodonium (DPI)  SB203580  SKI-II  0.00 0.00 6.48 0.99 0.98 1.15 7
7 22 apocynin  SB203580  SKI-II  3.46 0.00 7.43 0.99 1.02 1.01 3
7 23 apocynin  mevastatin  simvastatin  63.39 43.97 88.22 0.97 0.93 1.01 3
7 24 SIH  wortmannin  IKK inhibitor (BMS-345541)  SKI-II  0.00 0.00 8.39 1.09 1.52 1.53 4
7 25 SKI-II  16.36 22.79 29.50 0.99 0.99 1.02 1
7 26 IRAK 1  SKI-II  di-methyl sphingosine  0.00 4.22 4.89 0.98 0.97 0.95 3
7 27 SIH  rotenone  SB203580  6.95 5.21 12.23 1.01 0.95 1.09 3
7 28 LY294002 hydrochloride  wortmannin  SB203580  SKI-II  6.36 0.00 4.89 1.48 1.05 1.03 4
7 29 SKI-II  di-methyl sphingosine  25.94 8.49 10.95 1.06 0.90 0.92 2
7 30 tempol  rotenone  42.48 28.19 56.58 1.03 0.97 1.16 2
7 31 SKI-II  103.79 125.69 105.62 1.03 1.05 0.96 1
7 32 SIH  SB203580  PDTC  SKI-II  7.82 7.50 11.59 1.04 1.07 1.08 4
7 33 EGCG  86.42 75.58 134.79 1.02 1.00 1.11 1
7 34 SB203580  di-methyl sphingosine  8.41 8.82 9.35 1.00 0.99 0.93 2
7 35 apocynin  90.47 92.51 86.76 1.03 1.06 0.95 1
7 36 SIH  SB203580  SKI-II  mevastatin  simvastatin  0.00 0.00 4.58 0.97 0.99 0.93 5
7 37 alpha-tocopherol  SB203580  SKI-II  10.46 14.11 20.97 0.98 0.90 1.05 3
7 38 tempol  mevastatin  121.69 68.35 65.31 0.99 0.90 0.96 2
7 39 SIH  SB203580  PDTC  IKK inhibitor (BMS-345541)  6.07 0.00 5.53 1.02 0.94 0.96 4
7 40 SIH  desferrioxamine  alpha-tocopherol  tempol  SB203580  Y27632 dihydrochloride (ROCK inhibitor)  7.53 5.21 14.81 0.99 0.91 1.09 6
7 41 SIH  LY294002 hydrochloride  SB203580 IRAK 1  SKI-II  14.29 16.10 17.39 1.06 1.05 0.92 5
7 42 apocynin  SKI-II  95.21 98.49 129.70 1.01 1.04 1.07 2
7 43 desferrioxamine  97.61 99.62 137.56 1.04 1.02 1.07 1
7 44 desferrioxamine  SKI-II  genistein  Y27632 dihydrochloride (ROCK inhibitor)  EGCG  86.76 112.54 76.29 1.02 1.04 0.96 5
7 45 SIH  alpha-tocopherol  SB203580  PDTC  SKI-II  5.78 0.00 5.53 0.99 1.01 0.91 5
7 46 DMSO 86.76 93.26 156.78 1.04 1.07 1.06 0
7 47 LY294002 hydrochloride  SR 11302  SKI-II  Y27632 dihydrochloride (ROCK inhibitor)  21.73 25.49 18.69 1.08 1.02 0.94 4
7 48 SB203580  PDTC  10.46 7.50 10.31 1.06 1.01 0.96 2
7 49 TPEN  wortmannin  SB203580  SKI-II  simvastatin  5.78 0.00 5.85 1.54 1.42 1.23 5
7 50 SIH  desferrioxamine  tempol  SB203580  IKK inhibitor (BMS-345541)  8.11 0.00 9.03 1.02 0.95 1.14 5
8 1 SB203580  SP600125  SKI-II  mevastatin  17.42 12.03 13.51 1.23 1.04 1.00 4
8 2 N-acetyl cysteine  diphenylene iodonium (DPI)  Y27632 dihydrochloride (ROCK inhibitor)  47.47 51.12 52.55 1.09 1.11 1.01 3
8 3 SIH  LY294002 hydrochloride  SB203580  PDTC  SKI-II  genistein  17.42 17.11 14.47 1.13 1.08 1.02 6
8 4 tempol  SB203580  SKI-II  14.48 11.53 13.51 1.06 1.04 1.04 3
8 5 tempol  PD98059  simvastatin  96.73 88.58 80.62 1.09 1.10 1.05 3
8 6 SIH  SB203580  SP600125  IKK inhibitor (BMS-345541)  SKI-II  di-methyl sphingosine  mevastatin  10.97 9.51 10.15 0.99 1.01 1.04 7
8 7 SB203580  PDTC  genistein  22.15 20.18 21.23 1.08 1.07 1.07 3
8 8 SR 11302  genistein  60.43 83.51 102.17 0.99 0.99 1.05 2
8 9 VK-28  SIH  alpha-tocopherol succinate  w rtman in SB203580  14.48 10.52 11.11 1.17 1.17 1.12 5
8 10 SIH  SB203580  mevastatin  simvastatin  16.25 17.11 15.91 0.97 1.04 0.99 4
8 11 SIH  desferrioxamine  SB203580  IKK inhibitor (BMS-345541)  12.14 0.00 10.15 1.06 0.97 0.96 4
8 12 IRAK 1  SKI-II  19.19 13.05 15.91 1.37 1.03 0.98 2
8 13 SIH  SB203580  SKI-II  12.72 12.03 12.55 1.01 1.07 0.97 3
8 14 SP600125  di-methyl sphingosine  127.24 118.64 109.33 1.13 1.03 1.01 2
8 15 SB203580  SP600125  di-methyl sphingosine  22.15 18.65 19.29 1.05 1.02 1.04 3
8 16 apocynin  SB203580  PDTC  NSC23766 (Rac1 inhibitor)  22.15 19.67 16.87 1.10 1.07 1.04 4
8 17 SIH  PD98059  75.51 75.68 78.50 1.03 1.01 1.03 2
8 18 SB203580  genistein  19.78 21.21 20.74 1.03 1.04 1.01 2
8 19 diphenylene iodonium (DPI)  w rtmannin  genistein  13.90 11.53 15.43 1.12 1.11 1.12 3
8 20 diphenylene iodonium (DPI)  SB203580  15.07 14.57 12.55 1.12 1.06 1.01 2
8 21 N-acetyl cysteine  tempol  SB203580  simvastatin  19.19 20.69 16.87 0.99 1.00 1.01 4
8 22 SB203580  SKI-II  genistein  NSC23766 (Rac1 inhibitor)  10.97 0.00 11.59 1.02 0.97 0.99 4
8 23 SB203580 IRAK 1  simvastatin  0.00 0.00 0.00 1.00 0.98 1.06 3
8 24 SIH  tempol  147.76 105.76 116.01 1.19 1.03 0.97 2
8 25 IKK inhibitor (BMS-345541)  52.38 45.77 41.94 1.10 1.03 1.02 1
8 26 SB203580  genistein  23.34 21.21 21.23 1.05 1.02 1.00 2
8 27 VK-28  SIH  TPEN  SB203580  SP600125  SKI-II  mevastatin  16.25 17.62 14.47 1.01 0.95 0.98 7
8 28 apocynin  LY294002 hydrochloride  SB203580  28.11 24.81 23.66 1.07 1.00 0.99 3
8 29 VK-28  SB203580  SP600125  SR 11302  SKI-II  14.48 12.03 14.47 0.96 0.98 0.98 5
8 30 SB203580  di-methyl sphingosine  24.53 14.57 15.43 0.99 0.95 0.92 2
8 31 SIH  SB203580  SKI-II  0.00 0.00 10.15 0.98 0.99 0.98 3
8 32 apocynin  SB203580  32.30 25.33 25.13 1.13 1.03 0.98 2
8 33 SIH  apocynin  SB203580  20.97 25.33 19.77 0.98 1.05 0.99 3
8 34 SB203580  23.34 21.72 23.66 1.07 1.02 1.02 1
8 35 tempol  SB203580 IRAK 1  13.90 11.02 15.91 1.05 1.00 1.02 3
8 36 alpha-tocopherol  SB203580  simvastatin  20.38 17.11 14.95 1.11 1.04 0.99 3
8 37 SIH  SB203580 IRAK 1  SKI-II  12.14 9.00 11.59 1.28 1.06 1.03 4
8 38 SB203580  SKI-II  13.31 11.02 11.59 0.96 1.01 0.98 2
8 39 genistein  simvastatin  89.60 55.42 57.15 1.01 0.93 0.91 2
8 40 VK-28  N-acetyl cysteine  rotenone  SKI-II  Y27632 dihydrochloride (ROCK inhibitor)  EGCG  16.25 15.59 21.23 0.98 1.02 0.99 6
8 41 SB203580  SKI-II  14.48 11.53 11.11 1.11 1.04 1.02 2
8 42 rotenone  apocynin  SB203580  Y27632 dihydrochloride (ROCK inhibitor)  13.31 15.08 14.47 1.12 1.14 1.06 4
8 43 SB203580  SKI-II  13.31 14.06 13.03 1.16 1.05 1.05 2
8 44 TPEN  genistein  103.27 109.83 135.82 1.12 1.03 1.04 2
8 45 apocynin  SB203580  PD98059  21.56 18.14 16.39 1.13 1.10 0.99 3
8 46 N-acetyl cysteine  SB203580  NSC23766 (Rac1 inhibitor)  26.32 18.14 20.26 1.14 0.98 0.99 3
8 47 SB203580  SKI-II  simvastatin  12.14 10.52 11.11 1.09 1.06 1.00 3
8 48 SIH  desferrioxamine  tempol  SB203580  SKI-II  12.72 9.51 11.11 1.14 0.98 0.96 5
8 49 SIH  SB203580  PDTC  IKK inhibitor (BMS-345541)  11.55 9.51 0.00 1.14 1.06 1.04 4
8 50 tempol  SKI-II  31.10 28.95 30.03 1.12 1.02 1.04 2
9 1 diphenylene iodonium (DPI)  SB203580  IKK inhibitor (BMS-345541)  SKI-II  simvastatin  0.00 0.00 0.00 1.24 1.25 1.24 5
9 2 VK-28  alpha-tocopherol  tempol  PD98059  IKK inhibitor (BMS-345541)  mevastatin  simvastatin  19.22 19.77 8.23 1.02 1.13 1.06 7
9 3 IKK inhibitor (BMS-345541)  NSC23766 (Rac1 inhibitor) 27.95 16.48 16.85 0.98 0.96 0.95 2
9 4 tempol  141.29 179.90 94.85 1.03 1.03 0.98 1
9 5 SB203580  PDTC  di-methyl sphingosine  0.00 0.00 0.00 1.03 0.99 1.05 3
9 6 SB203580  SP600125  di-methyl sphingosine  Y27632 dihydrochloride (ROCK inhibitor)  0.00 0.00 0.00 1.01 1.02 0.97 4
9 7 alpha-tocopherol  tempol  SB203580  SP600125  NSC23766 (Rac1 inhibitor)  simvastat n 0.00 0.00 0.00 0.98 0.98 1.02 6
9 8 PDTC  78.24 87.64 88.52 0.94 0.95 0.99 1
9 9 VK-28  SIH  tempol  97.08 141.14 115.94 1.11 1.10 1.13 3
9 10 DMSO 97.08 138.29 73.50 0.98 1.05 0.98 0
9 11 SKI-II  NSC23766 (Rac1 inhibitor)  6.33 11.45 14.36 1.01 1.08 1.07 2
9 12 SIH  desferrioxamine  SB203580  0.00 0.00 0.00 1.03 1.03 1.06 3
9 13 IRAK 1  Y27632 dihydrochloride (ROCK inhibitor)  14.20 15.58 8.47 0.98 0.96 0.92 2
9 14 SKI-II  NSC23766 (Rac1 inhibitor)  10.13 0.00 11.40 1.02 1.00 1.04 2
9 15 IKK inhibitor (BMS-345541)  SKI-II NSC23766 (Rac1 inhibitor)  0.00 0.00 0.00 1.10 1.05 0.98 3
9 16 DMSO 108.61 121.23 112.90 0.97 0.96 1.00 0
9 17 SB203580  genistein  0.00 0.00 0.00 0.97 0.94 0.95 2
9 18 SIH  tempol  SB203580  IKK inhibitor (BMS-345541)  0.00 0.00 0.00 1.04 1.11 0.94 4
9 19 tempol  SB203580  PD98059  SR 11302  0.00 0.00 0.00 1.09 1.07 1.10 4
9 20 SB203580  0.00 0.00 0.00 1.00 0.99 0.95 1
9 21 SB203580  Y27632 dihydrochloride (ROCK inhibitor)  0.00 0.00 0.00 1.01 1.04 1.00 2
9 22 apocynin  SB203580  SP600125  SKI-II  mevastatin  0.00 0.00 0.00 1.00 1.05 1.01 5
9 23 SB203580  0.00 0.00 0.00 0.98 1.08 0.99 1
9 24 TPEN  tempol  U0126  34.40 40.12 27.02 0.98 0.98 0.91 3
9 25 SP600125  SKI-II  genistein  57.99 59.30 35.40 1.03 1.02 0.88 3
9 26 SIH  alpha-tocopherol succinate  SB203580 EGCG  0.00 0.00 0.00 1.02 0.99 1.00 4
9 27 genistein  85.13 88.71 62.02 1.00 0.97 0.90 1
9 28 U0126  genistein  44.85 34.15 33.02 0.99 0.94 0.94 2
9 29 N-acetyl cysteine  wortmannin  SB203580  SKI-II  di-methyl sphingosine  0.00 0.00 0.00 1.43 1.42 1.23 5
9 30 SIH  LY294002 hydrochloride  PD98059 IRAK 1  simvastatin  17.46 36.02 34.08 1.12 1.10 1.14 5
9 31 SB203580  0.00 0.00 0.00 0.94 1.00 0.92 1
9 32 desferrioxamine  alpha-tocopherol succinate  w rtman in SKI-II  Y27632 dihydrochloride (ROCK inhibitor)  0.00 0.00 0.00 1.31 1.30 1.37 5
9 33 SB203580  di-methyl sphingosine  Y27632 dihydrochloride (ROCK inhibitor)  0.00 0.00 0.00 0.99 1.02 0.98 3
9 34 apocynin  86.53 123.56 131.95 0.99 1.08 0.97 1
9 35 SB203580  SR 11302  0.00 0.00 0.00 0.98 0.98 0.90 2
9 36 tempol  SB203580  SKI-II  simvastatin  0.00 0.00 0.00 1.05 1.05 0.90 4
9 37 wortmannin  SKI-II  Y27632 dihydrochloride (ROCK inhibitor)  0.00 0.00 0.00 1.41 1.18 1.38 3
9 38 SIH  SB203580  0.00 0.00 0.00 1.00 1.00 0.92 2
9 39 TPEN  alpha-tocopherol succinate  SB203580 Y27632 dihydrochloride (ROCK inhibitor)  0.00 0.00 0.00 0.96 0.94 0.95 4
9 40 SKI-II  NSC23766 (Rac1 inhibitor)  EGCG 16.37 21.27 9.93 0.98 1.05 0.94 3
9 41 IKK inhibitor (BMS-345541)  EGCG 39.81 70.12 70.81 1.12 1.13 1.12 2
9 42 diphenylene iodonium (DPI)  SB203580  IKK inhibitor (BMS-345541)  SKI-II  simvastatin  0.00 0.00 0.00 1.11 1.19 0.95 5
9 43 SIH  SB203580  U0126  SP600125  0.00 0.00 0.00 1.06 1.06 1.05 4
9 44 apocynin  SB203580 IRAK 1  0.00 0.00 0.00 1.12 1.12 1.05 3
9 45 SB203580  di-methyl sphingosine  0.00 0.00 0.00 1.02 0.99 0.92 2
9 46 genistein  Y27632 dihydrochloride (ROCK inhibitor)  87.65 118.90 76.51 1.00 1.03 0.92 2
9 47 SIH  SB203580 IRAK 1  di-methyl sphingosine  geni tein  0.00 0.00 0.00 1.08 1.05 0.92 5
9 48 alpha-tocopherol succinate  tenone  SB203580 IRAK 1  SKI-II  di-methyl sphingosine  simvastatin  0.00 0.00 0.00 1.13 1.11 1.12 7
9 49 N-acetyl cysteine  tempol  PDTC  genistein  simvastatin  72.05 67.39 59.14 0.98 0.97 0.98 5
9 50 rotenone  NSC23766 (Rac1 inhibitor)  25.46 46.84 19.11 1.03 1.09 1.02 2
10 1 SIH  SB203580  9.23 11.38 11.83 0.98 1.02 1.03 2
10 2 SB203580  SKI-II  di-methyl sphingosine  2.97 5.47 4.32 1.00 1.06 1.02 3
10 3 SB203580  U0126  3.42 4.47 5.01 1.00 0.99 1.04 2
10 4 SB203580  PDTC  di-methyl sphingosine  NSC23766 (Rac1 inhibitor)  7.84 8.99 7.82 1.03 1.06 1.00 4
10 5 SB203580  11.57 12.58 9.67 1.01 1.05 1.01 1
10 6 TPEN  diphenylene iodonium (DPI)  Y27632 dihydrochloride (ROCK inhibitor)  23.43 39.88 35.80 1.04 1.09 1.06 3
10 7 SIH  SB203580  Y27632 dihydrochloride (ROCK inhibitor)  9.69 10.86 9.67 1.00 1.05 0.99 3
10 8 SIH  SB203580  NSC23766 (Rac1 inhibitor)  9.00 8.49 6.98 0.99 1.03 0.96 3
10 9 SB203580  SR 11302  9.92 10.18 7.26 0.95 0.99 0.93 2
10 10 TPEN  alpha-tocopherol succinate  SB203580 PD98059  Y27632 dihydrochloride (ROCK inhibitor)  6.01 6.97 7.97 0.96 0.98 1.02 5
10 11 SB203580  9.23 14.48 9.67 0.99 1.03 0.96 1
10 12 SB203580  U0126 IRAK 1  genistein  Y27632 dihydrochloride (ROCK inhibitor)  EGCG  Melatonin  0.00 0.00 3.34 1.02 1.02 1.05 7
10 13 PD98059  Y27632 dihydrochloride (ROCK inhibitor)  EGCG  Melatonin  109.94 142.32 135.89 0.98 1.07 1.02 4
10 14 TPEN  alpha-tocopherol succinate  SB203580 SP600125  Y27632 dihydrochloride (ROCK inhibitor)  10.98 8.15 8.96 0.95 1.00 0.99 5
10 15 alpha-tocopherol  apocynin  IKK inhibitor (BMS-345541)  22.79 41.04 37.41 0.97 1.06 1.01 3
10 16 rotenone  SB203580  di-methyl sphingosine  3.76 5.80 3.90 1.07 1.11 1.04 3
10 17 genistein  82.38 143.45 124.22 0.96 1.04 1.01 1
10 18 SR 11302  Melatonin  88.68 70.37 55.36 1.00 1.00 0.93 2
10 19 alpha-tocopherol succinate  SB203580  8.65 12.58 9.25 0.98 1.03 0.97 2
10 20 SB203580  di-methyl sphingosine  Y27632 dihydrochloride (ROCK inhibitor)  8.65 8.32 7.26 0.97 0.97 0.93 3
10 21 LY294002 hydrochloride  SB203580  di-methyl sphingosine  12.87 15.52 10.82 0.96 0.98 0.93 3
10 22 TPEN  alpha-tocopherol succinate  Y27632 dihydrochloride (ROCK inhibitor) 55.66 53.75 74.05 0.97 0.99 1.00 3
10 23 TPEN  SR 11302  genistein  125.38 169.99 75.97 0.99 1.06 0.95 3
10 24 TPEN  diphenylene iodonium (DPI)  SB203580  genistein  3.98 5.63 6.70 1.03 1.10 1.05 4
10 25 SIH  TPEN  SB203580  10.39 12.92 12.41 0.99 1.05 1.02 3
10 26 TPEN  alpha-tocopherol succinate  SB203580 Y27632 dihydrochloride (ROCK inhibitor)  7.50 10.86 7.12 1.01 1.03 0.98 4
10 27 alpha-tocopherol succinate  U0126  47.71 86.05 76.93 0.97 1.02 1.01 2
10 28 SB203580  8.88 8.83 6.70 1.02 1.01 0.95 1
10 29 SB203580  genistein  10.16 15.69 11.68 1.02 1.03 1.01 2
10 30 SIH  SB203580  IKK inhibitor (BMS-345541)  3.20 4.30 3.21 0.96 0.99 0.92 3
10 31 TPEN  SB203580  di-methyl sphingosine  Y27632 dihydrochloride (ROCK inhibitor)  EGCG  7.27 8.83 6.41 0.96 0.96 0.94 5
10 32 di-methyl sphingosine  136.40 170.29 86.99 1.01 1.04 0.97 1
10 33 EGCG  105.90 105.38 123.99 1.00 1.02 1.01 1
10 34 TPEN  SB203580  SR 11302  PDTC  Y27632 dihydrochloride (ROCK inhibitor)  8.65 13.44 11.83 0.97 1.07 1.01 5
10 35 SB203580  di-methyl sphingosine  geni tein  10.51 13.96 9.67 1.00 1.04 0.98 3
10 36 SB203580  SP600125  genistein  Y27632 dihydrochloride (ROCK inhibitor)  simvastatin  8.65 13.44 12.55 0.95 1.06 1.00 5
10 37 genistein  118.25 156.73 81.61 1.01 1.07 0.97 1
10 38 SB203580  U0126  di-methyl sphingosine  simvastatin  2.53 4.14 3.76 1.00 1.04 1.03 4
10 39 VK-28  SB203580  Melatonin  8.30 11.03 6.27 0.98 1.02 0.93 3
10 40 SIH  apocynin  wortmannin  SKI-II  4.43 7.31 5.01 1.09 1.14 1.08 4
10 41 SIH  SB203580  7.15 10.69 6.70 0.95 0.96 0.92 2
10 42 SIH  SB203580  9.23 8.83 10.53 1.02 1.02 1.07 2
10 43 SB203580  SR 11302  10.27 15.00 8.39 0.98 1.06 0.97 2
10 44 DMSO 109.94 154.67 117.11 1.00 1.07 1.03 0
10 45 alpha-tocopherol succinate  wortman in  SB203580  Y27632 dihydrochloride (ROCK inhibitor)  4.77 5.13 3.48 1.01 1.06 1.00 4
10 46 wortmannin  SB203580  di-methyl sphingosine  NSC23766 (Rac1 inhibitor)  4.09 5.63 3.48 1.09 1.14 1.07 4
10 47 desferrioxamine  alpha-tocopherol succinate  SB203580 Y27632 dihydrochloride (ROCK inhibitor)  7.96 9.16 6.84 0.98 1.03 0.95 4
10 48 SIH  genistein  73.88 131.82 105.36 1.03 1.07 1.04 2
10 49 SB203580  PDTC  di-methyl sphingosine  7.61 12.41 6.55 1.01 1.03 0.98 3
10 50 TPEN  alpha-tocopherol succinate  SB203580 Y27632 dihydrochloride (ROCK inhibitor)  5.67 9.16 5.29 1.08 1.03 0.95 4
11 1 rotenone  10.89 36.18 36.16 0.94 0.99 1.04 1
11 2 genistein  116.62 123.79 81.31 0.99 0.99 1.00 1
11 3 VK-28  92.99 58.81 88.46 1.02 0.94 0.99 1
11 4 SB203580  di-methyl sphingosine  Y27632 dihydrochloride (ROCK inhibitor)  0.00 8.69 7.01 0.90 1.05 0.99 3
11 5 N-acetyl cysteine  37.72 68.07 103.46 0.92 0.96 1.03 1
11 6 VK-28  SIH  SB203580  IKK inhibitor (BMS-345541)  0.00 0.00 4.43 0.94 0.95 1.01 4
11 7 IKK inhibitor (BMS-345541)  33.87 17.73 19.32 1.00 0.97 0.94 1
11 8 IRAK 1  SKI-II  0.00 0.00 5.90 0.93 0.95 1.00 2
11 9 SKI-II  10.89 21.21 11.08 0.99 1.01 0.93 1
11 10 LY294002 hydrochloride  SB203580  5.98 10.40 7.75 0.93 1.02 0.95 2
11 11 SIH  TPEN  SB203580  SP600125  IKK inhibitor (BMS-345541)  0.00 5.28 4.43 1.01 1.02 0.96 5
11 12 VK-28  TPEN  SB203580  SR 11302  genistein  5.98 14.70 14.81 0.89 0.93 1.04 5
11 13 SP600125  95.80 113.29 87.62 0.98 0.98 0.99 1
11 14 alpha-tocopherol succinate  PDTC  mevastatin  64.34 50.58 59.51 1.00 0.94 0.99 3
11 15 SB203580  5.98 10.40 10.71 0.91 0.95 1.01 1
11 16 N-acetyl cysteine  SB203580  U0126  0.00 0.00 0.00 0.95 1.00 1.02 3
11 17 SIH  SB203580  IKK inhibitor (BMS-345541)  NSC23766 (Rac1 inhibitor)  0.00 0.00 0.00 0.97 0.95 0.97 4
11 18 SIH  SB203580  genistein  0.00 6.13 9.97 0.93 0.94 0.98 3
11 19 Y27632 dihydrochloride (ROCK inhibitor)  57.25 68.07 78.80 0.95 0.99 0.95 1
11 20 N-acetyl cysteine  SB203580  5.98 13.41 13.32 0.90 0.93 1.02 2
11 21 VK-28 IRAK 1  Y27632 dihydrochloride (ROCK inhibitor)  33.45 35.73 22.35 0.96 0.99 0.99 3
11 22 SB203580  PDTC  mevastatin  7.61 8.26 8.49 1.00 0.93 0.99 3
11 23 diphenylene iodonium (DPI)  12.53 43.79 29.98 0.96 1.05 0.97 1
11 24 TPEN  61.23 86.48 117.07 0.95 0.97 1.00 1
11 25 EGCG  32.17 59.26 98.71 0.89 0.94 1.01 1
11 26 alpha-tocopherol  94.86 58.81 77.55 0.96 0.94 0.92 1
11 27 SIH  33.02 50.58 77.13 0.92 0.95 0.99 1
11 28 alpha-tocopherol succinate  60.79 76.04 64.38 0.96 0.99 1.01 1
11 29 SB203580  PD98059  SR 11302  di-methyl sphingosine  0.00 0.00 0.00 0.92 0.99 0.95 4
11 30 wortmannin  20.82 27.77 21.59 1.06 1.05 1.08 1
11 31 tempol  57.69 95.15 112.65 0.91 0.94 1.06 1
11 32 IKK inhibitor (BMS-345541)  48.49 50.58 37.32 0.96 0.98 0.99 1
11 33 desferrioxamine  111.36 77.92 98.71 1.03 0.96 0.98 1
11 34 wortmannin  SB203580  di-methyl sphingosine  0.00 4.85 5.90 0.95 1.07 1.01 3
11 35 di-methyl sphingosine  35.15 42.44 77.13 0.91 0.97 1.04 1
11 36 SB203580  8.43 9.97 11.45 0.99 1.00 0.96 1
11 37 PDTC  30.48 62.03 99.57 0.89 0.96 0.98 1
11 38 genistein  92.99 61.57 103.03 0.96 0.97 0.95 1
11 39 tempol  25.00 56.97 103.90 0.89 0.96 0.96 1
11 40 SR 11302  67.46 71.80 76.71 0.98 0.99 0.95 1
11 41 apocynin  35.57 81.72 70.93 0.91 1.02 0.95 1
11 42 mevastatin  28.36 74.15 76.30 0.92 0.99 1.05 1
11 43 U0126  15.83 45.14 41.22 0.93 1.03 0.99 1
11 44 LY294002 hydrochloride  34.30 100.98 129.60 0.94 1.01 1.07 1
11 45 simvastatin  85.61 92.72 69.70 1.03 1.06 0.99 1
11 46 NSC23766 (Rac1 inhibitor)  29.63 61.57 70.52 0.96 0.99 0.98 1
11 47 PD98059  66.57 51.94 51.90 1.03 0.96 0.97 1
11 48 SB203580  0.00 9.12 14.07 0.93 0.98 1.00 1
11 49 IRAK 1  18.74 28.21 28.83 1.02 1.02 1.03 1
11 50 Melatonin  33.87 101.47 82.98 0.95 1.02 0.96 1
1 DMSO 116.89 101.55 115.70 0.97 0.97 0.98
1 DMSO 126.20 134.75 127.23 1.03 1.05 1.02
1 DMSO 109.11 116.40 138.89 1.00 0.98 1.00
1 IKK inhibitor (BMS-345541) 0.00 21.00 17.00 1.08 1.06 1.11
2 DMSO 64.27 81.86 53.41 0.94 1.01 1.02
2 DMSO 129.97 86.61 92.67 1.02 1.00 1.01
2 DMSO 116.57 131.21 125.52 0.98 1.06 0.96
2 DMSO 87.99 106.75 112.29 1.01 0.96 0.97
2 DMSO 105.51 97.12 119.73 1.05 0.96 1.03
2 IKK inhibitor (BMS-345541) 57.97 28.74 23.74 1.19 NA NA
3 DMSO 128.48 150.32 162.43 1.06 1.05 1.07
3 DMSO 120.13 97.90 122.99 1.03 0.97 1.04
3 DMSO 78.63 84.12 56.83 1.00 1.01 0.95
3 DMSO 80.44 71.25 96.87 0.96 0.96 0.97
3 DMSO 93.21 97.90 68.11 0.96 1.01 0.96
3 IKK inhibitor (BMS-345541) 0.00 0.00 0.00 1.65 1.45 1.91
4 DMSO 137.18 130.31 113.27 1.06 1.03 1.00
4 DMSO 132.36 118.28 115.09 1.05 0.99 0.98
4 DMSO 104.05 94.44 81.93 0.97 1.00 1.03
4 DMSO 71.27 89.11 82.83 0.98 0.98 0.98
4 DMSO 72.11 74.91 111.63 0.94 1.01 1.01
4 IKK inhibitor (BMS-345541) 1.00 2.00 2.00 1.24 1.33 1.22
5 DMSO 159.47 121.78 92.20 1.02 1.01 1.02
5 DMSO 124.41 171.31 95.81 0.99 1.03 0.93
5 DMSO 117.22 74.10 121.97 1.01 0.97 1.03
5 DMSO 64.48 75.17 84.32 0.97 1.06 0.97
5 DMSO 53.20 73.20 108.73 1.01 0.93 1.05
5 IKK inhibitor (BMS-345541) 5.00 5.00 4.00 1.45 1.32 1.29
6 DMSO 92.68 111.47 107.84 0.99 1.01 1.01
6 DMSO 105.51 110.53 107.64 1.00 0.99 1.01
6 DMSO 104.62 99.55 75.87 1.02 1.01 0.98
6 DMSO 120.88 111.94 106.38 1.01 0.99 0.99
6 DMSO 77.62 68.88 103.69 0.98 1.00 1.01
6 IKK inhibitor (BMS-345541) 0.00 0.00 0.00 1.51 1.55 1.56
7 DMSO 86.08 84.73 88.22 1.01 0.99 1.07
7 DMSO 107.95 121.02 92.97 1.03 1.04 0.92
7 DMSO 89.45 106.42 55.54 1.00 1.00 0.92
7 DMSO 92.15 89.91 116.97 0.97 1.00 1.03
7 DMSO 124.53 98.87 150.71 0.98 0.96 1.07
7 IKK inhibitor (BMS-345541) 0.00 0.00 0.00 1.43 1.07 1.09
8 DMSO 111.18 145.72 109.88 0.94 1.03 1.00
8 DMSO 99.34 91.98 106.02 1.02 0.98 1.02
8 DMSO 79.33 86.33 94.01 0.99 0.99 1.00
8 DMSO 89.60 93.13 94.55 1.01 0.99 0.97
8 DMSO 122.52 84.62 95.09 1.05 1.01 1.01
8 IKK inhibitor (BMS-345541) 12.00 11.00 11.00 1.12 1.05 1.00
9 DMSO 107.41 102.60 94.22 1.00 1.06 1.03
9 DMSO 80.70 87.28 90.09 0.99 1.07 1.01
9 DMSO 102.34 107.45 118.34 0.97 0.95 0.97
9 DMSO 100.29 86.92 83.23 0.98 0.96 1.00
9 DMSO 110.42 116.20 115.94 1.06 0.96 0.99
9 IKK inhibitor (BMS-345541) 0.00 0.00 0.00 1.20 1.19 1.38
10 DMSO 145.60 98.06 87.99 1.00 1.00 0.98
10 DMSO 102.73 92.35 132.02 1.09 0.97 1.00
10 DMSO 87.05 101.94 60.34 0.96 0.97 0.92
10 DMSO 91.45 89.76 120.52 0.97 1.05 1.07
10 DMSO 79.04 119.60 105.57 0.99 1.02 1.03
10 IKK inhibitor (BMS-345541) 0.00 0.00 0.00 1.48 1.33 1.21
11 DMSO 86.06 82.66 104.33 1.02 0.99 0.99
11 DMSO 114.22 137.53 121.07 1.02 1.01 0.99
11 DMSO 76.48 82.19 87.20 0.96 0.98 0.97
11 DMSO 106.61 127.34 94.85 1.00 1.04 1.03
11 DMSO 119.04 74.62 91.86 1.00 0.99 1.02
11 IKK inhibitor (BMS-345541) 18.74 75.09 54.69 0.94 1.06 0.96
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Construction of an LPS directed signaling network map 
3.1 Introduction  
 
In the previous chapter (Publication number 01) there was no assumption made concerning 
the hierarchical or topological structure of protein nodes within the signaling network of 
LPS-activated macrophages.  Despite the limited chemical diversity of the library explored 
here, an initial unbiased random selection of reagents was evolved iteratively (in a biased 
fashion) to reflect a satisfactory outcome against the objectives to optimise against.  
Subsequent optimization of component reagents in paired combinations with respect to 
concentration yielded combinations that are theoretically, primarily inhibiting their 
intended pharmacological targets (i.e. SB203580 = p38 MAPK and BMS345541 = IKK). 
 
Barabasi and Oltvai (Barabasi and Oltvai 2004) provide a thorough overview of network 
architecture analysis and how the application of mathematical graph theory underpins this 
study.  Briefly, biological networks can be abstracted to nodes (e.g. transcription factors, 
metabolites) and edges (the links between the nodes, often transformative and encoded by 
enzymes). These networks of nodes (hubs) and edges (links) can have directionality (e.g. 
where a signal is transduced via a number of cytoplasmic intermediates from the 
membrane to the nucleus).  The number of edges that feed in or out of a node define the 
degree of the node, often represented by the nomenclature k in the literature, 
correspondingly <k> represents the average degree of all nodes within the network. The 
architecture of biological networks is characterized by their 'scale free' nature, conversely, 
random networks have nodes with an <k> that equates to a Poisson distribution - all nodes 
have approximately the same number of links.  Scale free networks exhibit a power law 
distribution, where, the probability of any node displaying exactly k links (P(k)) 
is given by the relationship (14). 
 
P(k) ≈ k-γ          (14) 
 
 
Where γ is the degree exponent and often takes a value between 2 and 3. Nodes 
within scale free networks display a non-uniform distribution of links, with few 
nodes being highly connected and the majority displaying low numbers of links. 
Another property of scale free networks is that they are ultra-small (i.e. they 
exhibit small world properties), with any two nodes being connected to each other 
by only a few edges. The significance of this in the context of a signal transduction 
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network could be interpreted in the sense that any marked perturbation to a node 
is quickly propagated to the remaining network. The evolution or emergence of 
biological scale free networks is thought attributable to two phenomena (Barabasi and 
Oltvai 2004): 
 
1. Disassortativity - where highly connected nodes avoid connecting to one another. 
2. Preferential attachment - where nodes will attach to nodes that have a greater 
number of links than themselves. 
 
Modularity of networks can be defined in terms of clustering coefficients, which is an 
index of the networks potential modularity. Recurrent modules often referred to as motifs 
are key signatures of biological networks.  However, the genesis of such network maps is 
dependent on data from the literature and associated datasets.  
 
3.2 Network map construction 
 
Mining published data concerning the LPS directed signaling and molecular biology of IL-
1β expression from the last ~ 30 years enables a model or map to be created.  Delineating 
publications where dynamic roles for transcription factors in IL-1β expression have been 
shown limits the mapped space of the network to those nodes and edges that have a 
demonstrable role in IL-1β expression.  This is almost certainly an underestimate of the 
interactions.   Network maps, provide a reference and address topological and hierarchical 
issues of node positioning.  Furthermore qualitative network analysis is a necessary 
precursor to the building of quantitative models of biological phenomena capable of 
simulation as their study can lead to the detection of emergent behaviour.                     
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Abstract 
 
Interleukin-1-beta (IL-1β) is a potent, pleiotropic, pro-inflammatory cytokine and its 
transcriptional regulation and expression are key steps in the mounting of robust 
inflammatory responses.  Lipopolysaccharide (LPS)-induced IL-1β expression 
requires toll-like receptor 4 (TLR4) in myeloid cells and is driven in large part via 
the MyD88-IRAK-1-IRAK4-TRAF6 complex and consequently p38-MAPK, JNK 
and NF-κB signaling networks.  LPS triggered responses involve signaling networks 
that are utilised by many other inflammatory stimuli and therefore presents a very 
useful experimental model.  Here we present a signaling network map of LPS-
induced IL-1β transcription.  Transcription factors (TF) targeted by these signaling 
networks coalesce at precise nucleotide binding elements within the IL-1β 
regulatory DNA.  Constitutive binding of PU.1 and C/EBP-β TF’s are obligate for 
IL-1β expression.  We suggest that PU.1 and C/EBP-β TF’s form scaffolds for the 
tailored modulation of dynamic control exerted by other TF’s, exemplified by c-Jun.  
Similarly, IL-1β expression induced via NF-κB, CREBP and Fox01 provides a 
further layer of modulation.  High-throughput parallel measurements of interactions 
show that combinations of TF regulate transcription..  Epigenetic factors, such as the 
hetero-euchromatin balance, are also important in the relative transcriptional 
efficacy in different cell types.  The development of network maps such as these are 
a mandatory first step in the building of dynamic models capable of being simulated 
in silico.  A deeper understanding of the transcriptional regulation of IL-1β will 
inform a broader understanding of cytokine modulation at the cellular level and the 
development of chronic inflammatory diseases.   
 
Number pages: 38 
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Introduction 
Pro-inflammatory cytokines and particularly interleukin-1 (IL-1) 1 are implicated in 
acute and chronic inflammatory conditions associated with common diseases such as 
atherosclerosis, asthma, cancer, stroke 2, chronic obstructive pulmonary disease, 
obesity, inflammatory bowel disease, and rheumatoid arthritis 3.  IL-1 family 
consists of 11 members (ILF1 – ILF33) 1.  The prototypical and pleiotropic IL-1 
receptor I (IL-RI) agonists IL-1 alpha (IL-1α) and IL-1 beta (IL-1β) are synthesised 
primarily by cells of the innate immune system such as macrophages and 
monocytes.  They are first translated as 31 kDa precursors and later converted to 
their 17 kDa mature forms by proteolysis promoted by either calpain and caspase-1, 
respectively 4.  Mature IL-1β is released in response to stimuli that activate a 
potassium ion efflux (e.g. via P2X7) of myeloid cells and acts as a paracrine 
mediator of inflammation.  IL-1α is also thought to play a role as an autocrine 
growth factor 5, 6.  The three step process of expression, activation and release of IL-
1β compared to the two step process of other pro-inflammatory cytokines (i.e. 
expression, release) is indicative of the important role of this protein in innate 
immune signaling and inflammation.  Nevertheless, this still belies the extensive 
negative feedback that takes place at TLR4 and downstream complexes to further 
attenuate IL-1 mediated signaling (for review see 7).   
 
Lipopolysaccharide (LPS) is a primary constituent of the Gram-negative bacterial 
outer membrane and mediates mammalian endotoxic responses; a major 
complicating factor in sepsis 8.  The recognition of LPS by toll-like receptor 4 
(TLR4) was demonstrated by Poltorak 9.  The high affinity interaction (EC50 = 4.41 
± 0.16 pg / mL, 10) between TLR4 and LPS, convoluted and sequential assembly of 
proteins (i.e. LBP, CD14, MD-2) and their evolutionary conservation suggests that 
the LPS signal and, unsurprisingly by proxy, that bacterial infection is sufficiently 
noxious to warrant their co-ordinated expression.  Interest in TLR4 mediated 
responses extends beyond the paradigm of infection to include sterile injury 11, 
where it is becoming arguably recognized that intracellular molecules (e.g. HSP60, 
HMGB1) also transduce their effects via TLR4 12 and particularly macrophage 
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expression of IL-1β 13, 14.  The requirement for an integrated and coherent map of 
TLR4 mediated IL-1β expression in myeloid cells is of vital importance to an 
understanding of both fundamental mechanisms of cell signaling and the 
pathogenesis of inflammation. 
 
Here, we present an integrated and mechanistic signaling network map detailing the 
detection of LPS, transduction of the signal from the cytoplasm to the nucleus and 
consequent expression of IL-1β in macrophages and monocytes of human and 
murine origin.  This includes an overview of the transcription factors (TF) that bind 
the regulatory DNA and modulate pro-IL-1β gene expression.  Further, to describe 
regulation of IL-1β gene expression by indirect kinase mediated signaling (p38 
MAPK 15 and JNK 16) and direct transcriptional control via nuclear factor kappa-
light-chain-enhancer of activated B cells (NF-κB) mediated signaling 17.  This 
review focuses on the molecular interaction map presented as a systems biology 
graphical notation (SBGN) 18 process diagram (Fig 1) and supplementary systems 
biology mark up language (SBML)19 file.  
 
Owing to the degenerate nomenclature of transcription factors over preceding 
decades, it is important to specify these entities in a clear way.  Table 1 lists the 
relevant TFs uniquely identified through the UNIPROT database 20 naming 
conventions and identifiers, as well as their related synonyms (Table 1).  This should 
facilitate unique identification of these molecules. 
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Table 1.  Transcription factors (TFs) involved in IL-1β transcription.   
Transcription 
factor 
Human 
gene name 
Synonyms Human / murine 
UniProt Accession 
ID 
PU.1 SPI1  Spi1, NFIL-1βA (NF-βA) P17947 / P17433 
 
NF-κB p65 NFKB3 p65, RelA, NFKB3p50 
(p105/NFKB1 precursor) 
 
Q04206 / Q04207 
NF-κB p50 NFKB1 KBF1, NF-kappaB, 
NFkappaB, NFKB-p50, 
p50, p105 
 
P19838 / P25799 
C/EBP-β CEBPB  NF-IL6, LAP, TCF5, 
PP9092 
P17676 / P28033 
 
IRF8 IRF8 NF-β1, ICSBP1  Q02556 / P23611 
 
IRF4 IRF4 NF-β2, NF-EM5, LSIRF, 
MUM1 
Q15306 / Q64287 
 
Methods and search criteria 
 
A comprehensive map of TLR signaling has been constructed, but provided no detail 
regarding transcriptional events 21.  We have interrogated published data using 
literature already known to us21, 89, 90, 103.  Additionally, we show the initial genesis 
of targeted PubMed135 search queries (Table 2) that were used to update known post-
translational modifications (PTMs) of signaling proteins from 21 and the actions of 
TF’s at IL-1β regulatory DNA where an effect has been observed on a reporter (e.g. 
luciferase).  We present the IL-1β regulatory DNA sequence (Figure 1) in 
accordance with the structure of the BDC454 clone (a 14 kb sequence containing the 
entire transcriptional unit of the IL-1β gene) 22.  It has been necessary to assume that 
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biochemical interactions validated in cell types (e.g. HEK293) other than myeloid 
cells and often in the absence of LPS stimulation also occur in macrophages and 
monocytes under these conditions. 
 
Table 2.  Publications and search terms used in PubMed for extracting literature 
concerning LPS-directed IL-1β transcription. 
Author Reference 
# 
search terms References 
returned 
Reference 
# 
 
Toll-like receptor signal transduction a 
 
Oda and 
Kitano 
2006 
21   7, 9, 14, 
19, 27, 30, 
31, 41, 49, 
55, 56, 60, 
73,   
  (LPS activation of MKK) OR 
((TLR4 and TRAF6) AND and 
macrophage) OR (TLR4 
activation of MKK) OR (traf6 
activation of MKK) OR 
(TAK1 activation of MKK) 
 
51 29, 82, 41 
  LPS OR 
lipopolysaccharide[Title/Abstr
act] AND Toll-
like[Title/Abstract] AND 
receptor*[Title/Abstract] AND 
TLR4 [Title/Abstract] 
 
2042 9, 10, 55, 
56, 27, 31, 
63, 25, 12, 
67, 126,  
  LPS AND TAK1 OR TAB1 
AND phosphorylation 
 
92 49 
  LPS OR lipopolysaccharide 
OR TLR4 AND MKK6 AND 
p38 
 
12 41 
IL-1β transcription 
 
Zhang et 
al., 2008 
89  14 104, 100, 
107, 110, 
115, 103, 
90, 116, 
7 
102, 109, 
121, 101, 
111, 88 
Unlu et 
al., 2007 
103  10 22, 97, 98, 
106, 90, 
104, 100, 
101, 102, 
110 
 
Liang et 
al., 2006 
90  10 100, 107, 
108, 106, 
116, 102, 
104, 88, 
111, 109 
 
  LPS OR lipopolysaccharide 
OR TLR4 OR toll-like receptor 
4 AND (p38 MAPK OR NF-
κBb) AND interleukin-1 beta 
OR IL-1 beta AND expression 
AND transcription AND 
macrophages 
 
471 117, 118, 
113, 120, 
114, 121, 
104, 111, 
109, 106, 
98, 72 
  ((Interleukin-1 beta OR IL-1 
beta) AND and Promoter) 
AND and macrophages 
118 117, 118, 
113, 120, 
114, 121, 
104, 109, 
106, 99 
  
a
 Additional search terms relating to Toll-like receptor signal transduction included "Mal TLR4", 
"LPS TLR4 MD-2", "IRAK TLR4", "TLR4 Pellino", "Pellino IRAK", "TLR4 TAK1", "TLR4 
Tollip", "TRAF6 UeV1A Ubc13" 
b
 Replacement of ‘p38 MAPK’ with ‘NF-κB’ yielded an identical set of search results. 
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Structural overview of the signaling network map effecting IL-1β expression 
 
The sequence of events that convert the LPS sequestered signal via 
lipopolysaccharide binding protein (LBP) 23 and glycosylphosphatidylinositol (GPI) 
linked glycoprotein: CD14 24 into an IL-1β output are presented in Figure 1. Control 
mechanisms facilitating the numerous feedbacks are encapsulated in Table 2.  
Leucine rich repeats (LRR) in TLR4 aid the detection of LPS and modulate TLR4 
interaction with lymphocye antigen 96 (MD2) respectively 12,25.  This leads to the 
recruitment of signaling adaptor proteins containing Toll-like/IL-1 receptor (TIR) 
domains.    
 
TIR domain signaling adaptors specify initial output signal 
 
Signaling catalysed by the TIR containing adaptor protein, myeloid differentiation 
primary response gene (88) (MyD88) 26 in conjunction with the TIR domain 
containing adaptor protein (TIRAP, also called Mal) 27-29 is of primary concern here. 
These early MyD88 dependent signaling events activate IL-1β expression via p38 
MAPK, JNK and NF-κB dependent transcription 30.  Endosomal internalisation of 
later TLR4 signaling occurs via the complexation of TLR4 with TIR-domain-
containing adapter-inducing interferon-β (TRIF) and TRIF-related adapter molecule 
(TRAM)31.initiating interferon expression.  We make no attempt to review TRIF / 
TRAM dependent responses here 28.    
 
IRAK-1/4 transduces MyD88-dependent signals 
 
Interleukin-1 receptor associated kinase (IRAK) proteins are recruited via their N-
terminal death domains to co-localise with MyD88 32, 33.  The activation of IRAK 
occurs via rapid phosphorylation, (potentially by IRAK4 in vivo) and subsequent 
auto-phosphorylation 34.  Hyperphosphorylation of key serine, proline and threonine 
residues in the proST domain 32 of IRAK1 achieve full kinase activation.  This 
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facilitates IRAK1 uncoupling from MyD88 and subsequent interaction with tumor 
necrosis factor receptor-associated factor 6 (TRAF6) 35. 
 
Ubiquitination; an essential post-translational modification for transduction 
and feedback   
 
Polyubiquitination of the Lys-63 residue of IRAK1 is mediated by the interaction of 
Pellino E3 ubiquitin ligases 36 and TRAF6 37 enabling IRAK1 binding to NF-κB 
essential modulator (NEMO) and consequent NF-κB activation 37, 38.  Ubiquitination 
is a vital post-translational modification necessary to ensure the efficient 
transduction of the LPS signal via IRAK proteins.  
 
 
TRAF6 and TAK1 specify the signaling sub-system 
 
TRAF6 functions as a central component of the LPS signaling complex which is 
bound to IRAK1 via interactions of both proteins with TRAF-interacting protein 
with a forkhead-associated (FHA) domain (TIFA) 39.  TIFA is required for inhibitory 
kappa kinase (IKK) activation and is thought to play a role in oligomerisation and 
polyubiquitination of TRAF6 40.  The E3 ubiquitin ligase activity of TRAF6 is 
conferred by its really interesting new gene (RING) domain and is necessary for its 
interaction with the dimeric E2 enzyme Ubc13/Uev1A (also called TRAF-6 
regulated IKK activator 1 (TRIKA1) 41).   
 
Transforming growth factor-β associated kinase-1 (TAK1) activation occurs at the 
plasma membrane via interactions with TAK1 binding protein 1 (TAB1) and TAB2.  
Phosphorylation of TAK1 occurs following TAB1 and TAB2 activation 42 by Lys-
63 poly-ubiquitination of TAB2 43.  A bifurcating output may occur here where a 
putative Lys-63 poly-ubiquitinated complex of 
.IRAK4.IRAK1.TRAF6.UeV1A.UBC13 that condenses with a TAK1 -TAB1/2 
complex in the absence of Mitogen-activated protein kinase kinase kinase 3 
10 
(MEKK3) 44(Figure 1) may activate IKK 45,46 via NF-κB inducing kinase (NIK) 47, 
48
 and p38α MAPK directly via its auto-phosphorylation 49.  This may occur ahead 
of MKK6, MKK7, and direct canonical IKK 50, 51 activation which has a requirement 
for MEKK3.   
 
The plethora of negative feedback loops (Table 2) in the upper echelon of the TLR4-
IL-1β network are indicative of the structured and coordinated regulation of this 
cytokine.  Ubiquitination and phosphorylation are two vital PTMs in mediating these 
effects.  Although TLR inputs other than TLR4 are not presented explicitly, it is 
reasonable to assume our map conforms to the ‘bow tie’ structure elucidated by Oda 
and Kitano 21.  Where signals are transmitted via the active 
TAK1.TAB1/2.IRAK4.IRAK1.TRAF6.UeV1A.UBC13 (here on in the TRAF6 
active) complex and ‘kinase pivot’ (e.g. all tiers of MAPK and NIK and IKK) 
(Figure 1) differentially to receiver TFs.  A member of the Nod-like receptor family, 
NLRP12 inhibits both the incorporation of IRAK1 and catalyses NIK degradation 52.  
The NLR family is involved with inflammasome formation, leading to IL-1β 
processing 53.  Although, not demonstrated as yet, NLRP12 may catalyse the 
maturation of IL-1β, whilst inhibiting its transcription.  This opposing feedback 
control exerted by NLRP12 at transcriptional and translational levels may function 
to resolve inflammation.  
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Table 3.  Feedback control of lipopolysaccharide stimulated signal transduction mediating IL-1β expression 
Complex / Protein 
affected (see Fig 1) 
Type of feedback Source Target Notes References 
Bound TLR4 Negative sTLR4 CD14, MD-2 and 
LPS 
Competes for 
targets, inhibiting 
TLR4 signaling 
54
, 
55
 
Bound TLR4 
 
Negative MD-2 TLR4 MD-2 dimerises, 
limiting interaction 
with TLR4 
56
, 
57
 
TLR4 Negative Triad3A TLR4 Ubiquitinates TLR4 
triggering 
proteasomal 
degradation 
58
 
Bound Receptor 
TIR complex 
Negative SIGRR TLR4-MyD88-
TIRAP 
Sequesters the 
complex preventing 
further signaling 
59
 
Bound Receptor 
TIR complex 
Negative ST2L TLR4-MyD88-
TIRAP 
Competes with 
TLR4 for MyD88 
and TIRAP 
60
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Table 3.  Feedback control of lipopolysaccharide stimulated signal transduction mediating IL-1β expression 
Complex / Protein 
affected (see Fig 1) 
Type of feedback Source Target Notes References 
IRAK1.IRAK4.TIFA. 
TRAF6 
Negative 186 aa of N-term 
residues of IRAK 
IRAK1 / IRAK4 N-terminal 
sequence facilitates 
the degradation of 
the IRAK protein  
61
 
IRAK1 Negative Tollip IRAK1 / IRAK4 Thr66 mediates 
interaction with 
Tollip, thus limiting 
interaction with 
MyD88 and IRAK4 
62, 63
, 
64
 
Bound Receptor TIR 
complex 
Positive IRAK Pellino Phosphorylation of 
Pellino by IRAK 
amplifying signal 
38
 
Bound Receptor TIR 
complex 
Negative viral-Pellino IRAK Lacks E3 activity 
and inhibits 
signaling 
65
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Table 3.  Feedback control of lipopolysaccharide stimulated signal transduction mediating IL-1β expression 
Complex / Protein 
affected (see Fig 1) 
Type of feedback Source Target Notes References 
Bound Receptor 
TIR complex 
Positive Smad6 / Smad7 Pellino Differential binding 
may enhance IRAK 
mediated signals 
66
 
Bound Receptor 
TIR complex 
Negative IRAK1 / IRAK4 TIRAP Degradation of 
TIRAP by IRAKs 
67
 
Bound Receptor 
TIR complex 
Negative IRAK-M TRAF6 IRAK-M prevents 
formation of an 
active TRAF6 
complex 
68
 
Bound Receptor 
TIR complex 
Negative TIFAB IRAK1 Impedes IRAK-1 – 
TRAF6 interaction 
69
 
Bound Receptor 
TIR complex 
Negative ZCCHC11 
MCPIP1 
TRAF6 Zinc finger proteins 
that de-ubiquitinate 
TRAF6  
70
 
71
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Table 3.  Feedback control of lipopolysaccharide stimulated signal transduction mediating IL-1β expression 
Complex / Protein 
affected (see Fig 1) 
Type of feedback  Source Target Notes References 
TAK1.TAB1. 
TAB2.IRAK4. 
IRAK1.TIFA. 
TRAF6.UeV1A. 
UBC13 
Negative p38α MAPK TAB1 TAB1 
phosphorylation 
impairs TAK1 
72
 
TAK1.TAB1. 
TAB2.IRAK4. 
IRAK1.TIFA. 
TRAF6.UeV1A. 
UBC13 
Negative A20 TRAF6 A20 (Tnfaip3) de-
ubiquitinates 
TRAF6 inactivating 
this complex 
73
 
p38 MAPK 
JNK1 
Negative DUSP1 p38 MAPK 
JNK1 
DUSP1 (MKP-1) 
attenuates the 
phosphorylation of 
both p38 and JNK1 
74
 
75
 
p38 MAPK Negative PTP4A3 p38 MAPK Decreases p-p38  76 
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The activation of indirect and direct transcriptional control of IL-1β expression  
 
The activation of indirect MAPK (c-jun N-terminal kinases (JNK) and p38) and 
direct NF-κB mediated signaling provides layers controlling IL-1β transcription. .  
The activation of both JNK and p38 MAPK sub-types is initiated via cellular 
stresses such as arsenite, ansiomycin, IL-1 and TNF 16,15 and potently by LPS 
stimulation 77,78.  Both JNK 79 and p38 MAPK 14 are regulated via the mitogen 
activated protein kinase kinase kinase (MAP3K or MKKK), apoptosis signal-
regulating kinase 1 (ASK1) 80 and MAP2K (or MKK) isoforms that include MKK7 
81, 82
, and MKK4 83,84, MKK3/6 83, 85 respectively.  Negative feedback mediated by 
dual specificity MAPK phosphatase 1 (DUSP1 or MKP-1) 86, 75 and the protein 
tyrosine phosphatase – PTP4A3 76 is summarised in table 2. 
 
A direct association of p38 MAPK with casein kinase II (CKII) under stress 
conditions in HeLa cells, albeit in the absence of LPS has been observed 87.  Lodie et 
al 88 established the LPS induced phosphorylation of PU.1 at a ser148 residue that sits 
within a CKII motif.  CKII inhibitors (e.g. apigenin, disogenin) have also been used 
attenuate LPS-induced IL-1β transcription 89-91 
 
NF-κB is the proto-typical inducible TF that initiates either cannonical (via IKK 
phosphorylation of IκBα) or non-cannonical signaling via NIK) freeing NF-κB 
dimers to engage in gene transcription 17.  Activation of this signaling complex 
involves stresses similar to that observed for MAPK signaling networks (e.g 
cytokines, protein kinase C activators, oxidants and viruses) 92 
 
The structure of IL-1β regulatory DNA  
 
The isolation of human and mouse complementary DNAs (cDNA) that initiated the 
study of IL-1 gene regulation has been well documented 93,94,95.  Identification of TF 
binding elements (i.e.TATA (-31) and CCAAT (-126 and -75) motifs) 22, TATAAA 
(-32 to -27) and CCAAG (-74 to -71) 96, the stimulation of human monocytes by 
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LPS 97,  phorbol 12-myristate 13-acetate 98 and definition of the CAP site proximal 
(CSP) promoter element (-131 to +1) and phorbol ester inducible enhancer (-2982 to 
-2795) 99 are presented in the references herein.  Enhancer (-3,757 to -2599) and 
promoter (-1807 to +1) regions are defined arbitrarily here for the sake of clarity 
(Figure 1) 
 
The LPS sensitivity of the IL-1β enhancer 
 
Regulatory regions that effect the LPS sensitivity of IL1B transcription are 
recognised as either overlapping or upstream of the phorbol ester sensitive element 
99
.  Shirakawa et al 100 defined three regulatory regions in the IL1B enhancer from 
the human BDC454 clone (a 14 kb sequence containing the entire transcriptional 
unit of the IL-1β gene) situated between -3757 to -2923 nucleotides that were LPS 
sensitive.  These nucleotide locations were later updated by the same group 101 
(legend of Table 3).  Regions were assigned as A (-3757 to -3132), B (-3132 to -
2987) and C (-2987 to -2923) (Table 3 and Figure 1) and thought responsible for 20, 
60 and 20 % of the LPS driven transcriptional response of IL1B, respectively.  
Although not necessary for an LPS-inducible signal, deletions of a downstream 
sequence (-2729 to -131) revealed impaired expression of the CAT reporter.  
Deletion of a region between -2729 to -2599 enhanced CAT expression, suggesting 
negative feedback on expression was mediated by elements within this region.  
Shirakawa et al summarise their findings by sub-dividing the -3757 to -2599 region 
into sub-regions denoted A - J (Table 3 and Figure 1) with varying degrees of 
importance in supporting LPS-inducible expression.  Regions C and E are specified 
as being 'required', regions B, H and I as being strongly supportive and region A as 
weakly supportive of a role in LPS-inducible expression.  This study 101 denoted the 
distal nucleotide of region B (-3134) to the proximal nucleotide of region I (-2729) 
as the upstream induction sequence (UIS). 
 
An update of the function of the UIS of the IL1B enhancer, specifically between 
regions F - G (named the LPS and IL-1 responsive element; (LILRE)101,102) has been 
17 
outlined 103.  A trimer of a non-tyrosine phosphorylated Stat 1, PU.1 and IRF8 is 
bound constitutively between a narrow element encompassing -2862 and -2831 
nucleotides in the LILRE (encompassed by elements -2866 through to -2833; Figure 
1).  The authors were able to attribute ~ 90 % of the reporter expression to IRF8 
phosphorylation, when comparing wild-type and a non-phosphorylatable mutant 
IRF8 Tyr -211-Phe expression vectors, co-transfected with TRAF6, PU.1 and an 
IL1B XT (-3757 to +12) – luciferase coupled reporter in LPS (10 µg / mL, 4 h) 
stimulated RAW264.7 cells.  Although knowledge of dimeric interactions between 
IRF and PU.1 proteins at the IL-1β enhancer had been noted much earlier 104.  
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Table 4.  Enhancer regulatory domains of the human IL-1β gene.  An earlier report 
100
 had missed the presence of two cytosine (C) nucleotides between positions -2748 
to -2747 that were later accounted for 101.  The corrected regions are shown.  
Nucleotide positions within regions correspond to their relative position to the 
transcriptional start site (+1) here and in the main body of the text. 
Region Binding Site Identity References 
-2982 to -2795 Putative AP-1 (-2892 to -2883) & IFN-β 
(-2853 to -2845)  
99
 
-3757 to 3132 Region A 101 
-3134 to -2989 Region B, Putative AP-1 
-2989 to -2925 Region C 
-2925 to -2896 Region D, Putative AP-1 
-2896 to -2866 Region E, NF-IL6 
-2866 to -2846 Region F, NF-β1 
-2846 to -2833 Region G, NF-β2 
-2833 to -2782 Region H 
-2782 to -2729 Region I, CREB / AP-1 & NF-κB site 
-2729 to -2599 Region J, Putative AP-1 
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The role of PU.1 and C/EBP-β TF’s in the IL-1β promoter  
 
Human IL1B and murine Il1b gene promoter architectures reside in open or 
accessible configurations and are not complexed with either acetylated or 
unmodified histone H3 90.  The constitutive association of both PU.1 and C/EBPβ in 
both mouse (RAW264.7) and human (MM6) macrophages was demonstrated via 
chromatin immunoprecipitation (ChIP) 90.  Within the map (Figure 1) these 
associations are demonstrated by interactions with elements from -199 through to 
+1.  Similarly, the TATA box binding protein (TBP) is constitutively bound to the 
IL1B promoter in MM6 monocytes 89, further exemplifying the transcriptional poise 
of this promoter. 
 
The critical involvement of PU.1 alone 105, 106 and in tandem with C/EBP-β 107, 108,  
in driving IL-1β expression has been reported widely.  Structurally, there are three 
PU.1 sites in the CSP promoter (-120 to -93; duplicate overlapping sites,106 -49 to -
38 105, 106, 108, 109) and two C/EBP-β sites (-90 to -82 107 and -41 to -33 108) (Figure 1).  
The promoter proximal PU.1 binding element and its position in relation to the 
TATA box motif is 100 % conserved between human and mouse sequences, 
suggesting a  primary role of PU.1 in directing the initiation of IL-1β transcription, 
likely via transcription factor IID (TFIID)105.  Co-transfection studies of wt PU.1 
with constructs encoding a mutated C/EBP-β element revealed decreased binding to 
a glutathione-s-transferase-basic leucine zipper domain (GST-bZIP) column.  
Similarly, co-transfection of a mutated PU.1 domain and wt C/EBP-β showed a 45 
% reduction in wt il1b (-59 to +12) coupled luciferase reporter expression 110.  Yang 
et al.,  suggest the synergistic enhancement of il1b expression via the PU.1 winged 
helix turn helix (wHTH) DNA binding domain tethering the bZIP domain of C/EBP-
β.  They further speculate interactions with PU.1 bound to its distal CSP site and the 
same protein bound to the UIS in the enhancer and modulation of this proximal 
PU.1/C/EBP-β overlapping element by p38 MAPK.  The transcriptional targets of 
p38α include the C/EBP-β TF via the sensitivity of IL-1β (-50 to 1) promoter and  
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CAT constructs display concentration-dependent sensitivity to the bicyclic 
imidazole; SB203580 111.  Heat shock factor (HSF) has also been shown to compete 
with PU.1s interaction with the bZIP domain of C/EBP-β, effectively decreasing the 
efficacy of these TFs 112 in THP-1 cells.  However, heat shocked (39.5°C) 
RAW264.7 cells show an increased IL-1β mRNA expression compared to a 
decreased THP-1 release of this cytokine 113.  These observations can be reconciled 
by the presence of a single adenine nucleotide present in the mouse (but not human) 
heat shock response element (HSE) that likely impairs binding of HSF to the 
promoter 113.  Conversely, high mobility group box protein 1 (HMGB1) has been 
shown to enhance IL-1β promoter (HT fragment) luciferase reporter expression in 
RAW 264.7 macrophages 114. 
 
The lack of a nucleosome associated promoter and focus of the p38 MAPK and 
HMGB1 and HSF TFs on the constitutively bound PU.1 and C/EBPβ promoter 
complexes points to the rapid and acute regulation of IL-β expression.  However, 
modulation can also be achieved via inducible signals.  
 
The role of inducible TF signaling in IL-1β transcription 
 
NF-κB 
 
A decameric nucleotide NF-κB binding motif (-297 to -288) is located in the IL1B 
promoter and concentration-dependently enhances CAT reporter expression 115.  
Similarly, NF-κB p50/p65 heterodimers have the greatest efficacy in driving CAT 
reporter expression from an IL-1β x2-κB plasmid 115.  Electrophoretic mobility shift 
assay (EMSA) analysis confirmed the binding of LPS (10 µg / mL, 1 h) stimulated 
THP-1 nuclear extracts to a labeled 25 bp oligonucleotide probe (-305 to -280) that 
was effectively displaced by competition for by unlabeled Ig NF-κB oligonucleotide 
116
.   
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The role of a novel IκB protein IκBβ has recently been established suggesting this 
protein maybe selective in modulating IL-1β transcription alone 117 (Figure 1).  ChIP 
analysis of LPS (100 ng / mL) stimulated RAW 264.7 (2h) and BMDM (1h) 
macrophages revealed association of NF-κB p65 and c-Rel with the Il1b promoter (-
300).  In contrast IκBβ (-/-) mutants have decreased c-Rel recruitment to their κB 
sites.  LPS stimulated (100 ng / mL, 8 h) IL-1β-luciferase reporter constructs 
containing variable numbers of -κB sites (-518; x2, -399; x1 and -133; 0) were 
transfected into RAW264.7 cells.  The -133 construct revealed a marked reduction in 
its reporter expression in comparison to both -518 and -399 constructs. 
 
Phosphorylation of Ser536 of the NF-κB p65 subunit is not necessary for this 
subunit’s recruitment to the IL1B promoter as measured by ChIP in PMA (10 ng / 
mL) differentiated U937 macrophages stimulated with LPS (1 µg / mL; for 2 or 6h) 
118
.  Leptomycin (10 nM: an inhibitor of IκBα nuclear export) markedly affected 
LPS (10 ng / mL; 2 h) stimulated IL-1β transcription and release in U937 
macrophages.  Similarly, leptomycin ablated the NF-κB DNA binding activity of 
U937 macrophage nuclear extract, but did not affect their ability to bind AP-1 and 
CREB DNA sequences 118.  NF-κB p65 subunit appearance in the nucleus and IκBα 
disappearance from the cytoplasm has also been observed in RAW264.7 
macrophages stimulated with LPS (1 µg/mL) at 15 and 30 min time points 119. 
22 
FoxO1 
 
A role for the FoxO1 TF (which is also implicated in insulin signaling) in LPS 
directed IL-1β expression has recently been discovered 120 (Figure 1 elements -1807 
through to -1296).  RAW264.7 cells transfected with an IL-1β luciferase reporter 
and vectors encoding FoxO1 and either p50, p65 or both revealed the synergistic 
interaction of FoxO1 and NF-κB p50 in response to LPS stimulation (100 ng / mL, 
24 h)120.  
 
cAMP response element binding protein (CREBP) 
 
Enhancer located cAMP response elements were identified (Figure 1, Table 3) in the 
BDC454 clone 101.  The over-expression of constructs co-expressing C/EBP-β and 
CREBP in LPS (10 ng / mL, 24 h) stimulated THP-1 cells inhibited this LPS 
stimulated I/fos CAT reporter expression 101.  However, the treatment of reporter 
transfected THP-1 cells with LPS and either di-buturyl cAMP (100 µM) or the 
catalytic subunit of protein kinase A enhanced CAT reporter expression in a 
concentration-dependent manner 101. 
 
c-Jun  
 
Attenuated real-time (RT) PCR measurements of c-Jun were made in LPS 
stimulated (10 ng / mL; 45 min) JNK1 knockout (vs. wt) bone marrow derived 
macrophages (BMDM) 74.  The small molecule JNK Inhibitor II, SP600125 
suppressed expression of the luciferase reporter in RAW264.7 cells from a wild-type 
PU.1 lipocalin-prostaglandin D synthase (L-PGDS) promoter but not that of a PU.1 
S148A
 mutant 119. Treatment with ChIP also confirmed a direct interaction between 
PU.1 and c-Jun in RAW264.7 macrophages and BMDM's from C57BL/6 mice.  
Nuclear extracts derived from either cell type treated in the presence or absence of 
LPS (1 µg / mL, 4h) were immuno-precipitated with either anti-PU.1 or anti-c-Jun 
antibodies and the corresponding DNA extracted and amplified by PCR (using 
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primers flanking the PU.1 site).  In both LPS stimulated macrophage types, PU.1 
and c-Jun were detected by immunoblots .  A ChIP assay in RAW264.7 
macrophages 119established that c-Jun binding to the PU.1 site in the L-PGDS 
promoter was reduced by addition of SP600125 (10 µM) or SB-220025 (10 µM) 
reflecting predominant, if likely non-selective JNK and p38 MAPK inhibition.  
However, neither JNK or p38 MAPK inhibition affected PU.1 binding to the L-
PGDS promoter in LPS stimulated RAW macrophages. 
 
The binding (compared to wt) of [35S] labeled mutant c-Jun homodimers to GST-
C/EBP-β columns revealed a relatively decreased binding compared to that observed 
in the GST-PU.1 column.  However, co-transfection of these homdimers with PU.1, 
C/EBP-β and an IL-1β131 luciferase reporter construct showed a marked activation 
of reporter expression vs. wt.  In summary, c-Jun co-activation of PU.1 and C/EBP-
β complexes via the DNA binding domains of c-Jun necessitate their interaction and 
preclude c-Jun engaging in direct transcriptional activation 121.  
 
Induced binding of the NF-κB, c-Jun and CREBP TFs presented here point to an 
additional layer of regulation that may reflect the phased fine-tuning of IL-1β 
expression in response to environmental stimuli.  For example, LPS stimulated 
CREBP-C/EBP-β complexes may provide a tonic inhibition of IL-1β expression in 
the absence of protein kinase A mediated phosphorylation of CREBP.  Enhancement 
of IL-1β expression may commence once this CREBP phosphorylation has been 
completed 101.  The co-dependency of FoxO1 and NF-κB p50 in  regulating IL-1β 
expression also suggests that combinatorial TF binding and action being a general 
strategy by which TF achieve their aims (see next section - Parallel measurements of 
LPS stimulated transcription in myeloid cells)  
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Parallel measurements of LPS stimulated transcription in myeloid cells 
 
Network maps compiled from the literature often present the observer with a biased 
set of interactions with respect to environment and experimental perturbation where 
often only limited sets of TF’s are monitored.  Increasingly the use of high-
throughput, parallel measurements allow measurement of genome-wide changes in 
TF expression, progressively alleviating this bias (Table 4).   
 
The degenerate nature of TF binding motifs and the often overlapping nature of 
these sites in conjunction with the native chromatin structure of the gene make it 
difficult to assign a predominant transcriptional regulation by any one factor.  
Indeed, the combinatorics of TF binding and dynamics of these interactions make 
understanding IL-1β expression very complex (e.g. sub-proteins of the NF-κB 
family). 122 explored combinatorial interactions of TFs using mammalian-2-hybrid 
(M2H) and qRT-PCR assays in tandem. The authors provide a classification of TFs 
into ‘facitlitators’ or ‘specifiers’.The former have a broad tissue expression that in 
combination with the narrower tissue expression of ‘specifier’ TFs dictates 
development and or embryogenesis dependent on the cellular context.  Progress 
already made by applying these parallel measurement technologies will hopefully 
continue to provide even more detail concerning IL-1β transcription. 
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Table 5.  LPS directed changes in innate immune cells of myeloid type measured via parallel measurement methods  
Cell type  LPS 
(ng / 
mL) 
Time 
(hours) 
Method Results Conclusion Ref 
BMDM (p300) 
RAW264.7(PU.1) 
10 2 ChIP-seq Identification of 2432 (p300 acetyl-transferase) inducible 
peaks (vs.control).  
PU.1 association not different between LPS treated 
(44,243) and untreated (44,4453). 
p300 acetyltransferase binding is LPS induced at 
promoter (-184) and enhancer (-39461) regions, but not 
other enhancers (-9901 and -2466)  relative to the il1b 
gene. 
PU.1 association is largely 
constitutive. 
p300 plays a role in inductive 
gene transcription.  
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BMDM 10 2 cDNA 
microarray 
qPCR 
Identification of 2892 transcripts.   
Notable transcripts down-regulated 2h after LPS 
stimulation: Tlr4, Stat4, Sirt1 
 Notable transcripts up-regulated 2h after LPS 
stimulation: Nfkb2, Tlr2, MAP3K8, Bcl3, Cxcl2. 
Notable TF’s up-regulated 2h after LPS stimulation: 
Atf4, Cited2 (p300 interacting protein), Nfkbiz, Bcor 
Transcripts clustered based on 
promoter structure were 
significantly co-expressed. 
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Abbreviations.  BMDM: Bone marrow derived macrophage 
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Table 5.  LPS directed changes in innate immune cells of myeloid type measured via high-throughput methods  
Cell 
type  
LPS 
(ng / 
mL) 
Time 
(hours) 
Method Results Conclusion Ref 
BMDC 100  6 Microarray, 
shRNA perturbation 
Identification of 2322 significant regulatory 
interactions noted.  shRNA perturbation of LPS 
stimulated cells revealed that Nfkbiz,  Nfkb1, 
Socs6, Runx1, Bhlhb2, Hat1, Hhex, Trim12, 
Cebpb,Cited2, Bcl3 were all up-regulated for il1b 
expression. 
Delineated transcriptional programs.  
PAM (TLR2) inflammatory response 
and a poly(I:C)  (TLR3/MDA5) 
antiviral response.  Both are induced 
by LPS (TLR4). 
125
 
BMDM 100 0.75 SILAC and phosphopeptide 
enrichment based MS and in 
silico promoter analysis.  
siRNA knockdown 
in silico promoter analysis of 50 TF families with 
phosphorylated members identified enrichment of 
NF-κB, CREB and IRFF in LPS induced genes. 
siRNA knockdown of Cebpz, Hsf1, Atf7and Cic 
suggested Il1a and Il1b as target genes. 
Merging of TF phosphorylation data 
alongside experimental and in silico 
transcriptome analysis identified non 
redundant roles for TFs in Il1b 
expression.   
126
 
Abbreviations.  BMDM: Bone marrow derived macrophage. BMDC: Bone marrow derived dendritic cell.   
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Discussion 
 
Here we present a map of the LPS stimulated signaling network in macrophages and 
monocytes of human and murine origin (Figure 1).  We have limited the scope of 
our map at the transcriptional level to TF’s with demonstrated functional roles in 
driving IL1β transcription.   Nevertheless, we are aware that these efforts are subject 
to the ‘cartographers curse’ where a map is made redundant by an inevitable and 
perpetual increase in further information. 
 
The prevailing view of IL1B expression is that the enhancer mediates inducible 
signaling in conjunction with the proximal CAP site proximal (CSP) promoter 
region.  This is thought to occur via topographical interaction of TF bound UIS 
enhancer elements that are able to fold onto the accessible promoter structure 110.  In 
contrast, the CSP promoter appears to be required for basal expression 89.  Although 
this picture is largely accurate, it belies the acute regulation of the CSP promoter by 
p38 MAPK and c-Jun, HSF and HMGB1 as discussed previously.  A20 (also called 
TNFAIP3) displays ubiquitinating and de-ubiquitinating activities that activate 
proteins and target the same for proteasomal degradation respectively.  These 
processes operate above and below the ‘kinase pivot’.  A20 deactivates the TRAF6 
active complex 73 and modulates the ubiquitination status of the IKK complex127.  
On-going investigations should attempt to resolve how macrophage signaling 
networks interpret the similarities and differences in PTM’s.  
 
It is becoming increasingly clear that epigenetic parameters also impact the 
expression of IL-1β.  The equilibrium between hetero and euchromatin respectively 
can mediate IL-1β transcription and LPS tolerance in sepsis 128.  Demethylation of 
undifferentiated and differentiated HL-60 monocytic cells caused increases in IL-1β 
expression that was augmented by LPS (250 ng / mL; 4 h) stimulation 129 
  
Inevitably, attempting to represent a four dimensional dynamic system (x,y,z and 
time) in two dimensions (x,y) is a limiting factor in the utility of these maps.  
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Dynamic reconstructions of the network map, in the form of event based models 
130
,
131could be used to investigate the temporal element of this control.  Systems 
biology approaches are likely to significantly enhance our ability to generate testable 
hypotheses 132 that will allow verification of basic disease mechanisms that 
contribute to chronic inflammatory conditions and particularly non-communicable 
disease 133, 134.   
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Figure legends 
 
Figure 1.  A network map of lipopolysaccharide (LPS) directed signaling in 
macrophages and monocytes of human and murine origin.  LPS directed signals are 
received via the TLR4-CD14-MD-2 complex (top, left-hand side of diagram) before 
ejection of CD14 and dimerisation of the TLR4-MD-2 complex.  Further signal 
transduction proceeds through a series of TIRAP and IRAK proteins inter alia (top, 
middle, through to mid section).  Subsequently, JNK, MAPK or NIK, IKK proteins 
are then capable of phosphorylating transcription factors (TFs) or IκB proteins 
respectively enabling direct interaction of TFs or IκB with IL-1β regulatory DNA.  
The thicker beige box bounding the diagram represents the cell membrane and 
contains the cytoplasmic signaling reactions.  Similarly, the thinner beige box 
represents the nuclear membrane and details the interactions of TFs and IκB proteins 
with the IL-1β regulatory DNA therein. 
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Discussion 
 
5.1      Introduction 
 
The major findings of this thesis were that machine learning and design of experimental 
methods coupled to wet experimental techniques in an iterative loop revealed that a p38α 
MAPK inhibitor in conjunction with either an iron chelator or IKK inhibitor could 
synergistically inhibit LPS-dependent IL-1β expression in macrophages.  Levels of 
inhibition were achieved at concentrations below those that any compound at an identical 
concentration alone could achieve.  Additionally, construction of a TLR4 signalling map of 
IL-1β expression has revealed the modular complexity of its transcriptional activation.  
This general discussion aims to summarise the research context in a way that has not been 
explored previously in either of the chapters presented above.  
  
5.2 Efficient discovery of anti-inflammatory drug combinations using 
evolutionary computing 
 
The discovery that a p38α MAPK inhibitor, the bicyclic pyridinyl-imidazole - SB203580 
(Cuenda et al., 1995), was the common component between both paired combinations 
causing synergistic inhibition of IL-1β expression is confirmatory of the importance of 
p38α MAPK in driving expression of this cytokine rather than insightful.  When p38α 
kinase (MAPK14) was found to be sensitive to this class of compound (Lee et al., 1994) it 
was labelled as a cytokine suppressive anti-inflammatory drug binding protein (CSBP).  
Similarly, the synergistic inhibition of IL-1β expression via SB203580 and the IKK 
inhibitor, BMS-345541 (Burke et al., 2003)combination was consistent with reports that 
these two signalling networks are necessary for IL-1β expression in macrophages 
(Baldassare et al., 1999, Basak et al., 2005, Hsu and Wen, 2002, Scheibel et al., 2010).  
However, discovery of the iron chelator; SIH (Horackova et al., 2000) as a highly ranked 
reagent in the post-hoc analysis of the EA directed search of reagent combinations was 
novel.  The disproportionation (4.1) of superoxide by superoxide dimutase to hydrogen 
peroxide and the subsequent production of hydroxyl radicals (OH) by the Fenton reaction 
(4.2) (Wardman and Candeias, 1996) may tie the labile ferrous (Fe2+) iron pool to effects 
on the NF-κB signalling network (Droge, 2002, Kell, 2009).   
Disproportionation: 
  
H+ + O2- → HO2·   
HO2·  + O2- + H+ → H2O2 + O2  4.1 
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Fenton reaction: 
Fe2+ + H2O2 → Fe3+ + OH- + OH·    4.2 
 
Similarly, the regeneration of ferrous iron (Fe2+ ) from its corresponding ferric form by 
antioxidants (e.g. ascorbate) thus creates a pool of pro-oxidant capable of catalysing the 
further production of the hydroxyl radical that has a deleterious effect on cell viability.  
 
The decision to not include variable concentration of each component as a search objective 
in the decision space of the EA was appropriate (see Chapter 2).  Had just three 
concentrations been included (the minimum number required to define an IC50 
measurement) of each reagent then the search space would have increased to 299 (6.3 x 
1029) possible combinations.  Retaining the same population size would have slowed the 
search, required more iterations to reach convergence in any given objective and still, as a 
stochastic search strategy, not delineated a specific set of reagent concentrations that we 
could confidently suggest as optimal in inhibiting IL-1β expression.  Rather, the adaptive 
dose matrix search protocol, enumerated the activity of sets of paired reagents over a range 
of concentrations lower than that used in the stochastic algorithm (and hence theoretically 
increased the pharmacological specificity of the component reagents).  This ‘bracketing’ of 
concentration ensured, overall location of an optimal combination with respect to both 
mode of action and concentration.  Others (Wong et al., 2008, Sun et al., 2009) have 
employed the ‘Gur-game’ stochastic search algorithm and varied concentration but with a 
limited set of component reagents (i.e. five).  However, positing that reagent concentration 
drives target interaction specificity, then activation or inhibition of ‘off-target’ processes 
by component reagents may have shielded the true extent of the combinatorial effect.    
 
The complete scan of all possible combinations in the search space of our assay (233  or 8.6 
billion combinations), even with ultra-high-throughput screening (uHTS) techniques that 
can screen in excess of 100,000 compounds a day (Wunder et al., 2008), would likely take 
over 235 years.  The use of machine learning in drug discovery has recently been reviewed 
(Murphy, 2011) and more pertinently to combinatorial strategies (Feala et al., 2010).  This 
latter group has demonstrated previously the use of 'top down' and 'bottom up' search 
algorithms for determining optimal drug combinations in a D.melanogaster model of 
decline in cardiovascular function and exercise capacity with age (Calzolari et al., 2008).  
The authors located 3 out of 5 best drug combinations performing approximately a third of 
the tests required in a fully factorial search (i.e. 24 - 27 vs. 81).   
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The application of EA directed approaches to finding optimal drug combinations are 
superior with respect to the number of objectives that can be specified relative to the stack 
sequential and top down methods used by Calzolari et al (Calzolari et al., 2008) on their 
data tree.  Similarly, progress in the application of the tandem approaches of particle 
swarm optimisation to fit phosphoproteomic data to an ODE model of IGF-1 signaling in 
MDA-MB231 cells (Iadevaia et al., 2010), and IC50 data from 60 tumourigenic cell lines to 
45,344 compounds derived from the National Cancer Institute, were fitted to minimal 
hitting set models via use of a simulated annealing algorithm (Vazquez, 2009).  
 
Hsueh et al., (Hsueh et al., 2009)examined whether increasing the number of inputs or 
stimuli (LPS,  IFN-β, TGF-β, IL-6, isoproterenol and a non-hydrolysable cAMP analogue) 
in RAW264.7 cells would elicit unique and iteratively complex responses that scaled with 
input number.  The authors demonstrated that most higher-order (>3) combinations 
produced less than additive responses in their individual cytokine outputs relative to the 
synergy observed for pair-wise combinations.  This is concordant with the results of the 
study presented here, in which the triple combination of p38α MAPK inhibitor, iron 
chelator and IKK inhibitor did not exhibit a synergistic inhibition of IL-1β expression.  
The authors interpret these observations as evidence for the encoding of multiple-signals 
along ‘sparse and discrete’ routes and the ‘limitation of interaction complexity’.  However, 
these conclusions are not supported by the data, where we might expect maintenance of a 
response type (i.e. synergy) if the effects were mediated via few types of signaling 
complex.  An alternative interpretation of the data might posit that additional stimuli 
activate either inhibitory networks or processes that compete for a common signaling 
molecule.  In the sparse instances where synergistic responses were observed in higher 
order combinations, the authors reflect this maybe representative of important phenotypes.  
Similarly, a report using a multiplexed fluorescent bead immunoassay method has shown 
the synergistic interactions of TLR8 and TLR3 or TLR4 activating NF-κB, IRF, MAPK 
and PI-3K signaling networks in human macrophages (Mäkelä et al., 2009). 
   
These observations in conjunction with the biological literature allow a more general 
question to be asked.  Cellular responses are multi-variate outputs that drive phenotype.  
Phenotype is likely constrained by the epigenetic landscape within the cell as described by 
Waddington in 1957 where cellular decisions or phenotypes are arrived at by occupation of 
distinct and specific permitted developmental trajectories (as reviewed by Goldberg et al, 
(Goldberg et al., 2007)).  More recently this theory has been described in the quantitative 
terms of networks of high-dimensional attractors that drive gene and protein expression 
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(Huang, 2006).  The choreographed expression of signaling proteins may result in them 
coalescing into distinct oligomeric protein- (Gibson, 2009) or cellular complexes (e.g. the 
inflammasome), ensuring that a signal is communicated efficiently.  In metabolic 
networks, the concept of ‘metabolic channeling’(Mendes et al., 1992), where a substrate is 
passed directly between active sites of enzymes, undergoing stepwise transformations is 
analogous to the sequence of reversible covalent modifications (e.g. phosphorylation, 
ubiquitination) that are transduced in signaling.  Dynamic construction and disassembly of 
discrete signaling complexes would reduce uncertainty, still allow for modularity (i.e. 
allow common components to be used in a variety of complexes), enhance the robustness 
of signal transduction (Aderem, 2005), explain the degeneracy of outputs and hence why 
only small sets of phenotype are realised macroscopically for low (≤2) numbers of stimuli.  
The question then becomes ‘can discrete models of low input number represent phenotype 
adequately?’  A preliminary examination of this area yielded data suggesting this to be the 
case (Saez-Rodriguez et al., 2009).       
 
This study described in chapter 2 would have been enhanced by the introduction of mass-
spectrometric techniques for the monitoring of multiple protein endpoints (e.g TNF-α, IL-6 
inter alia) via measurement of the mass/charge ratio of these.  The evolution of the 
selected reaction monitoring technique now makes this a possibility (Lange et al., 2008) 
with the potential to measure up to 200 different proteins.  Measurement of multiple 
protein outputs would have enabled determination of the selectivity and specificity of 
combination mechanism of action.  Although the EA can embrace this number of 
objectives (i.e. variables (proteins) that change after stimulus), the time and complexity 
required to run the algorithm is scaled approximately to an exponential relationship 
(formulated in big ‘O’ notation: O(dn(3)) where d is the number of objectives and n is the 
population size).  Thus, the time taken to run this problem could obviate its use dependent 
on machine constraints (e.g. cache size, number of processors).  A solution might be found 
partly via the application of high performance computing .   Also, using an expansive 
range of experimental methods available to the pharmacologist, elucidating the mechanism 
of action of these combinatorial inhibitors will present a valuable addition to the literature.  
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5.3 A network map of lipopolysaccharide dependent IL-1β expression in 
macrophages and monocytes 
 
The motivation for construction of a TLR4 signalling map impacting IL-1β transcription 
was to better understand the underlying reactions and feedbacks and provide an essential 
framework that will allow translation into dynamic models.  Previous and more extensive 
mapping of TLR networks were notably absent of any mapping of transcriptional effects.  
In the construction of such a map or network there are likely sources of error, namely; 
factual inaccuracies within papers and errors of interpretation (Oda and Kitano, 2006).  We 
attempted to limit factual inaccuracies by only utilising publications where there were 
demonstrable dynamic roles for transcription factors (TFs).  The likelihood of having 
obviated other TFs is high, as an in silico scan of the promoter region of the IL-1β gene 
has revealed sites for additional TFs (Hashimoto et al., 2009) that were not included here 
owing to an absence of dynamic data.   
 
Advantages of the précis of literature data in a network map form are numerous.  Data 
visualization (Tufte, 2001), allows an immediate appreciation of the relationship (or its 
absence) between one chemical species and another, that can’t be conveyed in the written 
word.  Similarly, they can condense (and abbreviate) a literature from the past 30 years 
with little loss of information (e.g. expression of complex relationships, spatial locations / 
transitions) except in one important respect - time.  A limiting factor in presenting a 
network map is that it necessarily attempts to compress four dimensional (space (x, y, z), 
time) data via a two dimensional representation (space (x, y)).  Although different, 
biochemical network maps are analogous to circuit diagrams and process flow diagrams in 
electrical and chemical engineering respectively.  However, in systems biology elucidating 
a network map is a necessary and very important precursor to the further development of a 
dynamic model, whether as a discrete or continuous representation (Janes and Yaffe, 2006, 
Fisher and Henzinger, 2008, Kholodenko, 2006). 
 
5.4      Conclusion 
 
This thesis has attempted to define signaling components responsible for TLR4 mediated 
IL-1β expression in macrophages and reconcile the complementary approaches of an 
iterative machine learning - ‘wet’ experimentation with the construction of a human / 
murine structural model from literature data.  Acquisition of the EA-directed and adaptive 
dose matrix search data confirmed literature reports on the importance of p38α MAPK in 
IL-1β expression and informed the construction of a structural model.  
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5.5 Back to the future 
 
Reflection on the philosophies and methodologies employed within systems biology (Kell, 
2006b) leads to the conclusion that their ongoing evolution conforms to a ‘back to the 
future’ trajectory.  AV Hill (Hill, 1910).  RA Fisher and Hodgkin and Huxley’s (Hodgkin 
and Huxley, 1952) work are all prescient examples of the great impact mathematical and 
statistical thinking has had in the biological sciences.  A common theme emerging here is 
that new experimental techniques and the application of mathematical tools have always 
been developed to make innovative discoveries in biology (e.g. biochemistry, genetics, 
physiology, pharmacology, ecology).  The arrival of ‘omics technologies in conjunction 
with improved data processing capabilities provided by computational platforms and 
programming languages is allowing the statistical modeling of datasets and the subsequent 
development and parameterization of in silico models.  This is just the latest iteration of a 
longer chain of technology development, clearly, with statistics as a hub science.  Quoting 
from (Wilkinson, 2009): 
 
‘Statistics is the science concerned with linking models to data [and vice versa, BGS], and 
as such it is absolutely pivotal to the success of the systems biology vision.’  
 
5.6 Future work 
 
Addressing important problems and posing important questions (Rothwell, 2002, Alon, 
2009) that are often derived from the humanities (we are often most interested in the 
propagation and welfare of our own species), is a fundamental first step within the arena of 
scientific discovery.  The tools and technologies described here within an ever burgeoning 
literature (Ananiadou et al., 2006) have the capacity to answer these questions with greater 
efficiency, with greater breadth (i.e. across species) and detail (increased resolution of 
temporal and spatial measurements) than has been previously examined.  Cooperative 
alliances, consolidation of data, its interpretation via these alliances and translation of these 
findings for publication and hence a reduction in the literature will be of benefit to all.  The 
Royal Academy of Engineering and Academy of Medical Sciences published a joint report 
outlining the importance of integrating the principles and methods of engineering into 
biology (Dollery et al., 2007).  Recently, a white paper from a cross-faculty panel at the 
Massachusetts Institute of Technology has renewed calls for greater efforts to support 
interdisciplinarity (Sharp et al., 2011).   
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5.6.1 Mixed messages; drug efficacy 
 
To conclude, the most pressing global healthcare problem is that of non-communicable 
disease (NCD) (e.g. atherosclerosis, diabetes, cancer) which affects a large proportion of 
populations in both the developing and developed world (Tunstall-Pedoe, 2006),(Reardon, 
2011).  A manuscript authored by a large and internationally diverse panel of scientists has 
proposed a systems medicine framework to combat the prevalence of NCDs (Bousquet et 
al., 2011).  The discovery and development of medicines is still seen as being critical for 
treating NCDs.   However, given the ethical concerns, expense and stringent regulations 
governing the use of animal models to discover remedies, the triage of potential molecules 
is conducted in in vitro cellular models.  Despite this, an understanding of drug efficacy at 
the cellular level still eludes us.  Signal transduction and drug efficacy are the result of the 
complex dynamics of the cell. A better understanding of cells as complex systems would 
result in more effective treatments and decreased toxicity, both of which would save the 
lives of many individuals worldwide, especially in developing nations. 
 
Macrophage cells would form the biological model of choice in which to study the efficacy 
concept.  Their isolation can be achieved without disrupting any syncytial connections and 
small molecule control of their internal environment can be performed.  The evolved 
function of a macrophage is broadly two-fold; to phagocytose pathogens and cellular 
debris (innate immune function) and also to provide a critical link to the adaptive arm of 
the immune system, via secretion of signaling molecules to activate lymphocyte 
populations.  This latter signaling function provides a convenient biological model for 
understanding the efficacy concept.   
 
Two successive tracks of experimentation could be advanced.  Utilising a MOEA we could 
determine combinations of stimuli and associated application regimes (concentration 
threshold, frequency and duration of application) and how these scale with the output (i.e. 
temporal profile of concentration, multiplicity).  This can be achieved by defining temporal 
system response indicators (tSRIs) (van der Greef & McBurney 2005) that are parallel, 
multi-variate measures of a response estimated as a ratio at a particular time.  Collectively, 
these tSRI’s could then be integrated into a system response profile (SRP) that could be 
shaped pharmacologically using the same MOEA method outlined in this dissertation 
(Publication number 01).  However, concentrations of secreted signaling molecules (e.g. 
cytokines) that are expressed via transcriptional mechanisms will vary over minutes to 
hours.  Additionally, monitoring intracellular Ca2+ mobilization allows a comparison 
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between relatively fast and slow, intracellular versus extracellular (secreted) and non-
transcriptional versus transcriptional signaling events respectively.       
Further, in defining what is a ‘desirable’ SRP, in vivo experiments of acutely inflamed 
mice (i.e. via intra-peritoneal administration of LPS and / or combinations of stimuli) 
would allow sampling of endogenous macrophages and their inflammatory outputs with 
varying time to gauge their tSRI’s and an organismal SRP of inflammation.      
 
The recent announcement by Harvard Medical School of the launch of an initiative in 
systems pharmacology and corresponding white paper (Sorger et al. 2011) on this subject 
has reinvigorated the search for basic and generalised principles governing signal 
transduction.  This proposal both strategically and tactically addresses the long-standing 
problem of efficacy in classic analytical pharmacology using novel systems methods.  
Similarly, non-communicable disease (Reardon 2011), the current and continuing dearth of 
prospective new drug candidates (the bulk of which fail in Phase II and III clinical trial 
stages via their lack of efficacy (Thomson-Reuters 2011) and the long-standing resolution 
of the efficacy concept in pharmacology are just three problems whose resolution could be 
realised via undertaking the work set out here. 
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